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ABSTRACT 
Background 
Alleviating the injury associated with ST-elevation myocardial infarction is central to 
improving the global burden of coronary heart disease. The chemokine stromal cell-
derived factor 1α (SDF-1α) and its receptor, CXCR4, have dual potential benefit in this 
regard: acutely protecting the heart from lethal ischaemia-reperfusion injury (IRI) 
whilst mitigating adverse ventricular remodelling by recruiting progenitor cells to the 
site of injury. 
This project hypothesised that SDF-1α mediates the acute cardioprotection conferred 
by remote ischaemic conditioning (RIC), the phenomenon whereby brief cycles of 
non-lethal tissue ischaemia and reperfusion remote from the heart protects against 
myocardial IRI. 
Methods and Results 
This thesis defines a paradigm for evidencing a role in RIC that includes induction of 
cardioprotection by exogenous administration of SDF-1α at the time of reperfusion, 
abolition of cardioprotection by specific antagonism of CXCR4, increased production 
of SDF-1α as a direct effect of RIC, and absence of cardioprotection in CXCR4-deficient 
mice. A murine in vivo model of myocardial IRI and a novel ELISA for active SDF-1α 
were established and used to investigate this paradigm. 
This thesis provides the first description of cardioprotection against myocardial IRI as 
a result of exogenous SDF-1α administered prior to reperfusion. Moreover, 
AMD3100, a highly specific inhibitor of CXCR4, abolishes the beneficial effect of RIC 
in vivo. Next, SDF-1α cleavage and inactivation was unexpectedly demonstrated to 
increase after RIC, which may be attributable to up-regulation of dipeptidyl 
peptidase-4. Finally, inducible cardiomyocyte-specific CXCR4 deletion unexpectedly 
conferred protection against myocardial IRI. The protective mechanism was not 
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established and, furthermore, it prohibited the use of these mice in experiments to 
validate the role of CXCR4 signalling in RIC. 
Conclusions 
The intrinsic role of SDF-1α in RIC remains equivocal. However, modulation of the 
SDF-1α-CXCR4 axis with other approaches, including exogenous SDF-1α, has 
potential utility in cardioprotection against myocardial IRI.  
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Chapter 1 General introduction 
1.1 Introduction 
Coronary heart disease (CHD) is the leading cause of death worldwide, accounting for 
an estimated 8.1 million deaths per year and strategies to mitigate the deleterious 
effects of ST-elevation myocardial infarction (STEMI) are therefore paramount.1 Early 
reperfusion by primary percutaneous coronary intervention (PPCI) is the most 
effective strategy for reducing infarct size (IS) and improving clinical outcome.2, 3 
However, adverse sequelae persist: in a recent study, 30-day, 1-year, and 5-year all-
cause (and cardiac) mortality rates following PPCI for STEMI were 7.9 % (7.3 %), 
11.4 % (8.4 %), and 23.3 % (13.8 %), respectively.4 Important therapeutic targets in 
this regard include platelet aggregation and adverse ventricular remodelling. Another 
potential target is the injury paradoxically inflicted by the therapeutic restoration of 
blood flow, known as reperfusion injury, which may account for up to 50% of final IS 
(Figure 1-1).5, 6 
 
Figure 1-1: Contribution of reperfusion injury to myocardial infarct size after therapeutic 
restoration of blood flow 
Reperfusion of an occluded epicardial artery is essential to limit cell death; however, 
reperfusion itself inflicts injury, known as reperfusion injury, which may account for up to 
50% of final IS. Figure from 7. 
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Myocardial ischaemia-reperfusion injury (IRI) describes the deleterious 
consequences of several pathological processes and cardiac interventions. Most 
commonly, it is caused by thrombotic occlusion of the coronary artery in STEMI and 
subsequent reperfusion by PPCI, but may result from a range of elective and 
emergent causes of myocardial ischaemia, including cardiopulmonary bypass and 
spontaneous reperfusion of STEMI. The pathophysiology of IRI is not fully 
understood, but proposed mechanisms include oxidative stress,8 deranged calcium 
metabolism,9 rapid restoration of physiologic pH,10 inflammation,11 and deranged 
metabolism of glucose, insulin and potassium.12, 13 Several potential mediators have 
been studied, however, manipulation of these mechanisms has largely failed to 
translate to benefit in clinical trials (reviewed by Hausenloy et al., 201314). 
The chemokine stromal cell-derived factor 1α (SDF-1α) potentially delivers a ‘two-
pronged’ defence of the myocardium with respect to IRI: acute protection from 
reperfusion injury and subsequent beneficial modulation of ventricular remodelling 
by recruiting progenitor cells to the site of injury.15 
SDF-1α is known to play a central role in stem cell homing, retention, survival, 
proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling 
following myocardial infarction (MI).16-19 It acts as a specific ligand for its receptor 
CXC Receptor 4 (CXCR4) and the SDF-1α-CXCR4 axis is activated in both experimental 
and clinical studies of MI.17 SDF-1α-CXCR4 has been used to target stem cells to 
ischaemic tissue with consequent improvement of left ventricle (LV) dimensions and 
function.20-23 Importantly, the SDF-1α-CXCR4 signalling axis exerts these effects via a 
Gα1 dependent mechanism and activation of phosphoinositide 3 kinase (PI3K), 
mitogen activated protein kinase (MAPK), and Janus kinase (JAK)-signal transducer 
and activator of transcription (STAT) signalling. 
These signalling pathways are the same pathways that it is postulated are responsible 
for the protection against IRI conferred by all forms of conditioning such as pre-, post- 
and remote ischaemic conditioning (RIC).24-26 The latter describes the phenomenon 
whereby non-lethal ischaemia and reperfusion applied to an organ or tissue remote 
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from the heart protects the myocardium from lethal reperfusion injury. The mechanism 
of cardioprotection conferred by RIC is so far unknown, but is thought to be due to a 
humoral factor that has been shown by biochemical fractionation studies to be a protein 
between 3.5 kDa and 15 kDa in size.27, 28 
 
Figure 1-2: The SDF-1α-CXCR4 signalling axis 
Remote preconditioning may enable both acute and chronic cardioprotective pathways (see 
text for details). SDF-1α, stromal derived factor-1α; HIF-1α, hypoxic inducible factor-1α; 
ADRCs, adipose tissue derived regenerative cells; BMSCs, bone marrow stem cells (including 
mesenchymal stem cells, haematopoietic stem cells and endothelial stem cells); ECSCs, 
endogenous cardiac stem cells; JAK, Janus kinase; STAT, signal transducer and activator of 
transcription; PI3K, phosphoinositide 3 kinase; MEK1/2, mitogen-activated protein kinase; 
Erk, extracellular signal-regulated kinases; eNOS, endothelial nitric oxide synthase; NO, nitric 
oxide; MPTP, mitochondrial permeability transition pore. 
It is therefore hypothesised in this thesis that in addition to its chronic effects, SDF-1α 
has a direct role in the protection observed after RIC and a proposed paradigm for its 
roles is described in Figure 1-2.15 Preliminary evidence for its role in RIC include a 
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demonstrable increase in circulating SDF-1α in animals subjected to RIC.29-31 
Furthermore, RIC, which was shown to significantly decrease IS and improve papillary 
muscle functional recovery in an ex vivo model, could be blocked by AMD3100, a 
highly specific inhibitor of CXCR4.31, 32 This, together with the identification of SDF-1α 
as an 8 kDa peptide and its induction in response to hypoxia, has made it a prime 
candidate for a role in RIC.33 
1.2 SDF-1α-CXCR4 
Chemokines, or chemoattractant cytokines, play a critical role in the regulation and 
trafficking of leukocytes as well as haematopoietic and other progenitor cells.18 They 
are also involved in a variety of other functions, including degranulation, mitogenesis, 
gene transcription, apoptosis, and angiogenesis.34 There are over 50 human 
chemokines that are classified according to the position of two N-terminal cysteine 
residues as CXC, CCC, C or CX3C.18 In myocardial ischaemia, several chemokines, 
including CXC and CC subtypes, have been shown to be upregulated in both 
experimental and clinical studies of MI.18, 35, 36 
SDF-1 (also known as CXCL12) is a CXC chemokine, so-called because the two 
cysteines nearest the N-terminus are separated by a single amino acid.37 It is a small 
(8 kDa), 89 amino acid peptide that is encoded by a gene originally cloned from 
murine bone marrow stromal cells, hence its name.37 It is highly conserved (more 
than 92% similarity at the protein level) between species and has been shown to 
confer protection between species.28, 38 Several isoforms of SDF-1, namely SDF-1 
alpha (α) to zeta (ζ), arise from alternative splicing and have been identified by 
polymerase chain reaction (PCR).18 All isoforms are agonists at CXCR4 but have 
distinct properties. For example, SDF-1β is more resistant than SDF-1α to 
proteolysis.39 Interestingly, expression of SDF-1ɣ has recently been reported in non-
vascular tissue that is susceptible to infarction, including the heart.39 However, the 
predominant and best described isoform is SDF-1α,40 which was the focus of this 
thesis. Note that many studies do not specify which isoform they are investigating 
and henceforth where this is the case the more general SDF-1 descriptor is adopted. 
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SDF-1α protein or mRNA expression has been reported in several organs, tissues and 
cells, including bone marrow, heart, liver, kidney, thymus, spleen, skeletal muscle, 
brain and, more recently, platelets,18, 41-44 although it is likely that in some tissues this 
reflects expression in the vascular endothelium. In the heart, SDF-1α is expressed by 
endothelial cells, cardiac fibroblasts, vascular smooth muscle cells and 
cardiomyocytes.45-47 It is a chemoattractant for a variety of cell types including T 
lymphocytes, bone marrow stem cells (BMSCs; including haematopoietic, endothelial 
and mesenchymal subtypes), adipose-derived regenerative cells (ADRCs) and c-kit+ 
endogenous cardiac stem cells (eCSCs).17, 48, 49 It also has a role in maintaining 
hematopoietic stem cell niches in bone marrow.18 
SDF-1α is widely studied due to its pleiotropic biological processes, which are 
described in Figure 1-3. These functions have been investigated in a range of pre-
clinical and clinical disciplines including, but not limited to, cardiology, neurology, 
oncology and haematology.  
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Figure 1-3: The pleiotropic biological processes of SDF-1α 
The biological processes described in this figure are adapted from the Gene Ontology 
Consortium list of biological processes for SDF-1α.50 
SDF-1α is cleaved by exopeptidases including dipeptidyl peptidase-4 (DPP4), matrix 
metalloproteinase (MMP)-2 and MMP-9 (albeit all acting at different positions),51 
although DPP4 predominates in this regard.52 Injected SDF-1α has an estimated half-
life in vivo by radiolabelling of 25.8±4.6 min.53 However, it is unclear whether this 
represents full-length or cleaved SDF-1α, which are likely to have different kinetics. 
Similarly, all commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits 
measure both intact and cleaved SDF-1α and may therefore offer a skewed view of 
the role of SDF-1α in MI. 
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The best described receptor for SDF-1α is CXCR4. CXCR4 is a G protein-coupled 
receptor (GPCR) that, once activated, is thought to initiate a signalling cascade that 
regulates the functions described.18, 54, 55 CXCR4 is expressed by a range of cell-types, 
and is known to be critical in embryogenesis, including cell migration and 
development of neuronal, cardiac, vascular, haematopoietic and craniofacial 
systems, which is reflected by its expression on a range of progenitor cells, including 
haematopoietic, endothelial and cardiac stem cells.17, 18, 37 Importantly, CXCR4 is also 
known to be expressed by both platelets and endothelial cells.44 Indeed, during 
angiogenesis, expression of CXCR4 on vessel endothelium correlates with areas of 
high SDF-1α expression.56 In embryonic development transgenic homozygote mice 
lacking either CXCR4 or SDF-1α have abnormal B-lymphocyte development, as well 
as abnormal hepatic and cardiac development, including ventricular septal defects 
(VSD), and die in utero.57 Similarly, in humans, CXCR4 mutation causes impaired 
mobilisation of neutrophils and B-cell lymphopaenia.58 
More recently it has become apparent that CXCR7 plays a central role in regulation 
of SDF-1α. CXCR7 expression is known to be up-regulated in hypoxic conditions by 
HIF-1α and is thought to scavenge SDF-1α.59 Hoffman et al. demonstrated rapid 
spontaneous internalisation of SDF-1α by CXCR7, unlike Gβɣ protein-coupling via 
CXCR4, resulting in rapid release of SDF-1α degradation products.59 It has similarly 
been shown that serum SDF-1α is elevated in murine model in response to either 
genetic deletion or pharmacological inhibition of CXCR7.60  As well as hypoxia, CXCR7 
is thought to be upregulated in inflammation, cancer and autoimmune conditions.61 
It has been shown to improve the migration and paracrine function (angiogenesis and 
mitogenesis) of MSCs in mice subjected to renal IR, and consequently to reduce 
apoptosis and improve functional recovery.62 However, the relative contribution and 
relationship of CXCR4 and CXCR7 is not fully elucidated and its contribution, if any, to 
cardioprotection is not yet known.17 Furthermore, CXCR7 was not specifically 
investigated in this thesis and should be acknowledged as a potential confounding 
factor when considering the effects of SDF1α. 
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1.3 Chronic cardioprotection 
1.3.1 SDF-1α-CXCR4 after acute myocardial infarction 
In the cardiovascular field, most is known about the SDF-1α-CXCR4 axis in the context 
of myocardial repair after acute MI (‘chronic cardioprotection’). In hypoxic 
conditions, the transcription factor hypoxia inducible factor-1α (HIF-1α) is 
upregulated and in turn up-regulates SDF-1α and CXCR4.17, 18, 63 In this way SDF-1α 
acts as a diffusible ‘homing beacon’ directing CXCR4-expressing cells towards hypoxic 
tissue. In health, since the bone marrow is physiologically hypoxic, SDF-1α expression 
results in the retention of BMSCs.17, 33 In response to MI, several clinical studies have 
demonstrated up-regulation of SDF-1α in infarct and peri-infarct zones, returning to 
baseline at 7 days,46, 63-65 and in the serum.66, 67 SDF-1α-CXCR4 signalling is also 
reportedly elevated in toxic liver damage, total body irradiation and after 
chemotherapy.41 Thus, expression of SDF-1 in infarcted myocardium has been 
associated with recruitment, retention, survival and proliferation of ADRCs, eCSCs 
and BMSCs.21, 49, 68-70 Conversely, decreased recruitment, angiogenesis and blood 
flow have been demonstrated when CXCR4 is blocked on infused progenitor cells or 
when SDF-1α is blocked in the recipient using neutralising antibodies.17, 33 
Although a number of mechanisms can mobilize stem cells, including cytokines 
(granulocyte- and granulocyte macrophage-colony stimulating factor (G-CSF, GM-
CSF), and stem cell factor (SCF)), interleukins (IL-7, IL-12, IL-3), chemokines (SDF-1α, 
IL-8), growth factors (vascular endothelial growth factor, hepatocyte- and insulin-like 
growth factor (VEGF, HGF, IGF)),71 and chemotherapeutic agents like 
cyclophosphamide,18 it is suggested that the SDF-1α-CXCR4 axis is the most potent 
and central to the process of mobilizing progenitor cells.71, 72 For example, G-CSF, a 
cytokine known to increase the mobilisation of stem cells from bone marrow and 
widely used therapeutically, does so by disrupting the association of SDF-1 on bone 
marrow stromal cells, osteoblasts and reticulocytes with CXCR4 on BMSCs.17, 71, 73 A 
similar mechanism may explain how AMD3100 increases circulating haematopoietic 
and endothelial progenitor cells.69, 74 
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Cardiomyocyte-expressed CXCR4 also seems to be important in ventricular 
remodelling after MI. This has been demonstrated in cardiomyocyte-specific CXCR4 
null mice subjected to MI.75 Wild type mice had better cell recruitment after BMSC 
engraftment and consequent improvements in ejection fraction (EF) and infarct size. 
Interestingly, this study identified a local paracrine effect of infused BMSCs, mediated 
by BMSC SDF-1α secretion. This study also identified a 33% reduction in SDF-1α 
expression in the infarct zone in cardiomyocyte-specific CXCR4-deficient mice. It is 
therefore apparent that in MI, transient increases in SDF-1α result in the gradient-
guided homing of progenitor cells from the bone marrow, as well as adipose and 
cardiac tissue, to sites of injury and inflammation. These cells then exert 
advantageous effects via SDF-1α-mediated activation of local CXCR4, among other 
mechanisms. In support of this, it is suggested that SDF-1α and CXCR4 are up-
regulated asynchronously after MI, with SDF-1α being increased as early as 1 h (to 
direct CXCR4-expressing cells towards injured tissue) and cardiomyocyte-specific 
CXCR4 being up-regulated some 36-48 h later,68, 76  perhaps in readiness for the arrival 
of circulating progenitor cells that are estimated to peak around day 5.77 
In both circulating cells and tissue-specific cells such as cardiomyocytes, SDF-1α-
CXCR4 exerts its effects by activating intracellular signalling cascades. These include 
the MAPK p42/44 extracellular signal-regulated kinases (Erk1/2), PI3K-Akt, JAK-STAT 
and protein kinase C (PKC) signalling cascades, as well as inositol-1,4,5-triphosphate 
(IP3)-induced SR/ER calcium release.78, 79 
1.3.2 Therapeutic application of SDF-1α-CXCR4 in chronic cardioprotection 
Several pre-clinical studies have adopted a range of approaches to therapeutically 
manipulate the SDF-1α-CXCR4 pathway. Broadly, these centre on one or a 
combination of the following approaches: (1) increased mobilisation and recruitment 
of progenitor cells; (2) increasing SDF-1α to coincide with peak myocardial CXCR4 
expression, including by inhibiting its breakdown; and (3) over-expression of CXCR4 
to coincide with peak myocardial SDF-1α expression. Examples of each of these are 
given in turn and these approaches are discussed in more detail in the chapters that 
follow. 
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Firstly, with respect to increased mobilisation and recruitment of progenitor cells to 
facilitate over-expression of SDF-1α, approaches have included use of a PEGylated 
fibrin patch for SDF-1α over-expressing mesenchymal stem cell (MSC) 
transplantation,68 intra-myocardial delivery of MSCs over-expressing SDF-1α,80 MSCs 
over-expressing IGF-1 to activate SDF-1α,79 and intra-cardiac injection of skeletal 
myoblasts over-expressing human SDF-1α.81, 82 Abbott et al. found that stem cells 
delivered to the coronary artery following MI were only retained alongside 
adenovirus-mediated cardiac expression of SDF-1α, an effect that was abolished by 
AMD3100.65 Finally, Misao et al. administered G-CSF or vehicle 3 days after IRI in 
rabbits and found increased BMSCs in the infarcted area, increased serum SDF-1α, 
reduced IS, improved EF and improved end-diastolic dimensions in the G-CSF group.22 
This was again abrogated by AMD3100.22 
Secondly, with respect to increasing SDF-1α to coincide with peak myocardial CXCR4 
expression, SDF-1α has been delivered by intra-cardiac injection after MI in mice and 
found to activate Akt in endothelial cells and cardiomyocytes, which was associated 
with improved cardiac function up to 28 days after infarction, increased VEGF, 
increased angiogenesis and reduced IS.20, 23 Continued expression of active SDF-1α 
(peak at 7 days) has been achieved by expression from adenovirus injected in the 
myocardium after infarction, which resulted in smaller IS, improved LV parameters, 
less fibrosis and a greater density of cardiomyocytes and blood vessels in a rat model 
of STEMI.21 Similar plasmid-based over-expression of SDF-1 has also been applied 1 
month after MI, with similar results.83 Askari et al. combined the injection of cardiac 
fibroblasts over-expressing SDF-1α into the infarcted myocardium of a rat with 
intraperitoneal G-CSF and found improved stem cell homing, angiogenesis and 
cardiac function.76 Pre-clinical and clinical studies that have attempted to interfere 
with the degradation of SDF-1α are addressed in Chapter 7. 
Thirdly, with respect to over-expression of CXCR4 to coincide with peak myocardial 
SDF-1α expression, this has likewise been achieved using viral vectors.84 Cheng et al. 
delivered MSCs over-expressing CXCR4 intravenously to rats 24 h after IRI and found 
improved homing, better preservation of LV dimensions, reduced fibrosis and better 
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LV function, as assessed by echocardiography.85 Similarly, injection of cultured stem 
cells with CXCR4 specifically upregulated by cultivation led to better angiogenesis.86  
Interestingly, the mechanism whereby 3-hydroxy-3-methylglutaryl-coezyme A 
(HMG-CoA) reductase inhibitors (statins) mobilise endothelial progenitor cells (EPCs) 
and affect angiogenesis at sites of endothelial injury has been attributed to the SDF-
1α-CXCR4 pathway.87 Specifically, atorvastatin and rosuvastatin have been shown to 
up-regulate CXCR4 expression in circulating EPCs, improve their homing to ischaemic 
tissue in a mouse model of permanent femoral artery ligation, and increase capillary 
density and flow. The authors attributed this to endothelial nitric oxide synthase 
(eNOS) as it was not only significantly increased in EPCs treated with statins but up-
regulation of CXCR4 was abrogated with the NO synthase inhibitor, L-NAME (NG-
nitro-L-arginine methyl ester). The potential relationship between this hitherto 
unexplained function of statins and the SDF-1α-CXCR4 axis is interesting because 
statin treatment may confound attempts to therapeutically increase the expression 
of CXCR4 in patients with cardiovascular disease. 
Despite these encouraging results, enthusiasm is tempered by (albeit limited) 
experimental data that indicate a deleterious role of SDF-1α-CXCR4 in MI. Chen et al. 
used adenovirus-mediated over-expression of CXCR4 injected into the rat heart 7 
days prior to myocardial IRI and found significantly increased scar size, worse 
fractional shortening (FS), increased cardiomyocyte apoptosis and more LV 
hypertrophy at 24 h.88 Most of the studies described above have up-regulated CXCR4 
after MI and the over-expression of CXCR4 7 days prior to MI might be important in 
the study by Chen et al., particularly with respect to inflammatory cell recruitment, 
and this is discussed further in Chapter 8. In another study, SDF-1α was injected into 
the peri-infarct zone of pigs 2 weeks after MI that, consistent with previous studies, 
resulted in increased vessel density.89 However, there was no significant 
improvement in IS or myocardial perfusion compared to controls, and there was a 
significant deterioration in LV function in the SDF-1α-treated group.89 This finding 
may have several explanations, including a requirement for combination therapy to 
both stimulate stem cell mobilisation from bone marrow niches and homing to sites 
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of injury. In addition, Koch et al. delivered only a single bolus of SDF-1, which could 
be expected to be rapidly proteolysed,52 and administered SDF-1 at 14 days while 
there is evidence that intravenous MSCs are only effective when given within 4 
days.90 
Furthermore, it should not be forgotten that SDF-1α is involved in the mobilisation 
and recruitment of various progenitor cell types to hypoxic areas of tumours in 
addition to the other ischaemic tissues described, and can therefore support tumour 
proliferation, angiogenesis, metastasis and survival.91 Similarly, stromal cell SDF-1α 
expression can induce leukaemia cell trafficking to the bone marrow, where 
malignant cells are provided with growth factors and protected from conventional 
chemotherapy.92 To this end, AMD3100 (Plerixafor) has been shown in various 
malignancies, including leukaemia, non-Hodgkin’s lymphoma and multiple myeloma, 
to increase drug responsiveness.92 This paradox is a challenge for the wider field of 
cardioprotection, which aims to protect cells from apoptosis. Thus, care should be 
taken until more is known about what, if any, specific differences in signalling exist 
between ischaemic myocardium and tumours. It is reassuring to note that in the 
recent STOP-HF trial of SDF-1α treatment in ischaemic cardiomyopathy, patients with 
any history of cancer, with the exception of curable non-melanoma skin cancer or 
resection with no recurrence in 5 years, were excluded from the study.93 
Likewise, SDF-1α may play a role in, atherosclerosis, a disease characterised by the 
recruitment of inflammatory cells to activated endothelium coupled with the 
migration and proliferation of smooth muscle cells in the intima. This is thought to be 
mediated by the expression of various chemokines, including SDF-1α.94 In particular, 
SDF-1α has been shown to induce arterial smooth muscle cell proliferation and 
promote plaque formation.95 Specific antagonism of chemokine receptors therefore 
presents a therapeutic opportunity with respect to atherosclerosis, although this has 
not been investigated with specific reference to SDF-1α-CXCR4. Furthermore, SDF-1α 
up-regulation was induced following smooth muscle cell-specific deletion of PTEN 
(phosphatase and tensin homolog), a lipid and protein phosphatase, in mice, 
resulting in pulmonary arterial hypertension (PAH) and pathological vascular 
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remodelling.96 In other studies,  pravastatin has been shown to mitigate hypoxia-
induced PAH by suppressing SDF-1α in mice,97 which was associated with fewer 
BMSCs in the pulmonary artery adventitia. This may represent a very specific contra-
indication to the therapeutic application of SDF-1α-CXCR4 and should therefore be 
considered when targeting SDF-1α-CXCR4 clinically. 
Finally, VEGF has been associated with SDF-1α-CXCR4-mediated recruitment of stem 
cells and subsequent myocardial repair.98 Specifically, in a model of permanent LAD 
ligation in Sprague Dawley rats, Tang et al. administered VEGF-expressing MSCs and 
found increased myocardial expression of SDF-1α, improved BMSC mobilisation and 
homing, extensive angiomyogenesis, reduced infarct size and improved left 
ventricular function. In a similar study by Saxena et al., described above, SDF-1α was 
delivered by intra-cardiac injection after MI in mice and found to increase VEGF and 
angiogenesis, and reduce IS.20 VEGF, like SDF-1α, is up-regulated in response to HIF-
1α and can promote angiogenesis in addition to many of the detrimental effects of 
SDF-1α described, including tumour growth and metastasis. Its similarity to SDF-1α 
in these respects, and apparent complex interaction of VEGF with SDF-1α, make it an 
intriguing alternative pathway for many of the processes described in this thesis and, 
despite not being specifically examined here, should be recognised. These are 
complicated issues for groups interested in utilising SDF-1α in the treatment of 
chronic ischaemic cardiomyopathy, and thus represent a confounding issue, but one 
which is not considered further in this thesis. 
Despite these potentially detrimental effects of SDF-1α-CXCR4, and the potential 
importance of VEGF, research into the potential utility of SDF-1α in ischaemic 
cardiomyopathy has begun to be translated. For example, Theiss et al. have 
confirmed in humans that mRNA of HIF-1α and SDF-1 are significantly higher in 
explanted heart tissue of patients with ischaemic cardiomyopathy versus dilated 
cardiomyopathy.99 The same group published a Phase I study of plasmid-based 
endomyocardial SDF-1 (pSDF-1) delivery to 17 patients with symptomatic ischaemic 
cardiomyopathy and found improvements in 6 min walk distance, New York Heart 
Association classification and quality of life after 12 months.100 Although EF was not 
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significantly affected, and neither inflammation nor scar formation recorded, the 
primary safety end-point was met. They proceeded to a Phase II, double-blind, 
randomised, placebo-controlled trial called Stromal Cell-Derived Factor-1 Plasmid 
Treatment for Patients with Heart Failure (STOP-HF).93 This was a safety and efficacy 
study of a single endomyocardial injection of pSDF-1 in patients with ischaemic 
cardiomyopathy. Ninety-three stable patients with mean LVEF 28±7% and on 
optimum medical therapy were included, 62 of whom received pSDF-1 with no 
adverse events. The primary endpoint of a composite of 6 min walk distance and 
quality of life, assessed at 4 months after injection, was not met. In a pre-specified 
subgroup analysis there was a significant 11% improvement in LVEF at twelve months 
in patients with the worst baseline EF (P=0.01). This finding may be related to the 
administration of a single dose of pSDF-1 or its timing (mean time since MI was 11±9 
years). 
1.4 Acute cardioprotection 
1.4.1 Ischaemic preconditioning 
The finding that the myocardium could be protected from lethal IRI by the application 
of multiple brief ischaemic episodes was first made by Murry et al., who found a 25% 
reduction in IS in dogs subjected to four 5 min circumflex occlusions, each separated 
by 5 min of reperfusion, prior to sustained occlusion of the circumflex artery.101 They 
termed this phenomenon ischaemic preconditioning (IPC).101 It has been 
demonstrated in numerous pre-clinical studies, and confirmed in a recent meta-
analysis,102 that the myocardium can be protected from lethal IRI by IPC. 
The mechanism of protection conferred by ischaemic conditioning, as it is currently 
understood, comprises extracellular autacoids acting on cardiomyocyte receptors in 
response to the conditioning stimulus and triggering protective intracellular signal 
transduction cascades.103 These are thought to unite at the mitochondria, particularly 
the mitochondrial permeability transition pore (MPTP), to inhibit apoptosis and 
preserve cardiomyocyte viability (Figure 1-2).104 
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Several endogenous extracellular factors, such as adenosine and opioid peptides, are 
known to mitigate the deleterious effects of IRI and are thought to play a central role 
in ischaemic conditioning (reviewed by Yellon et al., 20076). They originate from a 
variety of sources including cardiomyocytes, endothelium, smooth muscle cells, 
nerve endings, inflammatory cells, mast cells and macrophages in response to the 
conditioning stimulus, and have been extensively investigated.105-109 They are 
thought to have a number of actions, including reducing the activation of coronary 
vascular endothelium, reducing the production of pro-inflammatory cytokines and 
reactive oxygen species (ROS) and reducing adherence of neutrophils to the coronary 
artery, all of which contribute to ischaemic conditioning.103, 110, 111 As described, these 
factors exert these effects by recruiting the same protein kinase signalling cascades 
that are thought to be activated by the SDF-1α-CXCR4 axis.24, 26, 103 The best defined 
of these are the ‘reperfusion injury salvage kinase’ (RISK) and ‘survivor activating 
factor enhancement’ (SAFE) pathways.25, 109, 112 
The RISK pathway was first described by Yellon’s group in recognition of the 
activation of PI3K-Akt pathway and p42/p44 Erk1/2 MAPK by myocardial 
reperfusion.12, 24, 113-115 Pharmacological activation of this pathway has been shown 
to reduce IS by 40-50% at the time of reperfusion.103 Importantly, many of the known 
protective endogenous factors, including insulin, IGF-1, bradykinin and adenosine, 
have been shown to protect against IRI by recruiting the RISK pathway (reviewed by 
Hausenloy et al.24). IPC has also been shown to protect against lethal IRI by recruiting 
the RISK pathway.116-118 Specifically, the Akt1 isoform appears to be essential to IPC 
as demonstrated in Akt1-deficient mice that were resistant to protection from IPC.119 
Further, it has been shown that the RISK pathway is recruited equally by IPC, 
ischaemic postconditioning (IPostC) and RIC, indicating that this signal transduction 
pathway may represent a common pathway in ischaemic conditioning.120-123 
Lecour et al. described an alternative pathway, labelled the SAFE pathway, which 
activates JAK-STAT signalling.112 In mice subjected to simulated ischaemia and 
reperfusion, IPostC reduced IS and increased phosphorylated (active) STAT3.109 In this 
study, administration of a specific JAK-2 inhibitor (AG-490) reduced phosphorylated 
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STAT3 and abolished the beneficial effect of IPostC.109 Likewise, cardiac-specific 
STAT3-deficient mice were not protected from IRI by IPostC.109 Further, in a model of 
pharmacological preconditioning with tumour necrosis factor-α cardioprotection was 
not affected by inhibition of PI3K-Akt or Erk1/2 MAPK, but was abolished by inhibition 
of STAT3.124 Likewise, the SAFE signalling pathway is also required for RIC.123 The 
interplay between RISK and SAFE pathways is not fully defined, however it has been 
shown that in ex vivo mouse hearts functional protection conferred by IPostC was not 
only abolished by JAK-STAT inhibition, but also that STAT3 inhibition decreased both 
functional STAT3 and Akt, suggesting that these signalling cascades are not entirely 
independent.125 What is known is that both pathways converge on the mitochondria, 
particularly the MPTP, to affect cardioprotection. 
Many of the pathological processes thought to mediate IRI, including oxidative stress, 
deranged calcium metabolism and rapid recovery of physiologic pH, exert their 
effects at the mitochondria, resulting in cardiomyocyte death.6 Specifically, the 
MPTP, a voltage- and calcium-dependent channel in the inner mitochondrial 
membrane, is implicated.103 This is closed in ischaemia due to acidosis, a high 
mitochondrial membrane potential and high concentrations of Mg2+ and adenosine 
diphosphate (ADP).103, 126 However, in reperfusion, the MPTP opens in response to 
binding of cyclophilin D (Cyp-D), which is potentiated by depolarization, increased 
mitochondrial Ca2+, inorganic phosphate and ROS, and restoration of normal pH.103, 
127-131 Once open, the mitochondrial membrane potential rapidly dissipates, 
respiration becomes uncoupled, further elevating ROS formation, which establishes 
a vicious cycle of further MPTP opening and consequent loss of cell viability.103, 126 
Importantly, it is known that IPC and IPostC antagonise MPTP opening and 
significantly limit IS in animal models of IR.132-136 Furthermore, it is notable that 
several studies have associated activation of the RISK and SAFE pathways with 
inhibition of MPTP opening, indicating it may represent the final common effector of 
ischaemic conditioning.136-140 
In pilot pre-clinical studies, specific chemical inhibitors of MPTP, including NIM811,132 
ciclosporin A,127, 132, 133, 141 and N-methyl-4-valine ciclosporin A,133 have been shown 
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to reduce MPTP opening, limit apoptosis, improve functional recovery and limit IS. 
Likewise, transgenic Cyp-D-deficient mice subjected to simulated IRI have been 
shown to have reduced IS.142, 143 The improvement in functional recovery conferred 
by ciclosporin A, which prevents Cyp-D binding,103 has also been demonstrated in 
human atrial tissue,104 and successfully translated to a human pilot study of MI.144 
Despite this, a multi-centre, double-blind, randomised trial of 970 patients with 
STEMI who received IV ciclosporin prior to PPCI recently failed to meet its primary 
endpoint of a significant improvement in the composite of all-cause mortality, 
worsening in-hospital heart failure, rehospitalisation for heart failure or adverse LV 
remodelling at 1 year.145 Interestingly, this result might have been predicted based 
on a systematic review and meta-analysis that showed that while, overall, ciclosporin 
reduced infarct size by a standardised mean difference (SMD) of -1.6 (95% CI -2.17 to 
-1.03), there was no demonstrable benefit in swine, which are considered the most 
representative of humans.146 
1.4.2 SDF-1α and ischaemic conditioning 
Given the role of SDF-1α-CXCR4 in myocardial repair and the involvement of 
signalling kinases known to be integral to IPC, namely the Erk1/2, PI3K-Akt, JAK-STAT 
and PKC signalling cascades,82, 147 it has been hypothesised that SDF-1α may also be 
involved in the myocardial protection from IRI conferred by IPC. This is further 
supported by studies that have successfully used IPC to up-regulate SDF-1α and 
improve stem cell engraftment after MI. For example, Tang et al. applied IPC in a 
murine model of MI and demonstrated up-regulation of CXCR4 on cardiac progenitor 
cells, increased cardiac progenitor cell migration and recruitment, reduced IS and 
improved functional outcome, all of which were abolished by the addition of 
AMD3100.148  
SDF-1α has been shown to be cardioprotective in the context of IRI in a number of 
different models.46, 149, 150 As discussed in section 1.3.2, data from Yellon’s group using 
ex vivo rat papillary muscle indicates that SDF-1α increases recovery of function of 
muscle subject to simulated IRI, which can be blocked by AMD3100 (this is discussed 
further in section 5.2.1).31 Similarly, Huang et al. administered SDF-1 5 min before 
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ischaemia in isolated mouse hearts subject to ischaemia-reperfusion in a model of 
pharmacological preconditioning.149 They found that SDF-1 significantly improved 
functional recovery, reduced markers of apoptosis and increased activation of STAT3, 
a central mediator of the SAFE pathway.149 These effects were abolished by the 
addition of AMD3100.149 Interestingly, they did not see any increase in Akt or Erk1/2 
phosphorylation, and no attenuation of protection with LY294002, an inhibitor of the 
Akt pathway.149 Jang et al. used an ex vivo Langendorff model of IRI to show that five 
different concentrations of SDF-1 (250 pM to 5 nM) infused from 10 min before 
reperfusion to 30 min afterwards reduced IS significantly more than that seen with 
IPC and IPostC.150 They also saw an increase in Erk1/2 phosphorylation at 5 and 20 
min after reperfusion, thereby implicating the RISK pathway in the mechanism.150 Hu 
et al. demonstrated significantly increased SDF-1α release from isolated 
cardiomyocytes following hypoxia and reoxygenation.46 In this study, 25 nmol/L 
exogenous SDF-1α administered to cultured myocytes for 10 min resulted in 
increased phosphorylation of both Erk1/2 and Akt, less lactate dehydrogenase 
release and less apoptosis, an effect abolished by pre-treatment with AMD3100. In 
vivo, they demonstrated pharmacological preconditioning with SDF-1α infused into 
the LV cavity significantly reduced IS, which was abrogated by AMD3100. Preliminary 
steps have been taken towards translating the beneficial effect of exogenous SDF-1α 
to humans. Specifically, SDF-1α has been shown to mimic the cardioprotection 
conferred by hypoxic preconditioning in a model of simulated IRI using isolated 
human atrial trabeculae muscle.151 
The signalling cascades downstream of CXCR4 activation described above are 
inconsistent. CXCR4 is a GPCR that activates several signalling pathways, including 
both G protein-dependent and independent pathways.152 With respect to 
cardioprotection, CXCR4 activates the RISK pathway via Gβɣ and the SAFE pathway in 
a G protein-independent manner.153 Tong et al. related the cardioprotection 
conferred by IPC to Gβɣ by using a sequestering peptide in an isolated murine heart 
model of hypoxia and reoxygenation.154 This supports the hypothesis that SDF-1α-
CXCR4 is cardioprotective via the RISK pathway. CXCR7, on the other hand, 
phosphorylates MAPK pathway proteins, including Erk and p38, and signals via β-
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arrestin, which inhibits G protein-mediated signalling and has also been implicated in 
cardioprotection.155, 156 The relationship between these receptors is complex and 
remains poorly defined, especially in relation to cardioprotection. 
1.4.3 Remote ischaemic conditioning 
Despite promising experimental results for IPC, the translational potential of IPC is 
limited by the necessity to intervene before the index ischaemia, which is impossible 
to predict in STEMI. A potential solution is mechanical IPostC. Zhao et al. investigated 
repetitive ischaemia applied in early reperfusion of the left anterior descending (LAD) 
territory in a canine model, and found a 14% reduction in IS (compared to 15% in IPC 
in their model), a technique referred to as IPostC.110 Several studies have investigated 
this approach in a clinical setting, with mixed results.157-162 However, this mandates 
an invasive approach and risks associated procedural complications, including 
coronary artery dissection or perforation, access site complications, arrhythmias and 
stroke. 
In response to these concerns RIC has emerged as a potentially cheap, non-invasive 
alternative that can be applied before, during or after the index ischaemia (remote 
pre-, per- or postconditioning, respectively). RIC was first shown to be protective by 
Przyklenk et al. in 1993, who applied four episodes of 5 min circumflex occlusion 
separated by 5 min of reperfusion, before 1 h of sustained LAD coronary artery 
(henceforth abbreviated to LAD) occlusion and reperfusion for 4.5 h in a canine 
model.163 They found a 10% reduction in IS in the circumflex preconditioned dogs.163 
This has been developed by others who showed similar cardioprotective effects after 
applying a preconditioning stimulus to other remote organs and tissues, including the 
kidneys and skeletal muscle,164, 165 and using remote IPostC.166 
More recently it has been demonstrated that the application of brief cycles of 
ischaemia and reperfusion to a limb using a vascular occluder, tourniquet or blood 
pressure cuff has the same effect. Since the inception of limb RIC in 1997,165 several 
pre-clinical studies have demonstrated its efficacy in myocardial IRI. It can be 
achieved non-invasively by tightening a tourniquet or inflating a blood pressure cuff 
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on the arm or thigh to above systolic pressure to induce brief ischaemia and then 
deflating it to allow reperfusion,167 a finding which has greatly accelerated the rate of 
clinical trials.  
Several proof-of-concept clinical studies have translated these findings to a variety of 
clinical settings, albeit frequently using cardiac enzymes and myocardial salvage as 
surrogate markers of outcome, including coronary artery bypass surgery (CABG),168-
171 elective percutaneous coronary intervention,172 and in PPCI for STEMI.173-175 For 
example, for patients suffering STEMI, Botker et al. randomised patients to receive 
PPCI with or without a pre-hospital RIC protocol. The primary endpoint of improved 
myocardial salvage index at 30 days, measured by myocardial perfusion imaging, was 
met.173 Importantly, studies have demonstrated similar effects with RIC applied 
before,168, 169, 176 during,173 and after the index ischaemia,166, 175 thereby improving its 
clinical utility and potential to mitigate IRI in patients. 
A recent clinical study has also examined the combination of RIC with mechanical 
IPostC. The LIPSIA CONDITIONING trial was a prospective, controlled, single-centre 
study of 696 STEMI patients undergoing PPCI.177 The primary endpoint was 
myocardial salvage index assessed by cardiac magnetic resonance (CMR) 3 days after 
MI, which was significantly greater in the combined RIC and IPostC group than in an 
unconditioned control group (P=0.02), although IPostC alone was no better than 
control. There was no difference in a combined clinical endpoint of death, re-
infarction and new congestive heart failure at 6 months, although diverging lines on 
the Kaplan Meier curve suggest this might have been significant with longer follow-
up. Interestingly, the authors did not include a RIC-only control group so it is unclear 
whether the benefit with RIC plus IPostC versus IPostC alone was entirely attributable 
to RIC or whether additive protection can be achieved with the combination. 
Large clinical endpoint studies have so far only been published in the context of RIC 
in cardiac surgery. Hausenloy et al. found no difference in the primary end point of 
death from cardiovascular causes, nonfatal MI, coronary revascularization or stroke 
at 12 months between the sham and RIC arms of the Effect of Remote Ischemic 
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Preconditioning on Clinical Outcomes in Patients Undergoing Coronary Artery Bypass 
Surgery (ERICCA) study.178 Similarly, Meybohm et al. found no difference between 
the sham and RIC arms with respect to the primary endpoint of death, nonfatal MI, 
stroke and acute renal failure up to 14 days in the Remote Ischaemic Preconditioning 
for Heart Surgery (RIP-HEART) study.179 Furthermore, neither study identified any 
effect of RIC on troponin release as a secondary endpoint. Some potential reasons 
for the discrepancy between pre-clinical studies and these large randomised 
outcome studies are addressed in Chapter 3. Regarding STEMI, two randomised, 
multi-centre, controlled trials of RIC are currently recruiting, and the results are 
eagerly anticipated (ERIC-PPCI NCT02342522 and CONDI2 NCT01857414).180 
It is suggested that the protective effect of RIC may be due to a humoral factor(s), 
which may be one, or a combination of, the factors described above, or a novel 
molecule(s), which is carried by the blood from the transiently ischaemic limb to the 
remote target organ where it activates endogenous pro-survival signalling pathways. 
Evidence for this comes from studies wherein the cardioprotective effect of RIC 
applied to the lower limb is abrogated by occlusion of the femoral vein.181 Further, IS 
is significantly reduced when the effluent from an isolated perfused heart that is 
preconditioned is used to perfuse a second isolated heart prior to index ischaemia.182, 
183 The endogenous pro-survival signalling pathways in RIC remain poorly described 
and are assumed to be similar to those that mediate local IPC. The limited evidence 
to date has implicated PKC,184, 185 the RISK pathway,186-188 eNOS,189 and HIF-1α,190, 191 
with sarcolemmal and mitochondrial KATP channels their proposed targets.174, 192, 193 
Interestingly, there also appears to be a neural component to RIC whereby severing 
the femoral and sciatic nerve in an in vivo mouse model of IRI abolishes the protection 
conferred by RIC, although the relationship between neural and humoral 
components of this phenomenon is debated.181 It has recently been demonstrated 
that targeted inhibition of pre-ganglionic neurones in the dorsal motor nucleus of the 
vagus nerve, which generate parasympathetic tone, completely abolishes RIC.194, 195 
Furthermore, Mastitskaya and colleagues recently denervated various organs by 
sectioning specific branches of the vagus nerve, prior to RIC.196 They found that RIC 
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was abolished by total subdiaphragmatic, gastric or posterior gastric vagotomy, but 
not coeliac, hepatic or anterior gastric branches, implicating a cardioprotective factor 
released from the stomach, proximal duodenum, jejenum or pancreas. Interestingly, 
studies have successfully used plasma dialysate from preconditioned animals to 
protect both isolated, denervated hearts and cardiomyocytes, suggesting that 
neuronal involvement may be limited to the release of the humoral factor(s) and not 
necessary for signal transduction or distant cardioprotection.28, 197 The neural 
hypothesis is of considerable interest in the RIC field, but was not specifically 
examined in this thesis. 
1.4.4 SDF-1α and remote ischaemic conditioning 
The rationale for considering SDF-1α as part of this mechanism is fivefold. Firstly, the 
SDF-1α-CXCR4 axis has been implicated in RIC, albeit indirectly, using ex vivo 
models.31 Secondly, SDF-1α is an 8 kDa peptide, therefore fulfilling size criteria for a 
role in RIC.33 Thirdly, SDF-1α expression has been reported in several organs, tissues 
and cells, including bone marrow, liver, kidney, thymus, spleen, skeletal muscle, brain 
and, more recently, platelets.18, 41-44 Although it is likely that organ expression, in part, 
reflects expression in the vascular endothelium, it is likely that SDF-1α can be 
upregulated in peripheral tissues following the application of non-injurious ischaemia 
and reperfusion. Fourthly, SDF-1α-CXCR4 expression is upregulated in response to 
tissue hypoxia, via up-regulation of the transcription factor HIF-1α.17, 18, 63 This 
complements the hypothesis that the humoral factor involved in RIC is upregulated 
in response to cyclical, non-lethal, ischaemia (tissue hypoxia)-reperfusion, although 
it is unclear whether increased SDF-1α transcription via up-regulation of HIF-1α 
would be quick enough to explain RIC. Finally, SDF-1α is highly conserved (more than 
92% similarity at the protein level) between species and has been shown to confer 
protection between species.28, 38 
Despite this promise, an important drawback is the relatively short plasma half-life of 
SDF-1α, which might limit its therapeutic utility.51, 198 An approach to translating the 
potential of SDF-1α relates to its possible manipulation by a new class of anti-diabetic 
drugs. DPP4 inhibitors such as Sitagliptin, Vildagliptin, Alogliptin and Saxagliptin, have 
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been designed to prevent the breakdown of the incretin glucagon-like peptide-1 
(GLP-1) by inhibiting the protease DPP4 thereby increasing insulin and lowering 
glucose.199 Active SDF-1α is also cleaved by DPP4 at its position 2 proline residue, and 
thus, similar to GLP-1, DPP4 inhibition increases the half-life of SDF-1α by preventing 
its degradation.200, 201 This is discussed in more detail in Chapter 7. 
1.5 Research Objectives 
With this background in mind, the overall hypothesis of this project was that SDF-1α-
CXCR4 mediates the mechanism of cardioprotection conferred by RIC. The principle 
objectives are outlined below and described in detail in the chapters that follow: 
1. To perform a systematic review and meta-analysis of experimental variables 
in in vivo models of RIC. This objective is described in Chapter 3. 
2. To establish and verify murine in vivo models of myocardial IRI and RIC. This 
objective was investigated in both rats and mice, and is described in Chapter 
4. 
3. To investigate the cardioprotective utility of exogenous SDF-1α. This objective 
was investigated in a mouse model of myocardial IRI, and is described in 
Chapter 5. 
4. To investigate whether the SDF-1ɑ receptor blocker AMD3100 abrogates the 
cardioprotective effect of RIC. This objective was investigated in a rat model 
of myocardial IRI, and is described in Chapter 6. 
5. To investigate whether RIC increases the production of SDF-1α. This objective 
was investigated using an ELISA to the active (full-length) form of SDF-1α in a 
rat model of RIC, and is described in Chapter 7. 
6. To investigate whether RIC remains effective in cardiomyocyte CXCR4 null 
mice. This objective was investigated in a mouse model of myocardial IRI, and 
is described in Chapter 8.  
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Chapter 2 General research methods 
This chapter describes the general methods used throughout this thesis, with specific 
experimental details described in the relevant chapters that follow. All chemicals 
were from Sigma-Aldrich (Dorset, UK) and all antibodies from Abcam (Kent, UK) 
unless specifically stated. 
2.1 Experimental use of animals 
All use of animals was in accordance with the United Kingdom (Scientific Procedures) 
Act of 1986 and Amendment Regulations 2012, and local guidelines. All experiments 
were performed under Project Licence (PPL) 70/7140 prior to 3rd August 2015 and 
70/8556 thereafter. Animals were housed in 12 h light/dark cycles under pathogen-
free conditions. Standard chow and water were provided ad libitum and the 
temperature was maintained at 21⁰C. All routine care was provided by the Biological 
Services Unit (BSU) at University College London (UCL, UK). Experiments were 
performed in line with best practice described in the Home Office Licensee Training 
Course Modules 1-4 with further reference made to Laboratory Animal 
Anaesthesia.202 Each animal was inspected prior to use and any showing adverse 
features, including reduced weight gain, piloerection and hunching, were excluded 
from experiments. 
2.2 Standard rat strains 
Founder Sprague Dawley rats were purchased from Harlan Laboratories (Oxon, UK) 
and a colony subsequently maintained by the BSU (UCL, UK). Historically, Sprague 
Dawley is the strain of rat most commonly used for MI experiments,203 and is the 
strain used here due to cost and experience within our laboratory. This is discussed 
further in section 4.3.4. Male rats weighing 200-250 g were used throughout. 
2.3 Transgenic mouse lines 
Transgenic mouse lines were necessary for this thesis and the general method of their 
use is given here. 
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2.3.1 Generation of transgenic mice 
‘Floxed’ CXCR4 transgenic mice were generated externally by Dr Dan Littman, 
Columbia University, NY, USA using standard methods that are described 
elsewhere.204-207 Briefly, a targeting vector that is complementary to CXCR4, 
containing two loxP sites and a neomycin cassette either side of CXCR4 exon 2 (loxP 
sites flank CXCR4 exon 2, which is therefore referred to as ‘floxed’), was constructed. 
This was introduced into 129P2/OlaHsd-derived E14 embryonic stem cells (ES) 
causing homologous recombination and insertion of the targeted construct in place 
of the endogenous CXCR4 exon 2, which contains over 90% of the translated 
sequence.207  The loxP sites are 34 base pair (bp) sequences that allow DNA 
modification by Cre recombinase enzyme (Cre; Figure 2-1). The specific orientation 
of loxP sites relative to each other dictates whether Cre catalyses excision, inversion 
or integration of the target gene.208 In the present study, the loxP sites catalyse CXCR4 
exon 2 excision. The neomycin cassette confers neomycin resistance, which is 
exploited by treating ES with neomycin to remove untargeted cells. Mutant cells are 
injected into wild type blastocysts to generate chimeric progeny that are used, in 
turn, to produce mice that are heterozygous for the floxed CXCR4 allele, and the 
subsequent CXCR4flox/flox colony. This strain was backcrossed 18 times to a C57BL/6N 
genetic background and a breeding pair was imported into our facility from The 
Jackson Laboratory (ME, USA). 
Abbreviations used to describe genotypes throughout this thesis are as follows: wild 
type (WT, +/+); heterozygous (HET, +/-); knockout or mutant (KO, -/-); and 
homozygous loxP site insertion (flox/flox). 
2.3.2 Cardiomyocyte-specific gene ablation 
Transgenic mice expressing Cre recombinase were generated in a similar way to 
CXCR4flox/flox mice, described above. However, to investigate tissue-specific effects of 
CXCR4 deletion, Cre-driven recombination may be spatially regulated using upstream 
tissue-specific promoters.208 Therefore, in this case the Cre transgene was designed 
with an upstream mouse cardiomyocyte-specific alpha-myosin heavy chain promoter 
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(MYH6), which limits Cre-induced recombination of loxP-flanked sequences to 
cardiomyocytes. The transgene was injected into FVB/N embryos and the resulting 
progeny used to generate mice that are heterozygous for the Cre allele.209 
Furthermore, transgenic homozygote mice lacking CXCR4 die in utero,57 so it is 
necessary to temporally regulate Cre expression. This can be achieved by fusing Cre 
with ligand-dependent proteins.208 In this case, Cre is fused with two mutant murine 
oestrogen receptor (Mer) ligand-binding domains that are activated by the 
oestrogen-receptor antagonist tamoxifen but not by endogenous 17β-estradiol. 
Once activated, MerCreMer enters the cell nucleus from the cytoplasm to effect 
CXCR4 exon 2 excision,210 which results in a cardiomyocyte-specific knockout mouse. 
 
Figure 2-1: Inducible cardiomyocyte-specific CXCR4 exon 2 deletion 
(A) MerCreMer gene product expression is spatially regulated by the MYH6 promoter; (B) 
Once bound to tamoxifen, MerCreMer protein migrates into the cell nucleus; (C) MerCreMer 
affects excision of CXCR4 exon 2, which is flanked by loxP sites; (D) This results in a 
cardiomyocyte-specific CXCR4 knockout strain. 
MYH6-MerCreMer transgenic mice were backcrossed 15 times to a (B6 x 129/Sv)F1 
background and >9 times onto a C57BL/6J background prior to being imported into 
our facility from The Jackson Laboratory (ME, USA). They have subsequently been 
backcrossed for several generations onto a C57BL/6 background in our laboratory. All 
backcrossing was completed by other members of our research group. 
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MYH6-MerCreMer mice were crossed with CXCR4 floxed mice, resulting in an 
inducible, cardiomyocyte-specific CXCR4 null bitransgenic strain. 
2.3.3 Colony maintenance 
First, CXCR4flox/flox mice were bred in a ratio of 1:1 with heterozygous MYH6-
MerCreMer mice to yield CXCR4flox/+, including 50% wild type and 50% heterozygous 
Cre mice. Then, CXCR4flox/+ Cre+/- mice were bred with CXCR4flox/+ Cre+/+ mice to yield 
25% CXCR4flox/flox, 50% CXCR4flox/+ and 25% CXCR4+/+, 50% of which were Cre+/-, as 
expected by Mendelian inheritance. The colony was then maintained as follows: all 
mice were CXCR4flox/flox; heterozygous and wild type Cre transgenic mice were bred 
in a ratio of 1:1, to yield 50% wild type and 50% heterozygous Cre mice. 
The Cre transgene is maintained as heterozygous for three reasons; firstly, it is 
difficult to distinguish heterozygosity from homozygosity by PCR as the precise 
insertion site of the transgene is unknown; secondly, as the Cre transgene can cause 
deletion of the gene into which it inserts, it is desirable to maintain a wild type allele; 
and thirdly, it is preferable that all mice express the minimal sufficient levels of Cre 
recombinase to avoid unwanted effects of over-expression, including 
cardiomyopathy.211 
Breeding pairs were taken from different parents and females were allowed a 
maximum of five litters. All litters were weaned at 3-4 weeks old. The genotype of 
each animal was determined by PCR prior to experimentation as described below. 
2.3.4 Genotyping 
Mouse biopsies: Ear biopsies were taken from each mouse shortly after weaning (at 
approximately 3-4 weeks old) and labelled to facilitate matching of genotype to 
mouse. All ear biopsies were taken by BSU technical staff. 
Preparation of crude DNA lysates: Ear biopsies were lysed within 1 h of collection to 
obtain template DNA. Ear biopsies were incubated in 150 µl Proteinase K (Qiagen, 
Lancs, UK) and DirectPCR Ear Lysis Reagent (Viagen Biotech, CA, USA) at a ratio of 
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1:10 at 50⁰C in a heating block overnight. Lysis was terminated by incubation at 85⁰C 
for 45 min to 1 h, to denature Proteinase K. Lysates were then mixed and stored at -
20⁰C for a maximum of 1 week until their use for PCR and until the end of the study 
thereafter. 
Primer design: The region of DNA to be amplified by PCR is defined using specific 
primers. For example, CXCR4 primers bind either side of the loxP site upstream of 
exon 2 to detect wild type or loxP inserted CXCR4.207 Primers are short lengths of DNA 
that are complementary to the template DNA, bind following separation of the 
double-stranded (ds) DNA (denaturing), and serve as a starting point for replication 
and amplification, described below. The optimum DNA sequence and melting 
temperature (Tm) for primers used in genotyping were defined by The Jackson 
Laboratory (ME, USA) in the case of CXCR4 and were already established by our own 
laboratory in the case of MYH6-MerCreMer (described in Table 2-1). Primers were 
purchased from Eurofins Genomics (Ebersberg, Germany) and were diluted to 100 
pmol/µl in autoclaved distilled water on arrival. 
Primer Sequence (5’→3’) Properties 
Length Tm (⁰C) 
CXCR4 loxP forward CCACCCAGGACAGTGTGACTCTAA 24 64.4 
CXCR4 loxP reverse GATGGGATTTCTGTATGAGGATTAGC 26 61.6 
MYH6-MerCreMer 
forward 
ATCGGAAAAGAAAACGTTGA 20 51.1 
MYH6-MerCreMer 
reverse 
ATCCAGGTTACGGATATAGT 20 53.2 
Table 2-1: PCR primer sequences 
PCR primer sequences, length and melting temperature (Tm). 
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Amplification of DNA by PCR: DNA was amplified by PCR to determine the genotype 
of each animal. A commercially available DNA polymerase kit (Taq DNA Polymerase 
Kit, Qiagen, Lancs, UK) was used for all reactions. In this kit, Taq DNA polymerase, a 
recombinant enzyme, catalyses the replication and amplification of a specific region 
of DNA by assembling deoxyribose nucleoside triphosphates (dNTPs).  
Reagent Volume per sample (µl) Final concentration 
Qiagen 10X PCR Buffer 2.0 1X 
10 mM dNTPs 0.4 200 µM of each dNTP 
Forward primer 0.5 1.25 pM 
Reverse primer 0.5 1.25 pM 
Taq DNA polymerase 0.2 - 
Autoclaved distilled 
water 
15.4 - 
Template DNA 1.0 - 
Total volume per sample 
(µl) 
20  
Table 2-2: PCR reaction mix 
A master mix was prepared on ice according to Qiagen (Lancs, UK) guidelines and the 
composition given here. 1x Qiagen PCR buffer contains 1.5 mM Mg2+.  
Specifically, PCR reactions were performed by preparing a master mix of constituents 
from the Taq DNA Polymerase Kit (Qiagen, Lancs, UK). The same master mix 
composition, with the exception of different primers, was used in reactions for CXCR4 
loxP and MYH6-MerCreMer. A fresh master mix was made for each experiment (see 
Table 2-2). The volume of master mix was enough for a negative control (without 
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template DNA) and accounted for 10% extra PCR assays than required. The PCR 
Buffer contains a red and orange marker dye that facilitated estimation of migration 
distance during electrophoresis. 1 µl of the template DNA was added to each PCR 
tube. A negative control, with autoclaved distilled water in place of template DNA, 
was included in all experiments to exclude DNA contamination. 
After preparation, all PCR tubes were added to a thermal cycler with a heated lid (PTC 
200 Thermal Cycler, MJ Research, Quebec, Canada) and the reaction run using a 
touchdown technique as described in Table 2-3. Touchdown PCR overcomes any 
uncertainty associated with calculating primer Tm by beginning with an annealing 
temperature above the projected Tm of the primer (see Table 2-1) and using 
successively lower temperatures with each cycle.212 Ordinarily, it is possible to 
achieve highly specific binding of the primer to the DNA sequence of interest by 
annealing at a temperature just below the Tm of the primer. Touchdown PCR 
facilitates this highly specific binding at the first permissive temperature, and 
subsequent cycles use incrementally lower annealing temperatures to increase the 
efficacy of the reaction. By doing so, any difference in Tm between correct and 
incorrect annealing will create a fourfold advantage per ⁰C, thereby avoiding non-
specific binding at lower annealing temperatures.212 The sequences of interest out-
compete non-specific sequences that might otherwise bind to the primer at these 
lower temperatures, resulting in increased specificity, sensitivity and yield without 
the need for primer optimisation.212 Touchdown PCR was used for CXCR4 loxP and 
MYH6-MerCreMer PCR. 
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PCR stage Temperature and duration Description 
5 cycles: 
1 94⁰C for 30 sec DNA denaturing 
2 65⁰C for 30 sec, decreasing by 1⁰C per cycle until 
61⁰C 
Primer annealing 
3 72⁰C for 1 min DNA synthesis 
Then 40 cycles: 
16 94⁰C for 30 sec DNA denaturing 
17 60⁰C for 30 sec Primer annealing 
18 72⁰C for 1 min DNA synthesis 
Followed by 4⁰C until collection 
Table 2-3: Touchdown PCR thermocycling protocol 
Touchdown PCR was performed using a thermal cycler (PTC 200 Thermal Cycler, MJ Research, 
Quebec, Canada). 
Visualisation of DNA products by gel electrophoresis: PCR amplification produces 
products of a distinct size, defined in base pairs. This can be visualised by separating 
PCR products using agarose gel electrophoresis, whereby negatively charged 
products migrate through the gel upon the application of electrical charge and 
smaller products migrate further. In this case, 2% agarose gels were used to optimise 
separation. These were prepared using agarose (Thermo Fisher Scientific, MA, USA) 
in TAE buffer (Tris 40 mM, acetic acid 20 mM and EDTA 1mM). 0.001% Syto® 60 Red 
Fluorescent Nucleic Acid Stain (Thermo Fisher Scientific, MA, USA) was added to allow 
visualisation of DNA bands after fluorescent scanning. Gel electrophoresis was run in 
TAE buffer (constituted as above) in a Owl Easycast B2 Mini Gel Electrophoresis 
System (Thermo Fisher Scientific, MA, USA) set at 118 V for 40-50 min. The 
approximate migration distance was determined using the dyes contained within the 
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PCR Buffer, and electrophoresis was ceased when the leading edge reached 
approximately 75% of the available gel distance. Gels were subsequently scanned 
using the 700 nm laser of an Odyssey® Infrared Imaging System (LI-COR, Bad 
Homburg, Germany). 
PCR product size was estimated by comparison to a standard GelPilot® 100 Base Pair 
Plus Molecular Weight Marker (Qiagen, Lancs, UK). The genotype of each animal was 
determined by comparing the PCR result with expected DNA bands for each 
genotype. Expected DNA product sizes for CXCR4 loxP and wild type mice were 550 
bp and 481 bp, respectively. MYH6-MerCreMer+/- mice were expected to have a band 
of 650 bp, whilst wild types had no band. PCR products for all genotypes used in this 
thesis were reliably clear and easy to interpret using this protocol. Representative 
PCR results are shown in Figure 2-2. 
 
Figure 2-2: Transgenic mouse colony representative genotyping results 
Each animal was genotyped based on the presence or absence of PCR products. (A) CXCR4 
loxP wild type (WT) animals were expected to have a 481 bp band and mutant animals 
(flox/flox) a 550 bp band. Heterozygous (HET) animals were expected to have both; (B) 
MYH6-MerCreMer heterozygous (HET) animals were expected to have a 650 bp band and 
wild type (WT) animals no band. 
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2.3.5 Tamoxifen dosing 
As discussed above, it is necessary to exploit the fusion of Cre with tamoxifen- or 4-
hydroxytamoxifen-dependent proteins to temporally regulate Cre expression and 
avoid in utero death of mutated progeny. In the absence of tamoxifen or 4-
hydroxytamoxifen, the Cre protein remains in the cytoplasm. Once activated, Cre 
translocates to the cell nucleus to effect loxP-mediated CXCR4 exon 2 excision.210 
The tamoxifen administration protocol is well established within our laboratory, and 
is as follows. Tamoxifen was freshly prepared for each study by dissolution in 9 parts 
corn oil and 1 part 100% ethanol vehicle, to a final concentration of 5 mg/ml. This 
preparation was agitated at 37⁰C for 1 h to ensure full dissolution, and stored at 4⁰C 
between injections for a maximum of 5 days. Tamoxifen solution was administered 
as an intraperitoneal bolus daily for 5 consecutive days, at a dose of 20 mg/kg, in mice 
between 4 and 10 weeks old.209, 213 All mice weighed approximately 25 g, indicating 
a final volume of 100 µl. Animals were monitored closely for 30 min afterwards due 
to an expected mortality rate of 10-20% due to acute tamoxifen toxicity. Tamoxifen-
associated mortality was no higher in this thesis than expected (1/16, or 6.25%). 
Tamoxifen administration was performed at the same time each day to reduce 
confounding variables between groups. Mice were left for 3 weeks after completion 
of tamoxifen dosing prior to experimentation to ensure loss of protein. 
2.3.6 Experimental groups 
All offspring (CXCR4flox/flox, Cre+/+ and Cre+/-) were injected with tamoxifen as 
described, resulting in 50% of animals with deleted CXCR4 and 50% wild type control 
littermates. This approach was intended to abrogate the reported confounding 
effects of tamoxifen administration, which are discussed further in section 8.4.4. Use 
of littermate controls also minimised potential confounding from genetic drift of in-
bred colonies over time. All experiments were performed in male and female 
littermates aged 8-16 weeks old, unless specifically stated, with the upper limit 
imposed because of the susceptibility of the C57BL/6 background strain to develop 
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age-related obesity, type 2 diabetes and atherosclerosis.214 Specific experimental 
groups used for each experiment are described in the relevant chapters. 
2.4 In vivo non-recovery model of myocardial ischaemia-reperfusion injury 
This thesis describes the validation and characterisation of rat and mouse in vivo non-
recovery models of myocardial IRI. An overview of the method is given here, with 
detailed description of its characterisation and validation provided in sections 4.3 and 
4.4, respectively. 
2.4.1 Surgical protocol (rat) 
Rats were anesthetised by left upper quadrant intraperitoneal injection of 100 mg/kg 
pentobarbitone sodium (Animalcare, Yorks, UK) at a concentration of 200 mg/ml, 
with a top-up dose of 25 mg/kg pro re nata. Surgery was started once pedal and tail 
reflexes were abolished, and depth of anaesthesia was monitored throughout the 
procedure. 
After using tape to secure the animal in a supine position with limbs abducted, a loop 
of 5-0 suture (Ethicon, C of Edin, UK) was used around the upper incisors to secure 
the head in an extended position. Animals were subsequently intubated using cold 
light trans-illumination of the trachea (Photonic Optics PL2000, Oxon, UK), 200 mm 
angled dissecting forceps (all instruments from B. Braun (PA, USA) unless otherwise 
stated), and a modified 16G, 1.7 x 51 mm Abbocath-T intravenous cannula (Smiths 
Medical International Ltd, Kent, UK). Positive pressure ventilation was provided via 
connection to either a PhysioSuite (Kent Scientific, CT, USA) or Small Animal 
Ventilator (Harvard Apparatus, Kent, UK), supplemented with oxygen at a flow rate 
of 0.5 L/min. Correct intubation was confirmed by observation of chest expansion, 
appropriate airway pressure trace and tidal volume (PhysioSuite only), and the 
observation of gas bubbles from the ventilators’ submerged expiratory tubing (Small 
Animal Ventilator only). Tidal volumes were calculated using the following allometric 
formula: tidal volume = 7.2 ml/kg.215 The allometric formula for ventilation rate, 
provided by the ventilator manufacturer (Kent Scientific, CT, USA), is: 
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53.5 x (Body weight in kg)-0.26 
 
Figure 2-3: Surgical setup for rat in vivo model of myocardial ischaemia-reperfusion injury 
Surgeries were conducted in tandem using the following arrangement (suppliers stated in 
the text): (A) Rectal temperature sensor to animal 1; (B) Animal 1; (C) Homeothermic heat 
mat 1; (D) Lead wires to Animal Bio Amp from animal 1; (E) Inspiratory and expiratory tubing 
to PhysioSuite; (F) PhysioSuite; (G) Rectal temperature sensor to animal 2; (H) Lead wires to 
Animal Bio Amp from animal 2; (I) Animal 2; (J) Homeothermic heat mat 2; (K) Inspiratory 
and expiratory tubing to Small Animal Ventilator; (L) Cold light source. 
2 cmH2O of positive end expiratory pressure (PEEP) were added automatically 
(PhysioSuite) or by submersion of the expiratory tubing in water. This is important to 
prevent lung collapse during open chest surgery, and 1-5 cmH2O are recommended 
for small animals.215 Surgeries were conducted in a controlled environment with 
regulated room temperature (19-21⁰C). Core body temperature was monitored via a 
rectal temperature sensor and maintained at 37±0.5⁰C by adjustment of a 
homeothermic heat mat (Kent Scientific, CT, USA or Harvard Apparatus, Kent, UK). 
ECG was recorded throughout using PowerLab 4/25 and Animal Bio Amp coupled to 
Chart 7 (AD Instruments, Oxon, UK; Figure 2-3 demonstrates the surgical setup). 
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Figure 2-4: Main stages of the rat in vivo myocardial ischaemia-reperfusion injury 
procedure 
The main procedural stages are: (A) Tracheal intubation and connection to a ventilator; (B) 
After shaving the left lateral hemithorax, skin incision and retraction reveals the pectoral 
muscles; (C) Sharp dissection of the pectoral muscles reveals the fourth intercostal space; (D) 
The intercostal space is opened by blunt thoracotomy and the ribs retracted; (E) After 
removal of the pericardium, the LAD is under-run with 6-0 suture with loops on either end to 
facilitate reperfusion. Once tightened the suture is secured with counterweights; (F) 
Following reperfusion the heart is eviscerated via a bilateral anterior (clamshell) 
thoracotomy. 1 cm scale bar. 
The left thorax was shaved to facilitate surgery and a skin incision was made in the 
left lateral position, 1 cm below the forelimbs (Figure 2-4). Superficial muscles were 
sharp dissected. Blunt thoracotomy of the left fourth intercostal space was 
performed in order to gain access to the thoracic cavity. The pericardium was torn 
with splinter forceps. The LAD was under-run with a 6-0 braided silk non-absorbable 
suture with 9.3 mm, 3/8 curved needle (Ethicon, C of Edin, UK) positioned 
approximately 2 mm below the tip of the left atrium. After passing loops of 3-0 
braided silk (Ethicon, C of Edin, UK) over each arm of the suture to facilitate 
reperfusion, ischaemia was initiated by occlusion of the ligating suture. 
Successful ischaemia was confirmed by the occurrence of ST-segment elevation in 
the EGC trace (Figure 2-5), myocardial blanching and hypokinesia of the anterior wall 
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of the heart. Ischaemia, as indicated by ST-segment elevation, was maintained using 
surgical clamps as ballast on each end of the ligating suture. Following 30 min of 
ischaemia, reperfusion of the LAD territory was initiated by release of the occluding 
suture, which was left in place to facilitate subsequent analysis, and successful 
reperfusion confirmed by reversal of the ST-segment elevation and myocardial colour 
change. During ischaemia and reperfusion, the open wound was covered by a 
moistened swap to prevent desiccation and heat loss. 
 
Figure 2-5: Typical ECG changes seen during rat in vivo model of myocardial ischaemia-
reperfusion injury 
The typical sequence of ECG changes includes: (A) Baseline; (B) ST segment depression; (C) 
ST segment elevation (moderate); (D) ST segment elevation (severe); (E) Broad QRS 
complexes in early reperfusion; (F) Q-wave formation. 
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Figure 2-6: Staining of a rat heart with Evans blue to define area at risk 
Each extracted heart was arrested in ice-cold Krebs-Henseleit buffer and subsequently 
rapidly mounted and secured onto a suspended cannula. Hearts were retrogradely perfused 
with Krebs-Henseleit buffer warmed to 37⁰C (A) and the loosed LAD suture secured (B). 
Hearts were then retrogradely perfused with 0.5% Evans Blue to define the AAR (C). The area 
not at risk (Evans Blue area) is graphically represented in blue (blue arrow), whilst the 
remainder constitutes the AAR (pink arrow). After freezing, each heart was sliced into five 
transverse sections, indicated by the dashed lines. 
Following 2 h of reperfusion animals were extubated and eviscerated. A clam-shell 
thoracotomy with cranial reflection of the anterior rib cage was performed, and 
pericardial adhesions removed (Figure 2-4). The aorta was transected at the level of 
the arch. The heart was arrested by submersion in cold Krebs-Henseleit buffer (NaCl 
118.5 mM, NaHCO3 25.0 mM, KCl 4.8 mM, MgSO4 1.2 mM, KH2PO4 1.2 mM, CaCl2 1.7 
mM and glucose 11.0 mM). The heart was subsequently cannulated via the aorta, 
secured using 3-0 braided silk suture (Ethicon, C of Edin, UK) and retrogradely 
perfused with warm Krebs-Henseleit buffer in order to flush out any residual blood 
(Figure 2-6). The LAD suture was tied securely and approximately 500 µl 0.5% Evans 
Blue die retrogradely perfused through the same cannula to delineate an area at risk 
(AAR), whereby all areas of myocardium that were perfused during the index 
ischaemia are stained blue. Samples were labelled with a randomly-allocated four 
digit number to ensure operator blinding, and frozen for a minimum of 2 h at -20⁰C. 
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IS was assessed within 5 days of freezing the sample, as described in section 2.4.4. 
The characterisation and validation of this model is described in detail in section 4.3. 
2.4.2 Surgical protocol (mouse) 
This model was based on the in vivo surgical protocol for rats, described in section 
2.4.1, with relevant differences described here and further reference made to the 
description of this model by Fisher and Marber.216 
Mice were anesthetised by intraperitoneal injection of 100 mg/kg pentobarbitone 
sodium (Animalcare, Yorks, UK) at a concentration of 20 mg/ml in 0.9% (w/v) saline, 
with a top-up dose of 17 mg/kg pro re nata. Surgery was started once pedal and tail 
reflexes were abolished and depth of anaesthesia was monitored throughout. 
 
Figure 2-7: Orotracheal intubation of mice was performed under direct visualisation 
(A) The salivary muscles were divided to expose the sternothyrohyoideus muscles overlying 
the trachea, which were subsequently blunt dissected in the midline to expose the trachea 
(arrowed); (B) A 19G cannula attached via a plastic Y-connector to the ventilator was passed 
down the trachea (arrowed) under direct visualisation. 1 cm scale bar. 
All surgical procedures were performed using a standard binocular surgical 
microscope (EMX, Meiji Techno, Somerset, UK) at 5 times magnification. A midline 
skin incision was made over the anterior neck, and the salivary muscles were divided 
to expose the sternothyrohyoideus muscles overlying the trachea. These were bluntly 
dissected in the midline and retracted (Figure 2-7). A 19G cannula attached via a 
plastic Y-connector to the ventilator was passed, via the mouth, down the trachea 
under direct visualisation to prevent inadvertent oesophageal intubation. Positive 
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pressure ventilation was provided via connection to a PhysioSuite (Kent Scientific, CT, 
USA) without supplementary oxygen. 
In mouse experiments, core body temperature was monitored using a rectal 
temperature probe (Hanna Instruments, Beds, UK) and maintained at 37±0.5⁰C by 
adjustment of a heated veterinary operating mat (Peco Services, Cumbria, UK) Figure 
2-8 demonstrates the surgical setup. 
 
Figure 2-8: Surgical setup for mouse in vivo model of myocardial ischaemia-reperfusion 
injury 
Surgeries were conducted on one mouse at a time using the following arrangement 
(suppliers stated in the text): (A) Rectal temperature sensor to animal; (B) Animal; (C) 
Homeothermic heat mat; (D) Lead wires to Animal Bio Amp from animal; (E) Inspiratory and 
expiratory tubing to PhysioSuite; (F) PhysioSuite; (G) Cold light source; (H) Vivid i ultrasound 
system. 
Following intubation and stabilisation, hair was removed from the left thorax using a 
depilatory cream (Veet, Reckitt Benckiser, Berks, UK), to facilitate echocardiography 
and surgery. Mice were subjected to transthoracic echocardiography (TTE) 
assessment, as described in section 2.4.6. Then, to facilitate visualisation of the LAD, 
the left hind limb was adducted over the midline and secured. A left antero-lateral 
oblique skin incision was made using ligature scissors. The left major and minor 
pectoral muscles overlying the fourth intercostal space were blunt dissected and 
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retracted with blunt hook stays. Thoracotomy of the space, and cauterisation of any 
bleeding vessels, was performed with diathermy to the mid-clavicular line (Change-
A-Tip cautery handle, Bovie Medical, NY, USA), taking care not to injure the 
underlying viscera. The wound was opened using hook stays. As in the rat model, the 
pericardium was torn with splinter forceps. 
In the mouse model, the LAD was under-run with an 8-0 polypropylene non-
absorbable monofilament suture with 6.5 mm, 3/8 curved needle (Ethicon, C of Edin, 
UK) positioned approximately 2 mm below the tip of the left atrium. The LAD was 
identified according to its anticipated position and bright orange appearance. A short 
piece of polyethylene tubing (PE-50, Deutsch and Neumann, Berlin, Germany) was 
secured to the end of the suture and used to assemble a snare system for reversible 
occlusion of the LAD. This was secured with further pieces of PE-50 tubing and a 
modified P200 pipette tip (Figure 2-9). 
 
Figure 2-9: Left anterior descending 
coronary artery snare system used for 
reversible occlusion in mice 
An 8-0 polypropylene suture (A) secured 
at one end to polyethylene tubing (B) and 
passed beneath the LAD. The suture was 
passed back through the tubing and 
through a modified pipette tip (C). It was 
secured using ‘brake’ tubing (D) and the 
whole construction advanced onto the 
LAD (indicated by the arrow) to induce 
ischaemia. A further piece of tubing was 
placed above the LAD to prevent slicing of 
the myocardium (E). 
Ischaemia, as indicated by ST-segment elevation, was maintained for 40 min before 
reperfusion was induced by releasing the ‘brake’ tubing and disassembling the snare 
system. The suture was left in place to facilitate subsequent analysis. After 2 h of 
reperfusion, a repeat echocardiogram was performed and the heart was immediately 
removed. Hearts were prepared in the same way as described in section 2.4.1, with 
the exception that the aorta was secured on the cannula using a 5-0 braided silk 
suture (Ethicon, C of Edin, UK), 200 µl Evans blue dye was perfused under running 
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water, samples were frozen for 20 min at -80⁰C, and staining for assessment of IS was 
performed on the same day (described in section 2.4.4). 
The characterisation and validation of this model is described in detail in section 4.4. 
2.4.3 Treatments and interventions 
Pharmacological treatment: Pharmacological treatments were administered as a 
single bolus using either the left or right lateral tail vein. Injection was aided by 
ensuring the animal’s tail was on the surgical heat mat beforehand and, in the case 
of mice, tightening a 5-0 braided silk suture (Ethicon, C of Edin, UK) tourniquet around 
the proximal tail, thereby causing venous dilatation and facilitating correct placement 
of the needle. Treatment was administered using a 25G x 5/8” Microlance needle 
(BD, Oxon, UK) for rats and the tip of a 27G x 1/22 needle (BD, Oxon, UK) mounted in 
0.4 x 0.8 mm fine bore polythene tubing (Smiths Medical, Kent, UK). Successful 
venous puncture was confirmed by flash-back of venous blood, and successful 
delivery of the treatment was confirmed by washout of blood in the tail vein. Animals 
were excluded from the study if successful delivery of the treatment could not be 
confirmed. Saline (0.9%, Animalcare, Yorks, UK) was administered as a vehicle control 
to ensure the process of injection or administration of volume did not confound the 
results. The dose, volume and timing of pharmacological treatments is given in the 
relevant sections. 
Ischaemic preconditioning: IPC describes cyclical non-injurious ischaemia and 
reperfusion in the same coronary distribution as the index, lethal IRI, and is a potent 
such strategy in all mammalian species.102, 217 As IPC applied to the LAD is both 
effective and surgically feasible, it is an ideal positive control. After 5 min 
stabilisation, animals were subject to 5 min LAD occlusion and 5 min reperfusion prior 
to 30 min index ischaemia, which is a well-validated protocol for both rats and mice 
in our laboratory.218, 219 Control animals were subjected to 15 min stabilisation to 
ensure equal anaesthetic times between groups (Figure 2-10). 
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Figure 2-10: Ischaemic preconditioning protocol 
(A) Control: 5 min stabilisation, 30 min ischaemia and 2 h reperfusion; (B) IPC: 5 min 
stabilisation, 1 cycle of 5 min ischaemia and 5 min reperfusion, 30 min ischaemia and 2 h 
reperfusion. Figure not to scale. 
Remote ischaemic conditioning: In rats, RIC was applied using a modified human 
digital/penile cuff (1.6 x 9 cm cuff; Hokanson, WA, USA) around the right hind limb, 
which was inflated to 200 mmHg using a standard sphygmomanometer. Ischaemia 
was indicated by cyanosis of the right hind limb (arrowed in Figure 2-11). In mice, a 6 
mm lumen custom vascular occluder (Kent Scientific, CT, USA) was similarly used 
around the right hind limb, but inflated to 250 mmHg with a standard 
sphygmomanometer. 
 
Figure 2-11: Hind limb remote ischaemic conditioning in rats 
A human digital cuff was adapted for use on a rat hind limb. This figure shows the cuff 
inflated. Ischaemia is indicated by pedal cyanosis (black arrow) compared to the contralateral 
limb. 1 cm scale bar. 
 63 
 
In both rats and mice, after 5 min stabilisation, three cycles of 5 min ischaemia and 5 
min reperfusion was applied in the RIC group prior to 30 min index ischaemia and 2 
h reperfusion. Control animals were subjected to 35 min stabilisation to ensure equal 
anaesthetic times between groups (Figure 2-12). 
 
Figure 2-12: Remote ischaemic conditioning protocol 
(A) Control: 35 min stabilisation, 30 min ischaemia and 2 h reperfusion; (B) RIC: 5 min 
stabilisation, three cycles of 5 min ischaemia and 5 min reperfusion, 30 min ischaemia and 2 
h reperfusion. Figure not to scale. 
2.4.4 Blood samples and preparation 
Blood samples from mice and rats were collected on ice into tubes containing 
Sitagliptin to inhibit DPP4 and prevent degradation of full-length SDF-1ɑ during 
sample preparation (equilibrium inhibition constant (Ki) 9 nM),52, 220 to give a final 
concentration of 50 µM. Tubes were also pre-loaded with 1x citrate buffer to prevent 
coagulation. Aspiration of blood was performed by puncture of the right ventricle 
(RV) after thoracotomy using a wide-bore needle (19G x 1.5” Terumo needle (Surrey, 
UK) for rats, 21G x 5/8” Microlance needle (BD, Oxon, UK) for mice) to avoid platelet 
activation and subsequent release of SDF-1α (this is discussed further in section 7.6). 
Samples were immediately centrifuged at 1,600 g for 20 min then 10,000 g for 30 min 
to obtain platelet-free plasma (PFP), and frozen at -80⁰C. Blood fractionation was 
performed according to previously published protocols without specific 
measurement of platelet numbers.221 All experimental samples were defrosted at 
room temperature (RT) and used immediately. 
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2.4.5 Endpoint 1: Evaluation of infarct size 
The primary endpoint of this in vivo model was myocardial IS. This is expressed as a 
percentage of the AAR (IS/AAR), that being the myocardial territory subject to 
ischaemia during LAD occlusion. The AAR was defined as described in section 2.4.1 
and myocardial IS was established by staining of the ex vivo heart with 
triphenyltetrazolium chloride (TTC), a method that has been validated against 
histological assessment of necrosis in the early phase after MI.222 After freezing, each 
heart was sliced into five 2 mm sections from the level of the LAD suture to the apex. 
These sections were incubated for 20 min in the dark in 10 ml phosphate buffer (2 
parts 100 mM monobasic sodium phosphate and 8 parts 100 mM dibasic sodium 
phosphate) and 1% TTC. TTC is reduced by intracellular dehydrogenases in living cells 
to produce red formazan pigments. In areas of infarction TTC remains white, thereby 
allowing living and infarcted myocardium to be distinguished. Following incubation, 
the TTC solution was removed and sections were fixed in 10% formalin for 1-2 h at 
RT for rat sections and 24 h for mouse sections. This also has the effect of turning red 
blood cells brown, thereby facilitating their distinction from healthy myocardium. 
Sections were subsequently scanned for analysis using an Epson scanner (Epson 
Perfection V100 Photo, Epson, Herts, UK) at 1200 dpi, 48 bit colour and 50% 
brightness, and analysed by planimetry using ImageJ (version 1.45s, National 
Institutes of Health, MD, USA) (Figure 2-13). Mean AAR for each group is reported 
alongside the relevant experimental result, and all AAR and IS data are presented in 
scatter plots to clearly demonstrate any outliers. 
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Figure 2-13: Quantifying area at risk and infarct size in a mouse heart by planimetry 
(A) A scanned transverse heart section; (B) The background image was removed; (C) The 
Evans Blue area was measured by adjustment of the manual threshold of the green channel 
image to match the original image; (D) Quantification of Evans blue area by counting the 
number of pixels; (E) The IS was quantified by adjustment of the manual threshold of the red 
channel image to match the original image; (F) Quantification of IS by counting the number 
of pixels. Total myocardial area was calculated using the green channel image (not shown). 
AAR was calculated as (myocardial area – Evans Blue area) / myocardial area. IS was 
expressed as a percentage of AAR. 
2.4.6 Endpoint 2: Echocardiographic assessment of left ventricular function 
The secondary endpoint of this study was LV function assessed by TTE. TTE has been 
well validated as a non-invasive means of assessing cardiac function after MI in 
mice.223 In mouse studies only, 2D TTE was performed on supine mice with hair 
removed, using a Vivid i ultrasound system with i12S-RS 11 MHz paediatric intra-
operative phased-array transducer (GE Healthcare, Herts, UK) and ultrasound 
transmission gel (Skintact, Fannin, Gloucs, UK). An image depth of 1.5 cm was used 
throughout, and width and gain setting were carefully adjusted to maximise frame 
rates. 
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Figure 2-14: Representative images from 2D trans-thoracic echocardiography of mice 
(A) Parasternal long axis view with measurement of the long axis end-diastolic dimension. A 
papillary muscle is arrowed; (B) Parasternal short axis view of the LV in diastole at papillary 
muscle (arrowed) level; (C) Parasternal short axis view of the LV in systole at papillary muscle 
(arrowed) level; (D) LV M-mode with measurement of LVIDd and LVIDs; (E) Aortic valve 
outflow, measured with CW Doppler; (F) demonstration of measurement of a VTI envelope. 
First, a 2 sec cine loop was acquired in the parasternal long-axis view before 
interrogating the aortic root with pulsed wave (PW) Doppler in the same view. 
Observed peak velocities were within the Nyquist limit for PW Doppler and therefore 
not subject to aliasing. The possibility of aliasing was further reduced as the angle of 
incidence is approximately 15⁰ to the direction of flow in this view. This risks 
underestimating aortic root Doppler parameters but has previously been published 
and should not vary between experimental groups.224, 225 Next, a 2 sec cine loop was 
acquired at papillary muscle level in the parasternal short-axis view and an M-mode 
trace recorded using the papillary muscles as a reference point. Representative 
images are provided in Figure 2-14. Frame rates for parasternal long axis, PW Doppler 
and M-mode images were 409.8 Hz, 129.9 Hz and 706.6 Hz, respectively. After 
surgery to induce IRI, a 6-0 braided silk non-absorbable suture (Ethicon, C of Edin, UK) 
was used to oppose the wound edges when necessary to facilitate echocardiography. 
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All measurements were made by a single observer and were the average of six 
consecutive cardiac cycles. Analysis was performed offline using EchoPAC (GE 
Healthcare, Herts, UK) according to the experiments’ four-digit number to ensure 
operator blinding. 
LV end-diastolic and end-systolic internal dimensions (LVIDd and LVIDs, respectively) 
were measured in Motion (M) mode (Figure 2-14, Panel D). M-mode 
echocardiography records motion along a single scan line (displayed on the y axis) 
over time (on the x axis). This narrow focus permits high frame rates (temporal 
resolution) and therefore accurate assessment of chamber dimensions. Temporal 
resolution was further improved using anatomical M-mode, which digitally derives 
M-mode analysis from 2D images and has the added advantage of allowing 
assessment along any line irrespective of transducer position, allowing the further 
optimisation of M-mode analysis.226 LVIDd and LVIDs were used to derive fractional 
shortening (FS), which is a surrogate of LV function, according to the formula: FS = 
LVIDd – LVIDs / LVIDd x 100. End-diastole and end-systole were defined visually in the 
absence of integrated ECG recording. 
LV end diastolic volume (EDV) was calculated according to the formula for a prolate 
spheroid, where volume = 4/3 x π x A2 x B.227 Here, ‘A’ represents the long axis end-
diastolic dimension (Figure 2-14, Panel A), recorded in the parasternal long axis view, 
and ‘B’ represents LVIDd. Aortic root velocity-time integral (VTI) was measured using 
the PW Doppler trace (Figure 2-14, Panels E-F) and used to determine stroke volume 
(SV; µl), where SV = VTI x cross-sectional area (CSA). Mice of this weight have been 
shown from aortic casts to have an aortic root diameter of 1.2 mm and therefore CSA 
was assumed to be 1.1 mm2 (according to πr2) for all animals.228 Cardiac output 
(ml/min) was calculated as a product of SV and heart rate, itself calculated by 
measuring the time between cardiac cycles in M-mode. 
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2.4.7 Experimental design 
Animals were randomly assigned a four-digit number that was used to perform a 
blinded assessment of outcome, unless specifically stated. There was no formal 
randomisation to experimental group or blinded application of treatment protocols. 
Pre-defined exclusion criteria were applied to ensure consistency. Firstly, animals 
were excluded if their core body temperature deviated by more than 1⁰C from the 
acceptable range of 37±0.5⁰C, and this is discussed in detail in section 4.4. Secondly, 
if satisfactory ischaemia (indicated by ST-segment elevation in the EGC trace, 
myocardial blanching and hypokinesia of the anterior wall of the heart) was not 
achieved in ≤2 attempts at LAD ligation, the experiment was abandoned to exclude 
the potentially confounding effect of traumatic injury to the heart. Thirdly, animals 
were excluded if they failed to reperfuse satisfactorily, as indicated by reversal of the 
ST-segment elevation and myocardial colour change. Finally, hearts were excluded 
from analysis if the AAR was outside a pre-defined range of 35-70% in rats and 35-
75% in mice. 
2.5 Analysis of myocardial proteins by Western blot 
2.5.1 Preparation of ventricular lysates 
Mice were terminally anesthetised by intraperitoneal injection of 120 mg/kg 
pentobarbitone sodium (Animalcare, Yorks, UK) at a concentration of 20 mg/ml in 
0.9% (w/v) saline, and 50 IU heparin. Once pedal and tail reflexes were abolished, 
hearts were extracted using clean tools as described in section 2.4.2, cannulated and 
manually perfused with ice-cold phosphate buffered saline (PBS) until the effluent 
ran clear. This was important to remove blood cells and platelets, which are known 
to express CXCR4.44 Hearts were prepared as quickly as possible and in ice-cold 
conditions to prevent any protein modification. The atria were removed and the 
ventricles immediately homogenised in cold lysis buffer using a pestle and mortar. 
Lysis buffer was freshly made for each experiment, and consisted of Tris pH 6.8 (100 
mM final concentration), NaCl (300 mM), NP4O (0.5%), cOmplete Mini protease 
inhibitor tablet (Roche, Sussex, UK), and Halt phosphatase inhibitor cocktail (Thermo 
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Fisher Scientific, MA, USA). The total volume was made up to 100 ml with distilled 
water and the pH adjusted to 7.4. 100 µl of lysis buffer was added per 10 mg heart 
tissue, which was homogenised on ice. After 10 min, samples were centrifuged for 10 
min at 10,000 rpm at 4⁰C. The supernatant was placed in a fresh tube on ice and 
immediately frozen at -20⁰C pending further processing. 
2.5.2 Preparation of isolated cardiomyocytes 
Cardiomyocytes were isolated using a protocol established in the Hatter 
Cardiovascular Institute, UCL.229 Briefly, sterile 6-well tissue culture plates (VWR, 
Leics, UK) were coated with 500 µl laminin/well, diluted in distilled water and left for 
at least 2 h before use. A stock perfusion buffer was prepared in distilled water as 
described in Table 2-4, adjusted to pH 7.4 and filter sterilised into a sterile bottle. 
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Reagent Quantity for 
500ml (g) 
Final 
concentration 
(mM) 
Molecular 
weight (g/M) 
Sodium chloride (NaCl) 3.3 113 58.4 
Potassium chloride (KCl) 0.175 4.7 74.6 
Potassium phosphate 
monobasic (KH2PO4) 
0.041 0.6 136 
Sodium phosphate dibasic 
(Na2HPO4) 
0.0425 0.6 142 
Magnesium sulfate 
heptahydrate (MgSO4-
7H2O)  
0.15 1.2 246 
Sodium bicarbonate 
(NaHCO3) 
0.505 12 84 
Potassium bicarbonate 
(KHCO3) 
0.505 10 101 
HEPES Na Salt 0.12 0.922 260 
Taurine 1.875 30 125 
2,3-Butanedione 
monoxime (BDM) 
0.5055 10 101.1 
Glucose 0.4954 5.5 180 
Table 2-4: Stock perfusion buffer 
Stock perfusion buffer was prepared according to the composition given here. Components 
were added whilst stirring and the solution was adjusted to pH 7.4 before filter sterilising 
into a sterile bottle. 
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A Langendorff perfusion system was filled with perfusion buffer, with care taken to 
remove any air bubbles. Perfusion buffer was oxygenated by gently bubbling with 
oxygen throughout, and maintained at 37±0.5⁰C using a heated water jacket. Mice 
were anaesthetised and eviscerated as described in section 2.5.1, with the exception 
that hearts were placed in, and flushed with, ice-cold stock perfusion buffer. The 
heart was mounted onto a 21G cannula that was attached to the Langendorff 
apparatus and perfused at 3 ml/min. After 5 min of perfusion to empty the ventricles 
and coronary vasculature, perfusion buffer was replaced with a digestion buffer 
consisting of stock perfusion buffer, 0.2 mg/ml Liberase™ (itself containing two 
collagenase isoforms) and 12.5 µM calcium chloride. The heart was perfused for a 
further 20 min or until appropriate loss of tissue integrity. Once fully digested, the 
heart was transferred to a single-well tissue culture dish (VWR, Leics, UK) containing 
digestion buffer where the ventricles were isolated, gently dissected and agitated 
with a Pasteur pipette to further degrade the tissue. 5 ml of stop buffer (stock 
perfusion buffer with 10% foetal bovine serum (Thermo Fisher Scientific, MA, USA)) 
was added in stages before filtering out any undigested tissue through sterile gauze. 
Cells were allowed to pellet for 10 min. 
Next, calcium was gradually re-introduced by removing the supernatant and re-
suspending the cells in stop buffer with consecutively higher concentrations of 
calcium chloride (112 µM, 300 µM, 710 µM and 1 mM). Between each stage, cells 
were allowed to pellet for 10 min. The pellet was then re-suspended with gentle 
inversions in warmed standard M199 tissue culture media supplemented with 
penicillin (100 IU/ml), streptomycin (100 IU/ml), blebbistatin (25 mM), L-carnitine 
(2 mM), creatine (5 mM) and taurine (5 mM). 
Laminin was removed from the tissue culture plate wells, which were washed with 
supplemented M199. Two drops of cells were added per well or cover slip, with 
additional drops if 80% confluence was not achieved. Cells were placed in an 
incubator at 37⁰C with 5% CO2 for 1 h, after which the media was changed and the 
cells were ready for use in subsequent experiments. 
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2.5.3 Western blotting protocol 
A bicinchoninic acid (BCA)-copper(II) sulphate (CuSO4) colorimetric assay was 
performed to quantify the protein concentration of each sample, as per the 
manufacturer’s instructions (Thermo Fisher Scientific, MA, USA). This assay relies on 
the reduction of Cu2+ to Cu+ by protein and the subsequent chelation of two BCA 
molecules to each Cu+ ion. This causes BCA to change from green to purple, with an 
intensity proportional to the concentration of protein in the sample. Briefly, whole 
heart or cell lysates were diluted 1:100 in 50:1 BCA:CuSO4 solution and incubated at 
37⁰C for 15 min with agitation, and colour intensity was subsequently measured using 
a FLUOstar Omega microplate reader (BMG Labtech, Bucks, UK). Sample protein 
concentrations were interpolated using a standard curve of known concentrations of 
bovine serum albumin (BSA) in lysis buffer. 
Samples were subsequently prepared for standard sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) to separate proteins according to 
their size. Specifically, 40 µg of protein per sample was diluted in lysis buffer 
(described in section 2.5.1) so all samples occupied the same volume. 4X NuPAGE® 
LDS Sample Buffer (Thermo Fisher Scientific, MA, USA) mixed with 5% β-
mercaptoethanol was added and further diluted with lysis buffer to achieve a 1X 
solution. Samples were boiled at 80⁰C for 10 min to reduce the disulphide bonds and 
denature the proteins. Prepared samples were either run immediately or stored at -
20⁰C until use. 
NuPAGE SDS-PAGE 10% polyacrylamide pre-cast gels (Thermo Fisher Scientific, MA, 
USA) were mounted in a Criterion™ Vertical Electrophoresis Cell (Bio-Rad, Herts, UK) 
filled with running buffer (50 mM MOPS (3-(N-morpholino)propanesulfonic acid), 50 
mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7). The first lane of each gel was loaded 
with 6µl molecular weight marker (Precision Plus ProteinTM Dual Colour Standards, 
Bio-Rad, Herts, UK) and the remaining lanes were loaded with equal concentrations 
of protein, as described above. The chamber was kept on ice and the gel was run at 
60 V for 10-15 min followed by 100 V for 2 h. 
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After electrophoresis, wet transfer was performed to capture all of the separated 
proteins on a membrane to permit interrogation of proteins of interest with 
antibodies. An Immobilon®-FL polyvinylidene difluoride (PVDF) transfer membrane 
(Merck, Darmstadt, Germany) was activated with 100% methanol for 1 min and 
rinsed with transfer buffer (25 mM Tris base, 200 mM glycine, 20% methanol, pH 8.3) 
prior to use. Transfer of proteins was performed by mounting a standard stack in a 
Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad, Herts, UK) filled with transfer 
buffer under gentle stirring. Caution was taken to remove all air bubbles during this 
process to ensure smooth protein transfer. The transfer was run at 100 V and 0.35 
mA for 1 h and confirmed by either protein ladder transfer or staining with 0.1% 
Ponceau S Solution. 
Membranes were blocked by incubation in 5% BSA/PBS supplemented with 0.05% 
Tween® 20 (BSA/PBS-T; ‘blocking buffer’) for 1 h at RT with gentle rocking. This was 
then replaced with the relevant primary antibody diluted in blocking buffer. Details 
of specific antibodies and their concentrations for each experiment are given in the 
relevant chapters. Primary antibodies were incubated with gentle rocking at 4⁰C 
overnight. 
After overnight incubation, the primary antibody was removed and replaced with an 
anti-alpha Tubulin antibody as a loading control, diluted 1:5000 in BSA/PBS-T and 
added for 1 h at RT with gentle rocking. Non-specifically bound and unbound 
antibody was removed with six 10 min washes with 0.05% PBS-T followed by addition 
of the appropriate secondary antibody at 1:5000 dilution in 50% PBS and 50% 
Odyssey® blocking buffer (LI-COR, Cambs, UK) for 1 h at RT with gentle rocking. 
Details of specific secondary antibodies used for each experiment are given in the 
relevant chapters, with green fluorescent secondary antibodies being used 
preferentially. 
Finally, five 10 min washes in PBS-T were performed, followed by one wash in PBS. 
Membranes were imaged using the Odyssey® Infrared Imaging System (84 µm 
resolution, medium quality, red intensity 3.0, green intensity 6.0). Protein level was 
 74 
 
analysed by densitometry using Image Studio™ version 5.0 for Windows (LI-COR, 
Cambs, UK), with the index protein being normalised to the loading control for each 
sample and expressed as arbitrary units (AU). All values are presented as mean 
AU±SEM. 
2.6 Analysis of myocardial proteins by immunofluorescence 
2.6.1 Preparation of frozen sections for immunofluorescence (IF-F) 
Mouse hearts were extracted and manually perfused as described in section 2.5.1. 
The ventricles were isolated whilst submerged in ice-cold PBS and an approximately 
2 mm3 section dissected for further processing. This was placed in a Shandon™ Peel-
A-Way disposable embedding mould, covered with optimal cutting temperature 
(OCT) cryoembedding matrix (both from Thermo Fisher Scientific, MA, USA) and flash 
frozen by submersion in isopentane (to avoid OCT cracking) in a liquid nitrogen bath. 
Frozen sections were stored at -80⁰C until use. 
Samples were then cut into 8 μm sections at −20°C in a microtome-cryostat (OTF 
5030, Bright Instruments, Beds, UK; Figure 2-15). Specifically, OCT was used to mount 
samples on a sample stub and samples were then allowed to equilibrate to the 
cryostat chamber temperature. A microtome blade was mounted, and the height and 
angle adjusted to the sample. Samples were obtained by rotating a wheel mounted 
outside the chamber causing the mounted sample to pass over the microtome blade. 
Sections were kept flat using an anti-roll plate and subsequently transferred onto a 
glass microscope slide (VWR, Leics, UK). 
Sections were immediately fixed with HistoChoice® for 20 min at RT followed by a 
single wash with ice-cold PBS. To keep reagents localised, a circle was drawn around 
each sample using a hydrophobic barrier pen (Vector Laboratories, Cambs, UK) and 
slides were either stored at -20⁰C or immediately prepared for immunofluorescence, 
described in section 2.6.3. 
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Figure 2-15: Microtome-cryostat configuration 
Essential components of the microtome-cryostat are: (A) Tissue mounted in OCT and adhered 
to sample stub; (B) Screw to hold stub in place; (C) Section thickness control; (D) Anti-roll 
plate; (E) Screws to hold blade in place; (F) Tools kept in chamber to avoid melting samples; 
(G) Knife angle control. 
Human right atrial appendage samples were collected by Dr A. Hamarneh (Hatter 
Cardiovascular Institute, UCL, UK) from patients with chronic stable angina 
undergoing cannulation for cardiopulmonary bypass for CABG. Patients with 
diabetes, impaired renal or ventricular function, dilated left atria, unstable angina, or 
a history of arrhythmias or on rhythm stabilising medications were excluded. After 
harvest, atrial appendage samples were placed in ice-cold, oxygenated modified 
Tyrode’s buffer (NaCl 118.5 mM, KCL 4.8 mM, NaHCO3 24.8 mM, KH2PO4 1.2 mM, 
MgSO4.7H2O 1.44 mM, CaCl2.2H2O 1.8 mM, glucose 10.0 mM, pyruvic acid 10 mM, 
pH 7.4) and transferred promptly to the Hatter Cardiovascular Institute. Atrial 
trabeculae measuring ≤1.2 mm in diameter and ≥2.0 mm in length were carefully 
dissected whilst submerged in ice-cold modified Tyrode’s buffer by Dr D. He (Hatter 
Cardiovascular Institute, UCL, UK) and subsequently prepared as described above. 
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2.6.2 Preparation of isolated cardiomyocytes for immunofluorescence (IF-C) 
Cardiomyocytes were isolated as described in section 2.5.2 and subsequently 
prepared for immunofluorescence. Briefly, 22 mm cover slips (VWR, Leics, UK) were 
placed in sterile 6-well tissue culture plate wells and coated with 200 µl laminin/well. 
Reagents were applied to each well in a volume of 500 µl. After 1 h incubation, cells 
were fixed with HistoChoice® for 20 min at RT, then given three 5 min washes with 
ice-cold PBS. Cells were permeablised with 0.3% Triton non-ionic surfactant on ice for 
10 min and subsequently analysed by immunofluorescence, described in section 
2.6.3. 
2.6.3 Immunofluorescence protocol 
5 min washes with PBS were applied between every step of this immunofluorescence 
protocol. First, non-specific antibody binding was blocked by the addition of 5% BSA 
in PBS (BSA/PBS) for 1 h at RT. Samples were then incubated in primary antibody 
diluted in 1% BSA at 4°C overnight. Pre-adsorbed anti-rabbit secondary antibodies 
conjugated to Alexa Fluor 488 or 555 were diluted in 1% BSA/PBS and added to 
samples for 1 h at RT. 0.1 μg/ml Hoechst nuclear stain (Life Technologies, Renf, UK) 
was added with the secondary antibodies to all sections. Cover slips were mounted 
on glass microscope slides using fluorescence mounting medium (Dako, Cambs, UK). 
Samples were allowed to dry in the dark overnight. 
Preparation of control sections was as described above, with incubation in either 1% 
BSA/PBS only (unstained control) or with the relevant secondary antibody in the 
absence of any primary antibody. Control experiments were performed to confirm 
the absence of fluorescence bleed-through or non-specific staining with secondary 
antibodies alone. After drying, fluorescence was imaged using a 40× oil immersion 
objective by sequential scanning using the 405 nm, 488 nm, 543 nm and/or 633 nm 
lines of a Leica SP5 confocal microscope, as appropriate, and by collecting emitted 
light at 410-470 nm, 500-530 nm, 580-650 nm and 640-710 nm, respectively. 
 77 
 
2.7 Analysis of myocardial messenger RNA levels 
2.7.1 Extraction of RNA 
Care was taken throughout to avoid contamination of samples with ribonucleases 
(RNases). All tools and pipettes were cleaned prior to use and between samples, and 
gloves, sterile filter tips and disposable plasticware were used throughout. The whole 
procedure was performed at RT and as quickly as possible to prevent degradation of 
RNA. 
RNA was extracted using a dedicated kit according to the manufacturer’s instructions 
(RNeasy, Qiagen, Lancs, UK). Briefly, hearts were extracted as described in section 
2.5.1, and a 20-30 mg section of the LV promptly isolated, washed and immersed in 
600 µl RLT buffer with 1% β-mercaptoethanol. RLT buffer contains guanidine 
thiocyanate to denature RNases and β-mercaptoethanol reduces protein disulphide 
bonds. Samples were simultaneously disrupted and homogenised by sonication for 
10 sec (130 W, 20 kHz, Vibra-Cell, Sonics and Materials, CT, USA) and the lysate was 
subsequently centrifuged for 3 min at 20,800 g to remove any undigested tissue. The 
supernatant was removed and mixed with a matching volume of 70% ethanol to 
facilitate selective membrane binding. Samples were transferred to a RNeasy spin 
column containing a silica-based membrane that binds the RNA in the sample prior 
to washing and elution into water. The protocol is outlined in Table 2-5. 
RNA was quantified, and its purity measured, using an Lvis reader in a FLUOstar 
Omega plate reader (BMG Labtech, Germany), where 1 unit of absorbance at 260 nm 
corresponds to 44 µg/ml of RNA. The purity of each sample with respect to protein 
contamination was measured using the OD260/280 ratio and found to be 1.97±0.01 for 
all samples, where a ratio of 1.8-2.0 indicates good quality RNA.230 Purified RNA was 
either immediately subject to reverse transcriptase PCR (described below) or stored 
at -20⁰C until use. 
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Buffer Centrifugation speed and duration Description 
RLT 10,000 g for 15 s, discard flow-through Denature RNases 
RW1 700 µl 10,000 g for 15 s, discard flow-through Wash 
RPE 500 µl 10,000 g for 15 s, discard flow-through Wash 
RPE 500 µl 10,000 g for 2 min, discard flow-
through 
Wash 
Change collection micro-centrifuge tube 
RNAase-free water 
50 µl 
10,000 g for 1 min, keep flow-through Elute 
RNAase-free water 
50 µl 
10,000 g for 1 min, keep flow-through Elute 
Table 2-5: RNA extraction protocol 
RNA extraction was performed using a RNeasy kit (Qiagen, Lancs, UK) according to the 
protocol provided here. 
2.7.2 Reverse transcriptase polymerase chain reaction protocol 
250 ng RNA was converted to first-strand cDNA using the AffinityScript cDNA 
Synthesis kit (Agilent Technologies, Ches, UK), as per the manufacturer’s instructions. 
A master-mix was prepared in a micro-centrifuge tube, as per Table 2-6. 
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Reagent Volume per sample (µl) 
RNase-free water 20 
cDNA synthesis master mix (2X) 10 
Oligo(dT) primer 3 
AffinityScript reverse transcriptase/RNase block 1 
Template mRNA Variable 
Total volume per sample (µl) 34 + template mRNA 
volume 
Table 2-6: cDNA synthesis reaction mix 
A master mix was prepared on ice according to Agilent Technologies’ (Ches, UK) guidelines 
and in the composition and order given here. The volume of master mix accounting for 10% 
extra PCR assays than required and a negative control (without template DNA) was made for 
each experiment. Template mRNA was added to each PCR tube prior to placement in a 
thermal cycler. The cDNA synthesis master mix contains MgCl2 and dNTPs. 
First strand cDNA synthesis PCR was subsequently performed using a thermal cycler 
(PTC 200 Thermal Cycler, MJ Research, Quebec, Canada) according to the protocol 
given in Table 2-7. 
PCR stage Temperature and duration Description 
1 25⁰C for 5 min Primer annealing 
2 45⁰C for 25 min cDNA synthesis 
3 95⁰C for 5 min Terminate 
reaction 
Table 2-7: cDNA synthesis PCR thermocycling protocol 
cDNA synthesis PCR was performed using a thermal cycler (PTC 200 Thermal Cycler, MJ 
Research, Quebec, Canada). 
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Completed reactions were then placed on ice or frozen at -20⁰C prior to quantitative 
polymerase chain reaction (QPCR). 
2.7.3 Quantitative polymerase chain reaction 
QPCR allows real-time quantification of PCR product using a dye that fluoresces when 
non-specifically bound to the minor groove of double stranded DNA (dsDNA). During 
the annealing phase of PCR, primers bind to the target sequence and elongate to 
produce dsDNA, to which SYBR® Green is able to bind and fluoresce. As cDNA is 
amplified over successive cycles the signal intensity increases accordingly to a 
maximum dictated by the amount of template cDNA in the sample. 
The QPCR reaction was prepared according to guidelines from Agilent Technologies 
(Ches, UK). Specifically, 12.5 µl of 2X Brilliant II SYBR® Green QPCR Master Mix, which 
contains Taq DNA polymerase and 2.5 mM (at 1X concentration) MgCl2, was mixed 
with 1 µl each of forward and reverse primer, 8 µl nuclease-free water and 2.5 µl 
template cDNA per reaction (in that order and on ice). The specific primer sequences 
used in these experiments were obtained from the literature in the case of CXCR4,231 
and were already established by our own laboratory in the case of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and hypoxanthine guanine phosphoribosyl 
transferase (HPRT). Primers were purchased from Eurofins Genomics (Ebersberg, 
Germany) (described in Table 2-8) and were diluted to 2 pmol/µl in autoclaved 
distilled water on arrival. GAPDH and HPRT were included as constitutively expressed 
genes that served as a positive control in QPCR experiments. 
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Primer Sequence (5’→3’) Properties 
Length Tm (⁰C) 
GAPDH forward AGGTCGGTGTGAACGGATTTG 21 59.8 
GAPDH reverse TGTAGACCATGTAGTTGAGGTCA 23 58.9 
HPRT forward TCAGTCAACGGGGGACATAAA 21 57.9 
HPRT reverse GGGGCTGTACTGCTTAACCAG 21 61.8 
CXCR4 forward TCAGTGGCTGACCTCCTCTT 20 59.4 
CXCR4 reverse CTTGGCCTTTGACTGTTGGT 20 57.3 
Table 2-8: QPCR primer sequences 
PCR primer sequences, length and melting temperature (Tm). 
After gentle mixing and brief centrifugation, samples were placed in a 
spectrofluorometric thermal cycler (CFX Connect™ Real-Time PCR Detection System, 
Bio-Rad, Herts, UK) and run according to the two-step protocol given in Table 2-9. 
A representative amplification plot, showing increasing fluorescence over time, is 
given in Figure 2-16, Panel A. The quantity of template cDNA can be ascertained 
according to a threshold cycle (Ct), defined automatically as the PCR cycle number 
where SYBR® Green fluorescence is significantly higher than background, and is 
inversely proportional to the log of the initial number of cDNA copies.232 Therefore, 
the higher the amount of template cDNA in the sample, the quicker the threshold 
cycle will be reached. Results were normalised to two reference genes (GAPDH and 
HPRT) as internal controls using double delta Ct analysis.233 Double delta Ct analysis 
calculates the difference between reference and experimental cDNA Ct values for 
experimental and control samples. As the quantity of cDNA doubles with consecutive 
cycles, expression fold change is calculated according to 2-ΔΔCt.  
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PCR stage Temperature and duration Description 
1 95⁰C for 10 min Hot start 
Then 40 cycles: 
2 95⁰C for 30 sec DNA denaturing 
3 60⁰C for 1 min Primer annealing 
4 72⁰C for 30 sec DNA synthesis 
Followed by: 
5 65⁰C for 5 sec increasing at 
0.2⁰C/sec to a maximum of 
95⁰C 
Melt curve 
Followed by 4⁰C until collection 
Table 2-9: QPCR thermocycling protocol 
QPCR was performed using a CFX Connect™ Real-Time PCR Detection System (Bio-Rad, Herts, 
UK). The initial incubation (‘hot start’) activates Taq DNA polymerase. 
To confirm that observed signal was due to template cDNA accumulation rather than 
non-specific dsDNA (from contamination or primer dimers, for example) a 
dissociation (melt) curve was generated for all reactions (demonstrated in Figure 
2-16, Panel B). Based on the premise that non-specific dsDNA products have a lower 
Tm, samples were gradually heated to 95⁰C and loss of fluorescence due to SYBR® 
Green dissociation was plotted against temperature. Signal from primer dimers could 
then be identified by comparison to a control reaction lacking template cDNA. 
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Figure 2-16: Representative QPCR amplification plot (Panel A) and dissociation curve (Panel 
B) 
Panel A demonstrates a representative amplification plot, showing relative fluorescence 
units (RFU) against cycle number. Here, a sample including template cDNA reaches the 
threshold cycle after approximately 17 cycles whilst a sample without template cDNA takes 
approximately 38 cycles. Panel B demonstrates a representative melt curve, whereby 
fluorescence is lost at a lower Tm in a sample without template. 
Upon completion of the reaction, the PRC products were separated using 2% agarose 
gel electrophoresis, as described in section 2.3. This verified that a single product was 
created for each reaction (with no amplification of non-specific dsDNA), that the band 
size was correct and that the relative band intensity correlated with the Ct value 
obtained from QPCR. A representative image is given in Figure 2-17. During this 
process, every effort was made to prevent cross-contamination of pre-amplification 
samples with amplified cDNA. 
 
Figure 2-17: Representative gel electrophoresis showing products of QPCR 
RNA was extracted from WT C57BL/6N mice and converted to cDNA as described. QPCR was 
performed using primers for GAPDH, HPRT and CXCR4 messenger RNA, which were 
confirmed to have product sizes of 123 bp, 148 bp and 203 bp, respectively. 
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2.8 Analysis of SDF-1α by ELISA 
The characterisation and validation of this ELISA is described in detail in section 7.3. 
Briefly, blood samples were collected and prepared as described in section 2.4.4. Flat 
bottom, clear, 96-well plates (R&D Systems, Oxon, UK) were coated with either 5 
µg/ml human IgG bivalent anti-SDF-1α mini-antibodies to detect full-length SDF-1α 
(HCI.SDF1α, AbD Serotec, Oxon, UK), or 9 µg/ml of a commercially available 
monoclonal mouse IgG against mouse and human SDF-1α (MAB350, R&D Systems, 
Oxon, UK) in 0.2M anhydrous sodium carbonate-sodium bicarbonate buffer at 4⁰C 
overnight. Wells were washed three times for 5 min with 0.05% PBS-T before blocking 
with 5% BSA/PBS-T for 1 h at RT. After three further 5 min washes with PBS-T, 100 µl 
of sample was added to each well and allowed to incubate for 2 h at RT. Standard 
samples were prepared using known concentrations of recombinant human (rh)-SDF-
1α (R&D Systems, Oxon, UK), starting at 10,000 pg/ml with twofold dilution steps 
(range 156-10,000 pg/ml) in a diluent augmented with mammalian serum proteins 
(BUF037A, AbD Serotec, Oxon, UK). All standards and samples were measured in 
triplicate. Samples and standards were incubated for 2 h at RT. After three 5 min 
washes with PBS-T, 0.4 µg/ml of biotinylated polyclonal goat IgG against human and 
mouse SDF-1ɑ (BAF310, R&D Systems, Oxon, UK) was added to each well for a further 
1 h at RT. Following incubation, wells were washed a further three 5 min with PBS-T. 
The biotin tag was detected with 1:200 of streptavidin conjugated to horseradish 
peroxidise (streptavidin-HRP; R&D Systems, Oxon, UK) in Hispec buffer (AbD Serotec, 
Oxon, UK), which was incubated with the detection antibody for 20 min in the dark 
at RT. After five 5 min washes with PBS-T, 100 µl of Substrate Solution, composed of 
a 1:1 mix of hydrogen peroxide (H2O2) and tetramethylbenzidine (R&D Systems, 
Oxon, UK), was added and incubated for a further 20 min, in the dark at RT. Without 
further washes, 50 µl of 2N sulfuric acid (Sigma-Aldrich, Dorset, UK) was added per 
well to halt the oxidation reaction, and turn the solution yellow. Colour intensity was 
measured using a FLUOstar Omega microplate reader set to 450 nm and 20 flashes 
per well. 
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2.9 Experiments in humans 
Human studies received Local Research Ethics Committee approval (12/0448) and 
were carried out at the Hatter Cardiovascular Institute (UCL, UK) in accordance with 
the University College Hospitals London Hospitals NHS Trust guidelines. All 
experiments were performed on healthy volunteers, all of whom were provided with 
a Patient Information Sheet and a verbal explanation of the study, in line with Good 
Clinical Practice guidelines. All patients provided written informed consent and were 
free to withdraw from the study at any time. 
2.9.1 Remote ischaemic conditioning 
In humans, RIC consisting of three cycles of 5 min right upper limb ischaemia and 5 
min reperfusion was applied by inflation of a manual sphygmomanometer to a 
pressure of 200 mmHg. Ischaemia was confirmed by the absence of a pulse, pallor 
and paraesthesia. Blood samples were collected into citrated tubes at baseline and 
after the final 5 min of reperfusion via ipsilateral antecubital fossa venepuncture 
using a 21G x 1.5” Microlance needle and Vacutainer™ system (BD, Oxon, UK). 
Samples were collected into citrated tubes (BD, Oxon, UK) on ice and immediately 
supplemented with Sitagliptin to inhibit DPP4 and prevent degradation of full-length 
SDF-1ɑ during sample preparation,52 to give a final concentration of 50 µM. Samples 
were immediately prepared as described in section 2.4.4. 
2.9.2 Analysis of platelet-expressed SDF-1α by flow cytometry 
Blood was collected as described above and fixed immediately by diluting 1:20 in PBS 
containing 0.1% BSA and 1% paraformaldehyde (PFA) for 10 min at RT. A 10 µl aliquot 
of each sample was added to 500 µl PBS/0.1% BSA and incubated with 1:100 primary 
antibody (HCI.SDF1α) overnight, rotating at 4⁰C. Control samples were prepared in 
the same way but without the addition of HCI.SDF1α. Samples were washed (x3) by 
spinning at 10,000 g for 10 min to aggregate platelets, removing the supernatant and 
re-suspending in 500 µl PBS/0.1% BSA. Samples were subsequently incubated for 2 h 
at RT with 1:1000 phycoerythrin-cyanine dye (PE-Cy5) mouse anti-human CD41 (BD 
Pharmingen, Oxon, UK) to identify platelets and 1:400 goat anti-human IgG Fab-
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fluorescein isothiocyanate (FITC, AbD Serotec, Oxon, UK) to detect HCI.SDF1α. 
Control samples were incubated with PE-Cy5 mouse anti-human CD41 and goat anti-
human IgG Fab-FITC alone and in combination, or with no secondary antibody. A 
further sample was incubated in HCI.SDF1α as described and subsequently stained 
with PE-Cy5 mouse anti-human CD41 only to exclude cross-reactivity. 
Blood platelet count (x109/L) was determined by flow cytometry using double-gated 
events according to forward light scatter (height; FSC-H), with a trigger threshold of 
25,000 to exclude debris, and PE-Cy5 fluorescence (FL3 channel, >670 nm), as per 
published protocols (BD Accuri™ C6 Flow Cytometer, BD Biosciences, Oxon, UK).234 
Positive PE-Cy5 fluorescence was set at 5000 AU, based on precedent in our 
laboratory. The count was multiplied by 1000 to account for the final dilution of the 
blood sample, and all samples were measured in duplicate. Platelets expressing SDF-
1α were quantified by selecting the platelet population as described here, and further 
gating them according to FITC fluorescence (FL1 channel, 533/30 nm). Positive FITC 
fluorescence was set at 5000 AU. 
2.10 Statistics 
All analyses were performed using GraphPad Prism® version 5.00 for Windows (CA, 
USA). The specific statistical test used is reported next to each result. 
Comparison of means: The statistical test used to compare group means was 
contingent on the nature of the data being analysed. An unpaired t-test was used for 
two independent groups of continuous variables and a one-way analysis of variance 
(ANOVA) with Tukey’s multiple comparison test for three or more independent 
groups. For dependent observations, a paired t-test was used in the case of two 
groups and a two-way ANOVA with Bonferroni correction for multiple comparisons 
in the case of three or more. 
Data is presented as mean ± standard error of the mean (SEM). Statistical significance 
was reported if P<0.05 using the following nomenclature: *P<0.05, **P<0.01 and 
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***P<0.001. Results where P>0.05 were reported as non-significant (NS). Statistical 
significance is presented alongside all statistical analyses. 
Regression: For both SDF-1α and macrophage inhibitory factor (MIF) assays, sample 
and standard values were baseline corrected and transformed to a logarithmic scale 
(X=log[X]). Full-length SDF-1α assay values were interpolated from linear regression 
of the standard curve. All other standard curves were evaluated with nonlinear 
regression using log(agonist) versus response. Results were transformed according to 
X=10X and the data interpreted as described above. 
Sample size: Sample size calculations were used to estimate the minimum necessary 
sample size for in vivo experiments, except where specifically indicated. The 
assumptions regarding effect size upon which these calculations are based are 
outlined in the relevant sections. For all power calculations a Gaussian distribution 
was assumed, as discussed below, and a significance level of 5% (α=0.05) and 80% 
power (β=0.2) were used. Sample sizes are presented alongside all statistical analyses 
in the graph bars and/or the figure legend. 
Normality: The (parametric) statistical tests described above assume the data come 
from a Gaussian (normal) distribution. However, confirming this with statistical tests 
of normality (the D'Agostino-Pearson omnibus test, for example) is precluded by the 
small sample sizes. If a parametric test is applied to non-Gaussian data, the results 
are meaningless, especially when the sample size is small.235 However, non-
parametric statistical tests have significantly lower power and require much larger 
sample sizes. This is problematic in the context of a reductionist approach to animal 
experimentation. Therefore, data were assumed to be normally distributed 
throughout this thesis. This is discussed further in section 6.3.   
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Chapter 3 Remote ischaemic conditioning in in vivo models of ischaemia-
reperfusion injury: A systematic review and meta-analysis 
This chapter is derived from a manuscript that was jointly first authored with Mr J. 
Pickard. The statistical method was co-designed with Dr X. Rossello and executed in 
its entirety by him. Mr N. Burke and Dr O. Ziff collected the data for analysis of study 
quality. The study was conceived and the manuscript written by Dr D. Bromage. All 
contributors were from the Hatter Cardiovascular Institute (UCL, UK). 
3.1 Introduction 
To investigate RIC it is first necessary to establish a valid experimental model. As will 
be discussed in Chapter 4, this requires a model that provides the best chance of 
demonstrating protection (reduction of IS) by RIC. To achieve this requires a critical 
evaluation of the literature and, in particular, what experimental factors might 
influence the generation of a reproducible IS and demonstrable cardioprotection 
with RIC. 
Furthermore, as discussed in 0, the efficacy of RIC at ameliorating myocardial IRI in 
patients has been called into question by the neutral results of ERICCA and RIP-
HEART. As a result of the recent neutral clinical trials discussed in 0, there is renewed 
interest in the pre-clinical evidence base and potential impediments to successful 
translation.236, 237 The difficulty in translating RIC to the clinic may be attributed to 
several factors: (1) the animal models used in basic studies may not reflect the 
complex risk factor and comorbidity profile of humans with cardiovascular 
disease.238, 239 Indeed, several such comorbidities have been shown to abrogate the 
beneficial effect of RIC, including age and diabetes;240 (2) adjunctive medication and 
techniques administered to patients during cardiac surgery or treatment for MI 
(nitrites, volatile anaesthetics, cardioplegia, anticoagulants and opioids, for example) 
may confer cardioprotection such that RIC has no added potential,241-247 or interfere 
with RIC development;248 (3) the degree of IRI may be too small in cardiac surgery (or 
even STEMI) to be conducible to benefit from RIC or would require an enormous 
sample size to be proven; (4) unlike direct ischaemic conditioning, systematic pre-
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clinical characterisation of the optimal RIC stimulus is lacking.249 Consequently, 
optimal clinical study design is complicated by inconsistent experimental conditions 
used in basic in vivo RIC studies in animals. For example, in direct ischaemic 
conditioning, the number of cycles and the interval between the conditioning 
stimulus and index ischaemia are demonstrably important,102 but only a limited 
number of studies have investigated these factors in RIC; and (5) study quality and 
small study publication bias have also been shown to result in over-estimation of 
effect size and are consequently implicated as confounders in the translation of 
interventions that are cardioprotective in pre-clinical studies.237, 250 
This chapter therefore aims to describe an analysis of the existing literature relating 
to RIC to both inform the development of an in vivo model of RIC and investigate 
potential reasons for the neutral results of large outcome studies. 
3.2 Research aims and objectives 
The main objective of this chapter was to perform a systematic review and meta-
analysis of experimental variables in in vivo models of RIC. The research aims for this 
objective were: 
1. Perform a systematic review of studies of RIC in in vivo models of myocardial 
IRI; 
2. Perform a meta-analysis of studies of RIC in in vivo models of myocardial IRI. 
3.3 Aim 1: Perform a systematic review of studies of remote ischaemic conditioning in in 
vivo models of myocardial ischaemia-reperfusion injury 
3.3.1 Background 
Systematic reviews are indispensable tools for collating existing literature on a topic 
in a reproducible and accountable way. They are defined as an attempt to summarise 
all the empirical evidence according to pre-specified eligibility criteria to address a 
specific question, and can provide the basis for meta-analysis and facilitate 
conclusions that can inform clinical study design and practice.251 Despite this, 
systematic reviews are frequently poorly performed and reported, to which end the 
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Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines have been developed.251 These guidelines encourage the use of 
unambiguous (systematic) methods that minimise the risk of bias and support firm 
conclusions. These guidelines are used here to scrutinise pre-clinical studies of RIC in 
in vivo animal models of myocardial IRI. 
3.3.2 Methods 
A systematic review was performed, and is reported here, in accordance with PRISMA 
guidelines and all data sources, eligibility criteria, data extraction and data synthesis 
methods were pre-defined.251 A literature search was conducted on 21st August, 
2015. Keywords and MeSH terms were used to search Medline and Embase (via 
OVID) between 1997 and present, and further studies were identified by consultation 
with experts in the field. 
The search strategy was defined in an iterative manner, using previously published 
guidelines,252-254 and peer reviewed by members of the Hatter Cardiovascular 
Institute research group. The following search strategy was used, incorporating 
keywords and MeSH terms, for MEDLINE: 
1. (remote adj2 $condition$).mp. 
2. (remote adj isch$emic).mp. 
3. remote precondition$.mp. 
4. remote postcondition$.mp.  
5. remote percondition$.mp. 
6. limb $condition$.mp. 
7. ripc.mp. 
8. limb isch$emi$.mp. 
9. $condition$.mp. 
10. 8 and 9 
11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 10 
12. exp Reperfusion Injury/ 
13. exp Myocardial Ischemia/ 
14. Myocardial Infarction/ 
15. infarct size.mp. 
16. ("infarct size" or "size of infarct*").mp. 
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17. cardioprotection.mp. 
18. 12 or 13 or 14 or 15 or 16 or 17 
19. 11 and 18 
20. Limit 19 to animal 
21. Limit 20 to (english language and yr=”1997-Current”) 
22. Limit 21 to review articles 
23. 21 not 22 
Differences in the search strategy between Medline and Embase are described in 
Table 3-1. 
Search term Database 
 Medline Embase 
Cardioprotection cardioprotection.mp. 
(keyword) 
heart protection/(MeSH term) 
Search review 
articles 
limit 21 to review articles limit 21 to “reviews 
(maximizes sensitivity)” 
Table 3-1: Differences in search strategy between databases 
A combination of keywords and MeSH terms were used to search Medline and Embase (via 
OVID) between 1997 and present with differences in search terms given here. 
Study eligibility criteria were defined using the PICOS (Population, Intervention, 
Comparison, Outcome, Study design) approach.255 In vivo animal studies were 
included and were eligible if they investigated the effect of limb RIC (pre-, per- or 
post-) versus a control (sham procedure or no treatment) on myocardial IS, as 
measured by TTC,256 in any mammalian species, regardless of study design. Transient 
infra-renal aortic occlusion was considered as bilateral hind limb ischaemia. 
Studies were excluded if they did not include or report absolute myocardial IS as a 
percentage of AAR, defined as the myocardial tissue within the vascular territory 
distal to the occluded artery that, if not reperfused, is at risk of irreversible ischaemic 
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death.257 The AAR varies depending on the exact position of the LAD suture and 
variable LAD anatomy. IS has a strong positive correlation with AAR and therefore, 
without correction, a small AAR could create false-positive results for 
cardioprotection, and vice versa.258 Furthermore, studies were excluded if they 
specifically investigated only the ‘second window’ of cardioprotection (RIC to 
infarction interval >1 h),259-261 if the animals had co-morbidities, if IS was only 
measured using a method other than TTC, or if they were investigating the impact of 
RIC in the context of heart transplant. Groups in which RIC was administered in 
combination with another conditioning protocol (local conditioning, for example), or 
with pharmacological treatments known to have cardioprotective effects, were 
excluded. 
The search was limited to reports available in English due to limited time and financial 
resources for translation, and a publication date restriction of 1997-present was 
imposed in view of the first publication of the efficacy of RIC in the limb.165 Review 
articles, unpublished material and ongoing studies were excluded. 
Duplicate reports were excluded using Endnote for Windows (Thomas Reuters, PA, 
USA). Retrieved records were initially screened for eligibility using their title and 
abstract. Eligibility assessment was performed in an un-blinded, standardised 
manner by two assessors. To ensure reliability and improve the objectivity of 
screening, the assessors independently screened a randomly selected 10% sample of 
the search results. The exercise was repeated until 90% agreement was achieved, 
before screening all search results. During the title and abstract screening calibration 
exercise inter-rater agreement was 94%. Disagreements between reviewers were 
resolved by examining the full text of the article or by consensus in all cases. 
Next, the full text of all eligible records was retrieved and subjected to a second stage 
of eligibility screening in an independent, un-blinded, standardised way by two 
assessors. Overall, inter-rater agreement was 87%. The 13% of references upon 
which the assessors disagreed were accounted for by screening errors rather than 
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fundamental disagreement about the features of the study and disagreements were 
resolved by consensus in all cases. 
Category Data item 
Study details First author, senior author, date, report format 
(abstract/full), country of origin 
Populations/subjects 
(P) 
Species, strain, age/weight 
Interventions (I) Pre-/per-/post-conditioning, RIC cycle time, RIC number 
of cycles, number of limbs, RIC technique (cuff/clamp), 
time to index ischaemia, index ischaemic duration, 
coronary territory occluded, reperfusion duration, non-
recovery versus recovery, anaesthetic type, anaesthetic 
dose (mg/kg), other peri-operative medication, use of 
anti-coagulant, type of anti-coagulant, 
intubated/ventilated, supplementary oxygen 
Outcomes (O) IS as primary endpoint, mean IS (%AAR), mean AAR, AAR 
technique, standard deviation, SEM, other reported 
statistical analyses (pertinent to infarct) 
Study design (S) Sample size 
Table 3-2: Data items used for data extraction were developed using the PICOS approach 
Data items were selected according to their recognised effect on myocardial IRI, or their 
reported or potential impact on the efficacy of RIC. 
Experimental variables for which data were sought were developed using the PICOS 
approach.255 Data items were chosen if they had an evidence-based effect on 
myocardial IRI, or a reported or potential impact on the efficacy of RIC. These 
 94 
 
included species and strain, gender, choice of anaesthetic and duration of ischaemia 
and reperfusion. A full list of data items is given in Table 3-2. Prior to formal data 
extraction, the following assumptions were made: 
 When a report described ‘femoral artery occlusion’ it was assumed to be with 
a vascular clamp. Likewise, where hind limb occlusion was reported, the use 
of an external cuff or tourniquet was assumed. A cuff was defined as an 
external inflatable device, while a tourniquet described any other kind of 
external compression. In all cases it was assumed that the cuff was inflated to 
an appropriate pressure. 
 Any reperfusion duration ≤4 h was assumed to be non-recovery and anything 
over that to be a recovery model. 
 An interval >1hr from the last RIC cycle to the onset of index ischaemia was 
defined as the ‘second window’ of protection. This study was concerned with 
the acute cardioprotective potential of RIC, thus these studies were excluded 
from the analysis.  
 Descriptions of the LAD and left coronary artery were assumed to be 
interchangeable in rodents. 
 If the study did not mention whether supplementary oxygen was used, it was 
assumed the animal was ventilated with room air. 
A data extraction sheet was developed based on the Cochrane Consumers and 
Communications Review Group’s data extraction template,262 which was pilot-tested 
on ten randomly-selected included studies, and refined accordingly. Data was 
independently extracted by two reviewers using predefined data fields, including 
study quality indicators. To ensure reliability and improve subjectivity of data 
extraction, a similar calibration exercise as described above was performed. 
Disagreements were resolved by consensus in all cases. 
Following data extraction, searches were conducted according to first and senior 
author name, sample size and size of outcome to identify double counting. These 
parameters were chosen due to expected high completeness and based on 
recommendations in the PRISMA statement.251 If multiple reports for the same study 
were identified they were compared for logical inconsistencies, which were 
subsequently accounted for by contacting the report author by e-mail. Attempts 
were made to acquire key missing information in the same way.  
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Study quality was assessed using a component approach based on the study report, 
using the ARRIVE guidelines and a 12-item quality score.263-265 This approach is based 
on a recent meta-analysis of ciclosporin.146 The 12-item quality score was adapted 
from a 10-item quality score developed by Macleod et al. in response to a perceived 
failure of translation of promising neuro-protective agents in stroke,263-265 by 
removing two and adding four items (described in Table 3-3), resulting in a custom 
12-item quality score that was applied to all full studies in the meta-analysis. 
Abstracts were not subject to quality assessment due to their brevity. Study quality 
was assessed independently from data extraction and between assessors in an un-
blinded, standardised manner by two reviewers. Disagreements were resolved by 
consensus in all cases. It was assumed in this analysis that, if the monitoring of ST 
segments or rhythm was reported, heart rate monitoring was available. 
Added to Cochrane study quality score Removed from Cochrane study 
quality score 
Statement of measurement of PaO2 and SaO2 Use of animals with co-morbidities 
Statement of recording of ECG Blinded induction of ischaemia 
Statement of measurement of blood pressure  
Blinded application of conditioning protocol  
Table 3-3: Items removed and added from the Cochrane study quality score to make the 
adapted score used in the study 
A published quality score was adapted to be appropriate for in vivo studies of 
cardioprotection by RIC against myocardial IRI. 
3.3.3 Results 
The systematic review returned 539 records, including 169 duplicate reports. 370 
reports underwent title and abstract screening, which resulted in 256 exclusions. The 
remaining 114 reports were retrieved for detailed full text evaluation. 71 articles 
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were excluded, 57 due to failing to meet the inclusion criteria, 12 were duplicate 
reports of identical studies published in separate journals, and two were not 
retrievable. Of the remaining 43 reports (studies), nine were missing data on one or 
more important experimental variables that we were unable to retrieve by contacting 
the study authors, and were consequently excluded. The remaining 34 studies were 
included in the quantitative synthesis (Figure 3-1). 
 
Figure 3-1: Flow chart of the study selection process 
A systematic review yielded 539 reports. After removal of duplicates and the application of 
inclusion and exclusion criteria, 34 studies were included in the meta-analysis. 
All included studies and their main characteristics are described in Table 3-4. 
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266
 Pig M 25-30kg Per 5 5 4 1 20 Clamp N/A 40 LAD 120 NR Y Propofol, fentanyl N SEM 10 59.2 3.17 7 36.5 4.7 
166
 Pig M/F 18-22kg Post 5 5 4 1 20 Cuff N/A 90 LAD 4320 R Y Ketamine Heparin SEM 12 48.4 5.2 12 23 2.4 
267
 Rat M N/R Pre 15 10 1 2 30 Clamp 10 30 LAD 120 NR N Pentobarbitone N SD 8 46 7 10 19 5 
  Rat M N/R Per 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SD       10 21 7 
268
 Rat M Adult Pre 15 N/A 1 2 30 Clamp 10 30 LAD 120 NR N Pentobarbitone N SEM 8 41 2 12 19 1 
 Rat M Adult Per 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM    10 18 1 
 Rat M Adult Per 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM    10 18 2 
 Rat M Adult Post 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM    10 21 1 
  Rat M Adult Post 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM       10 43 3 
269
 Rat M Adult Pre 5 5 4 1 20 Clamp 5 40 LAD 120 NR N Pentobarbitone N SEM 6 66.5 5.5 6 48.2 5.2 
270
 Rat M 8-10 weeks Per 10 10 1 1 10 Tourniquet N/A 40 LAD 120 NR N Pentobarbitone N SEM 6 54.9 6.01 6 21.9 4.0 
188
 Pig M 27-35kg Pre 5 5 4 1 20 Clamp 5 60 LAD 180 NR Y Propofol, pancuronium, fentanyl Heparin SEM 5 48.8 4.2 5 13.3 2.2 
 Pig M 27-35kg Per 5 5 4 1 20 Clamp N/A 60 LAD 180 NR Y Propofol, pancuronium, fentanyl Heparin SEM       6 18.2 2 
271
 Rat M Adult Pre 5 5 4 2 40 Cuff 10 35 LAD 120 NR Y Pentobarbitone N SD 10 76 14 10 54 15 
272
 Rat M 8-10 weeks Pre 10 10 1 1 10 Clamp 10 40 LAD 120 NR N Pentobarbitone N SEM 9 64.9 2.6 11 52.2 3.7 
273
 Rat M 288+/-9kg Per 10 10 1 1 10 Tourniquet N/A 40 LAD 120 NR N Pentobarbitone N SEM 6 54.6 4.7 6 24.4 5.9 
274
 Rat M Adult Pre 5 5 4 1 20 Clamp 5 40 LAD 120 NR N Pentobarbitone N SEM 7 65.3 2.9 6 47.3 2.2 
190
 Mouse M N/R Pre 5 5 4 1 20 Clamp 5 30 LAD 120 NR N Pentobarbitone N SEM 9 40.6 3.6 6 24.1 2.8 
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  Rat M 2-3 months Pre 5 5 4 1 20 Clamp 5 40 LAD 120 NR N Pentobarbitone N SEM 7 65.1 2.7 6 47.3 2.1 
167
 Pig N/R 15kg Pre 5 5 4 1 20 Tourniquet 5 40 LAD 120 NR Y Midazolam, pentobarbitone Heparin SEM 8 53 8 9 26 9 
275
 Rat M N/R Per 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM 10 69 2 10 43.4 3.8 
 Rat M N/R Per 15 N/A 1 2 30 Clamp N/A 30 LAD 120 NR N Pentobarbitone N SEM 6 68.6 0.8 6 46.4 4 
276
 Rabbit M/F 2.5-3kg Per 5 1 1 1 5 Clamp N/A 30 LAD 180 NR Y Pentobarbitone Heparin SD 10 31.5 1.3 10 17.1 1.7 
181
 Mouse M 10-12 weeks Pre 5 5 3 1 15 Clamp 5 30 LAD 120 NR Y Ketamine, xylazine, atropine N SEM 10 56.7 3.2 9 21.6 1.6 
277
 Rat M 280-300g Pre 5 5 1 1 5 Clamp 5 30 LAD 120 NR N Pentobarbitone N SD 6 54.7 6 6 28.3 4.9 
 Rat M 280-300g Pre 5 5 3 1 15 Clamp 5 30 LAD 120 NR N Pentobarbitone N SD       6 51.1 7.4 
194
 Rat M Adult Pre 15 10 1 2 30 Clamp 10 30 LAD 120 NR N Pentobarbitone N SEM 7 54.6 3.1 8 36.6 3 
278
 Rat M 250-300g Pre 15 10 1 2 30 Clamp 10 30 LAD 120 NR N Pentobarbitone N SEM 7 42 3 7 28 4 
279
 Rat F 200-250g Per 5 5 4 2 40 Clamp N/A 45 LAD 120 NR N Ketamine, xylazine N SEM 22 48.7 3.4 22 42.2 3.9 
174
 Pig N/R 20kg Per 5 5 4 1 20 Tourniquet N/A 40 LAD 120 NR Y Midazolam, pentobarbitone Heparin SEM 10 60 5 10 38 5 
280
 Pig M/F Newborn Pre 5 5 4 1 20 Tourniquet 5 40 LAD 120 NR N Midazolam, azaperone, etomidate Heparin SD 8 16.5 3.6 8 19.4 1.7 
281
 Rat M Adult Pre 15 10 1 2 30 Clamp 10 30 LAD 120 NR N Urethane N SEM 6 55.5 3.1 6 21.5 3.5 
123
 Rat M 8-10 weeks Per 10 10 1 1 10 Tourniquet N/A 40 LAD 120 NR N Pentobarbitone N SEM 6 54.9 6.5 6 24.7 6.0 
189
 Mouse M 12±3 weeks Pre 5 5 4 1 20 Cuff 5 30 LAD 1440 R Y Ketamine, xylazine N SD 5 37 4 5 17 3 
282
 Rat M 250-280g Per 5 5 4 1 20 Tourniquet N/A 45 LAD 4320 R N Pentobarbitone Heparin SD 8 50.5 4.1 8 35.6 4.2 
283
 Rat M 250-350g Pre 15 0 1 2 30 Clamp 0 30 LAD 120 NR Y Pentobarbitone N SEM 6 62 5 6 52 4 
 Rat M 250-350g Pre 5 10 1 2 10 Clamp 10 30 LAD 120 NR Y Pentobarbitone N SEM    6 42 2 
 Rat M 250-350g Pre 10 10 1 2 20 Clamp 10 30 LAD 120 NR Y Pentobarbitone N SEM    6 37 8 
  Rat M 250-350g Pre 15 10 1 2 30 Clamp 10 30 LAD 120 NR Y Pentobarbitone N SEM       8 18 3 
284
 Rat M 300±25g Pre 5 5 3 1 15 Clamp 5 30 LAD 120 NR N Pentobabitone N SD 6 52.8 5.9 6 29.6 5.8 
285
 Rat M 8 week Per 5 5 4 1 20 Cuff N/A 45 LAD 120 NR N Pentobabitone Heparin SD 8 48.9 6.66 8 33.5 5.8 
286
 Rat M 8-9 weeks Per 10 N/A 1 2 20 Tourniquet N/A 30 LAD 180 NR Y Pentobarbitone N SD 9 60 3 9 48 1 
287
 Rat M 250-300g Per 5 5 3 1 15 Clamp N/A 45 LAD 180 NR N Pentobarbitone Heparin SEM 12 55.8 2.2 12 31.3 1.9 
288
 Rat M 8 weeks Per 10 N/A 1 2 20 Tourniquet N/A 30 LAD 120 NR Y Pentobarbitone N SD 20 71.6 8.7 20 56.9 8.8 
289
 Rat M 230-260g Pre 5 5 3 1 15 Clamp 5 30 LAD 120 NR Y Chloral hydrate N SD 6 51 6 6 20.3 2.4 
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290
 Rat M Adult Pre 5 5 3 2 30 Tourniquet 5 30 LAD 180 NR N Chloral hydrate Heparin SEM 12 34.7 5.9 12 14.5 3.5 
 Rat M Adult Per 5 5 3 2 30 Tourniquet N/A 30 LAD 180 NR N Chloral hydrate Heparin SEM    12 15.3 5.2 
 Rat M Adult Post 5 5 3 2 30 Tourniquet N/A 30 LAD 180 NR N Chloral hydrate Heparin SEM       12 19.8 5.9 
Table 3-4: Main characteristics of included studies 
The time between RIC and index ischaemia is included for studies of preconditioning only. N/R, not recorded; N/A, not applicable; LAD, left anterior descending; R, recovery; 
NR, non-recovery; SEM, standard error of the mean; SD, standard deviation. 
32 full studies were subject to quality assessment and a full breakdown of their score according to the ARRIVE guidelines is given in Table 3-5. 
Reference 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Quality score 
266 
1 1 1 1 1 0 0 1 0 0 0 1 0 1 1 1 0 1 1 1 13 
166 
1 1 1 1 1 1 0 1 0 0 0 1 0 0 1 1 0 1 1 1 13 
268 
1 1 1 1 1 0 0 1 0 0 0 0 0 0 1 1 0 0 1 1 10 
269 
0 1 1 0 1 0 0 1 0 0 0 1 0 0 1 1 0 1 0 0 8 
270 
1 1 1 1 1 1 1 1 0 0 0 0 0 0 1 1 0 1 1 1 13 
188 
1 1 1 1 1 1 0 1 0 0 0 0 0 1 1 1 1 1 1 1 14 
271 
1 1 1 1 1 1 0 1 0 0 0 0 1 1 0 1 0 1 1 0 12 
272 
1 1 1 1 1 1 0 1 0 0 0 1 1 0 1 1 0 1 1 1 14 
273 
0 1 1 1 1 1 0 1 0 0 0 0 0 0 1 1 0 1 1 1 11 
274 
1 1 1 1 1 1 0 1 0 0 0 0 1 0 1 1 0 1 1 1 13 
190 
1 1 1 1 1 1 1 1 0 0 0 0 1 0 1 1 1 1 1 1 15 
167 
1 1 1 1 1 1 0 1 0 0 1 1 1 1 1 1 0 0 1 1 15 
275 
1 1 1 1 1 1 0 1 0 0 1 0 0 1 1 1 0 1 1 1 14 
276 
1 1 1 1 1 1 0 1 0 0 0 0 0 1 1 1 0 1 1 1 13 
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181 
1 1 1 1 1 1 0 1 0 0 1 0 0 1 1 1 0 1 1 1 14 
277 
1 1 1 1 1 1 0 1 0 0 0 0 0 1 1 1 1 1 1 1 14 
194 
1 1 1 1 1 0 1 1 0 0 0 0 0 0 1 1 0 0 1 1 11 
279 
1 1 1 1 1 1 0 1 0 1 0 1 0 1 1 1 1 1 0 1 15 
174 
1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1 1 1 18 
280 
1 1 1 1 1 1 0 0 0 0 0 0 1 1 1 1 1 1 1 1 14 
281 
1 1 1 1 1 1 0 1 1 0 0 0 0 1 1 1 1 1 0 1 14 
123 
1 1 1 1 1 1 1 1 0 0 1 0 0 0 1 1 0 1 1 1 14 
189 
1 1 1 1 0 0 0 0 1 0 0 0 0 1 1 1 0 1 1 1 11 
282 
1 1 1 1 1 1 1 1 1 0 0 0 0 0 1 1 0 1 1 1 14 
283 
1 1 1 1 1 0 0 1 0 0 0 0 0 1 1 1 1 0 1 1 12 
284 
1 0 1 1 1 0 0 1 1 1 0 1 0 1 1 1 1 1 0 1 14 
285 
1 1 1 1 1 1 1 1 0 0 0 0 0 1 1 1 0 1 1 1 14 
286 
1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 0 1 1 1 17 
287 
1 1 1 1 1 1 1 1 1 0 0 0 0 1 1 1 0 0 1 1 14 
288 
1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 0 1 1 1 18 
289 
1 1 1 1 1 0 0 1 0 0 0 0 0 1 1 1 0 0 0 1 10 
290 
1 1 1 1 1 1 1 1 0 0 0 0 0 1 1 1 1 1 1 1 15 
Table 3-5: Study quality based on ARRIVE guidelines 
Study quality items are: (1) Title; (2) Abstract; (3) Background; (4) Objectives; (5) Ethical statement; (6) Study design; (7) Experimental procedures; (8) Experimental animals; 
(9) Housing and husbandry; (10) Sample size; (11) Allocating animals to experimental group; (12) Experimental outcomes; (13) Statistical methods; (14) Baseline data; (15) 
Numbers analysed; (16) Outcomes and estimation; (17) Adverse events; (18) Interpretation/scientific implications; (19) Generalizability/translation; (20) Funding. 
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A full breakdown of study quality score according to a 12-item quality score is given 
in Table 3-6. 
Reference 1 2 3 4 5 6 7 8 9 10 11 12 Quality score 
266 1 0 0 1 0 1 1 1 0 0 0 1 6 
166 1 1 1 1 1 1 1 0 0 0 0 1 8 
268 1 0 0 1 1 1 1 1 1 0 0 0 7 
269 1 0 0 1 1 1 0 0 0 0 0 0 4 
270 1 1 0 1 1 1 0 0 0 0 0 1 6 
188 1 1 0 1 0 0 1 1 1 0 0 1 7 
271 1 1 0 1 1 1 1 0 1 0 0 0 7 
272 1 1 0 1 1 1 0 0 0 0 0 1 6 
273 1 1 0 1 1 1 0 0 0 0 0 1 6 
274 1 1 1 1 1 1 0 0 0 0 0 1 7 
190 1 1 1 1 1 1 0 0 0 0 0 1 7 
167 1 1 1 1 1 1 1 1 1 0 1 0 10 
275 1 1 0 1 1 1 1 0 1 0 0 1 8 
276 1 1 0 1 1 1 1 0 1 0 0 0 7 
181 1 1 0 1 1 1 1 0 1 0 0 0 7 
277 1 1 0 1 1 1 1 0 1 0 0 0 7 
194 1 0 0 1 1 1 1 1 1 0 0 1 8 
279 1 1 0 1 0 1 1 0 0 0 0 1 6 
174 1 1 1 1 1 1 1 1 1 1 1 0 11 
280 1 1 1 1 1 1 1 0 1 0 0 1 9 
281 1 1 1 1 1 1 1 1 1 0 0 0 9 
123 1 1 1 1 1 1 0 0 0 0 0 1 7 
189 1 0 0 1 0 0 0 0 0 0 0 1 3 
282 1 1 1 1 1 0 1 0 0 0 0 1 7 
283 1 0 0 1 1 1 1 1 1 0 0 0 7 
284 1 0 0 1 1 1 1 0 1 1 0 1 8 
285 1 0 1 1 1 1 1 0 1 0 0 1 8 
286 1 1 1 1 1 1 1 1 1 1 1 1 12 
287 1 1 0 1 0 0 1 0 1 0 0 0 5 
288 1 1 1 1 0 1 1 1 1 1 0 0 9 
289 1 0 0 1 1 1 1 0 1 0 0 0 6 
290 1 1 1 1 1 0 1 0 0 0 0 1 7 
 102 
 
Table 3-6: Study quality based on a 12-item quality score 
Study quality items are: (1) Publication in a peer-reviewed journal; (2) Randomization to 
either control or conditioning treatment with RIC or placebo control; (3) Blinded assessment 
of outcome; (4) Statement of compliance with regulatory requirement; (5) Method of 
confirmation of ischaemia; (6) Statement of control of temperature; (7) Statement of 
recording ECG; (8) Statement of measuring PaO2 or SaO2; (9) Statement of measurement of 
BP; (10) Sample size calculation; (11) Blinded application of conditioning protocol; (12) 
Statement of conflict of interest. 
3.3.4 Discussion 
Experimental variables for which data were sought were chosen according to their 
evidence-based effect on myocardial IRI or on the efficacy of RIC. Further data items 
were discretionary and chosen according to their potential to impact on the efficacy 
of RIC. Although some data items have not been investigated in the literature in the 
setting of cardioprotection, this project aimed to address a broad range of 
experimental variables in order to obtain a clear picture of how the efficacy of RIC 
may be influenced in vivo. A separate systematic review to develop these data items 
was not performed, but all potentially relevant and recordable methodological 
variables are believed to have been included. The rationale for the main data items 
is briefly described below. 
Firstly, the choice of animal is central to any in vivo experimental model. For example, 
dogs have extensive collateral circulation which is known to afford cardioprotection; 
therefore, species with extensive collateral circulation have smaller IS after IRI 
relative to rabbits, pigs, rats and mice.258, 291 This is important because the 
confounding effect of a collateral circulation must be quantified, increasing the time, 
complexity and cost associated with the model. Conversely, rabbits, pigs, rats and 
mice have virtually absent collateral flow.258 These species therefore suffer a large 
enough insult after IRI to facilitate the demonstration of statistically significant 
cardioprotection with various experimental interventions, including IPC and RIC. 
Despite their smaller size and faster heart rates, murine models have the added 
advantages of relative low cost, speed and ease of breeding.292 It should be 
acknowledged, however, that although the paucity of a collateral circulation is 
desirable in an experimental model, it does not necessarily reflect the anatomy of 
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many patients who have extensive collateral circulations as a consequence of chronic 
CHD. 
Furthermore, although Sprague-Dawley is the strain of rat most commonly used for 
MI experiments,203 it has been demonstrated that Sprague Dawley rats have the most 
marked variability in IS and cardiac dysfunction after IRI owing to the least consistent 
LAD branching pattern of six strains tested.203 These factors may additionally impact 
on the efficacy of RIC. 
Similarly, in a recent meta-analysis, Lim et al. demonstrated that ciclosporin was not 
effective at limiting myocardial IS in pig models of IRI, compared to small animal 
models.146 This may be species-specific or related to species size more generally.146 It 
may also be a consequence of variable plasma concentrations of ciclosporin 
according to species, despite the administration of similar weight-adjusted doses.146 
For example, it has been demonstrated that swine have a lower blood concentration 
of ciclosporin than humans despite the same dosing regime.146 This reinforces the 
requirement to investigate species as an important experimental variable. 
Regarding gender, IRI experiments conventionally use male subjects. This is justified 
by reference to the cardioprotection conferred by oestrogen and potential temporal 
variability in cardioprotection as a result of the oestrous cycle of female rats,293-295 
and is therefore an important variable to include in a systematic review and meta-
analysis of cardioprotection. 
Pentobarbitone is a commonly used anaesthetic agent for non-recovery experiments. 
Pentobarbitone is comparable in its haemodynamic effects to two other commonly 
used regimens: isoflurane and ketamine/xylazine.296 However, all of these agents 
adversely affect cardiovascular functional indices, which include heart rate, cardiac 
output, blood pressure and LV dimensions, compared to tiletamine/zolazepam.296 
Furthermore, it has been suggested that propofol interferes with the development 
of RIC,248, 297 and it has been implicated as a potential reason for the apparent lack of 
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translation of RIC.298 For these reasons, it is an important variable in the context of 
this study. 
The duration of ischaemia and reperfusion are also important variables as increased 
ischaemic duration,299 and possibly reperfusion duration,300 have been reported to 
increase IS and may consequently impact upon the efficacy of RIC. For example, there 
is evidence that the degree of cardioprotection conferred by RIC is proportional to 
the duration of index ischaemia. Specifically, Kleinbongard et al. demonstrated longer 
cross-clamp (ischaemic) times to be associated with a greater efficacy of RIC in a study 
of patients undergoing CABG.301 
Furthermore, it has been hypothesised that the interval between the conditioning 
stimulus and the onset of index ischaemia might be an important determinant of the 
efficacy of remote preconditioning.249 
Finally, there is interest regarding the precise conditioning protocol, including 
number and duration of cycles. Johnsen et al. recently reported that four and six, but 
not eight, cycles of RIC were protective in mice subject to in vivo RIC prior to heart 
extraction and simulated IRI on a Langendorff apparatus.302 Similarly they found that 
2 and 5 min, in contrast to 10 min, cycles were beneficial in mice. These are all, 
therefore, important facets to synthesise as part of any systematic review and meta-
analysis of in vivo studies of myocardial IRI. 
3.4 Aim 2: Perform a meta-analysis of studies of remote ischaemic conditioning in in vivo 
models of myocardial ischaemia-reperfusion injury. 
3.4.1 Background 
Meta-analysis describes the quantitative synthesis of data from independent 
studies.251 In the context of pre-clinical in vivo studies of RIC in myocardial IRI, meta-
analysis facilitates calculation of the overall effect size compared to control (sham 
procedure or no treatment). It is likewise possible to investigate whether the 
heterogeneity of experimental conditions used between studies, including variables 
such as RIC protocol and use of supplementary oxygen, impacts on outcome and 
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might confound attempts at clinical translation, which is a further aim of this section. 
Finally, poor methodological quality and publication bias can result in over-
estimation of effect size.303-305 In turn, this can engender enthusiasm about the 
benefit of a treatment where, in fact, none exists. It is therefore essential to examine 
the impact of study quality on size of effect, which was a further aim of this section. 
3.4.2 Methods 
The primary outcome was pre-specified and defined as the weighted 
(unstandardised) mean difference (WMD) between IS in the RIC and control groups 
in in vivo models of myocardial IRI. WMD was used as all data were presented in the 
same units and it gives a biologically relevant value. In each publication, all 
independent comparisons of IS/AAR in RIC versus control groups were identified. 
Where a study made multiple comparisons to the same control group, the size of the 
control group was corrected for the number of comparisons made (n/number of 
comparisons).306 In studies that included additional groups that were, for example, 
subjected to RIC in addition to another conditioning protocol or to pharmacological 
treatments known to have cardioprotective effects, only the RIC and control groups 
(as per our eligibility criteria) were included in the analysis. 
For each independent comparison the effect size was calculated as a raw difference 
in IS/AAR means (the mean of the control groups minus the mean of the experimental 
group) and the corresponding 95% confidence interval (CI). To account for 
anticipated heterogeneity effect sizes were pooled using random-effects meta-
analysis, which considers the within-study and between-study variability and weights 
each study accordingly. Heterogeneity was quantified using I2 and T2 statistics.306, 307 
Studies with missing data on any of the pre-defined experimental variables were 
excluded from the meta-analysis. 
The secondary outcome was the effect of eight pre-defined experimental variables, 
which were considered most likely to impact on the efficacy of RIC, on WMD. These 
were defined as: 
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1. Species: Studies that used either mice or rats were grouped as ‘small animals’, 
and those using rabbits or pigs were grouped as ‘large animals’. 
2. Protocol: The retrieved studies contained several definitions of pre-, per- and 
post-conditioning. For clarity, despite the terminology used in the report, 
preconditioning was defined as any stimulus where the last cycle of ischaemia 
had been completed by the time of index ischaemia; perconditioning as any 
ischaemic stimulus that overlapped in full or in part with the index ischaemia; 
and postconditioning as any stimulus that began at or after the time of 
myocardial reperfusion. 
3. Cycle duration: The reported duration of ischaemia applied to the limb in each 
cycle. In the analysis, studies were grouped as 5, 10 or 15 min of limb 
ischaemia. 
4. Number of cycles: The number of times this ischaemic episode was applied in 
succession to the limb. Studies were grouped as using one, three or four cycles 
of ischaemia. 
5. Number of limbs: The RIC protocol reported by each study was either applied 
to one or both (bilateral) limbs. Conditioning by infra-renal aortic occlusion 
was classed as bilateral hind limb ischaemia, whereas studies using supra-
renal aortic occlusion were excluded. 
6. Oxygen: Each study was given a binary score according to its reported use of 
supplementary oxygen in their ventilation protocol. 
7. Technique of occlusion: Whether the study reported use of a cuff/tourniquet 
or femoral artery clamp to induce hind limb ischaemia. 
8. Heparin: A binary measure of whether the study reported the use of heparin 
as part of their in vivo protocol. 
Subgroup analyses were performed using univariate meta-regressions to explore 
which experimental factors and study quality indicators contributed to any observed 
heterogeneity. The percentage of between-study variance explained by variables of 
interest was assessed using the T2 and adjusted R2 statistics. The significance level 
was adjusted according to the number of comparisons using the Holm-Bonferroni 
method.308 
Sensitivity analysis was performed to assess the robustness of our findings by 
performing an additional analysis for both the primary and the secondary endpoints 
using the SMD (the mean of the control group minus the mean of the RIC group, 
divided by the pooled SD of the two groups). We performed a stratified meta-analysis 
by subgroup to validate the results obtained by meta-regression. 
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Potential publication bias was assessed by visual inspection of a funnel plot for 
asymmetry, and Egger’s regression analysis for small study effects. No protocols were 
available with which to examine for selective reporting, however, the methods and 
results sections of all included studies were carefully compared for inconsistencies. 
All analyses were pre-specified and performed using STATA/SE version 13.1 
(StataCorp, College Station, TX, USA); GraphPad Prism version 5.00 for Windows (CA, 
USA) was used in the production of figures. 
3.4.3 Results 
From the 34 included reports, we extracted data on 48 controlled comparisons of RIC 
in models of myocardial IRI. In total, our analysis includes data from 305 control 
animals and 418 animals undergoing RIC. Overall, RIC reduced IS/AAR by 20.9% (95% 
CI 18.2-23.7%), when compared to untreated controls (n=48 comparisons, P<0.001, 
Figure 3-2). Interestingly, significant heterogeneity in effect size was observed 
(T2=92.9 and I2=99.4%, P<0.001). 
Potential experimental sources of the observed heterogeneity were investigated 
using meta-regression analysis with IS/AAR as the dependent variable. However, 
there were no significant associations of experimental variables with efficacy of RIC 
(Figure 3-3). 
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Figure 3-2: Forest plot of meta-analysis of conditioning efficacy 
A forest plot of the effect of RIC on IS/AAR, pooled using random-effects meta-analysis. 48 
controlled comparisons were included, amounting to data from 305 control animals and 418 
animals undergoing RIC. 
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Figure 3-3: Impact of experimental factors on the efficacy of remote ischaemic conditioning 
WMD and the corresponding 95% CI for each variable were obtained by subgroup 
stratification. However, the reported P-value was obtained by meta-regression to reduce 
false-positive findings. Studies that used either mice or rats were grouped as ‘small animals’, 
and those using rabbits or pigs were grouped as ‘large animals’. 
Furthermore, the reduction in IS/AAR after RIC was not statistically contingent upon 
the duration of index ischaemia. However, there was a pattern of increasing efficacy 
of RIC at longer index ischaemic durations that appears to diminish at the longest 
durations, especially in small animals, but this should only be considered exploratory. 
In the group of studies in which RIC was applied before the index ischaemia 
(preconditioning), the interval between the conditioning stimulus and the onset of 
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index ischaemia did not affect the efficacy of RIC. Results of both of these analyses 
are provided in Table 3-7. 
Experimental 
variables  
WM
D 
(95% CI) % 
Weight 
P-
value 
Adj R-
squared  
Interval between RIC and index ischaemia  0.387 -1.35% 
0-5 min 20.1     (14.5, 
25.6) 
60.5   
10 min 23.7     (18.2, 
29.2) 
39.6   
Duration of index ischaemia (small animals)  0.569 -1.88% 
30 21.0     (17.5, 
24.5)         
69.9   
35 22.0     (9.3, 34.7)          1.8   
40 22.8    (17.9, 
27.6)          
18.1   
45 15.3     (2.9, 27.7)      10.1   
Duration of index ischaemia (large animals)  0.271 6.80% 
30 14.4    (13.0, 
15.7)         
12.8   
40 17.2     (7.6, 26.9)         50.6   
60 33.0 (28.2, 
37.8) 
24.8   
90 25.4     (20.3, 
30.5)         
11.8   
 
Table 3-7: Meta-analysis evaluating the effect of experimental variables on WMD 
Analysis of the effect of the interval between the last cycle of RIC and index ischaemia on 
WMD included only studies of remote preconditioning (n=25 comparisons). Analysis of the 
impact of index ischaemia duration on WMD in studies using small animals (rat or mouse) 
included n=40 comparisons; the 35 min group included only 1 comparison. In large animals 
(rabbit or pig) there were n=8 comparisons; the 30 and 90 min groups included only 1 
comparison.  
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Figure 3-4: Reporting of study quality indicators 
Study quality was assessed using the ARRIVE guidelines on reporting in vivo experiments (A) 
and a 12-item quality score (B). Values are expressed as the percentage of studies reporting 
each quality indicator. 
Meta-regression indicated that study quality according to the ARRIVE guidelines 
score and a 12-item quality score was not associated with the overall effect (P=0.663 
and P=0.557, respectively). Reports achieved a median ARRIVE guidelines score of 14 
(IQR 12-14) and a median 12-item quality score of 7 (IQR 6-8). Figure 3-4 
demonstrates graphically the reporting of study quality indicators. 
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The impact of publication bias on the overall effect was assessed by visual analysis of 
the funnel plot, which suggested that small and negative studies might be under-
represented (Figure 3-5). In Egger’s regression test the null-hypothesis of no small-
study effect was not rejected at P=0.392 (estimated bias coefficient 2.45±2.83 SE). 
 
Figure 3-5: Assessment of publication bias 
A funnel plot comparing treatment effect to a measure of study size (precision of the effect 
estimate). The vertical line represents the mean effect size. This plot was assessed visually, 
with further analysis of publication bias performed using Egger’s regression test. 
When the analysis was re-run using the SMD, all results were similar to those found 
using the WMD. There was a highly significant overall effect (SMD of 10.49, 95% CI 
8.93-12.05, P<0.001), as well as a similar level of heterogeneity (I2=92.9%). None of 
the experimental variables were significant after correction by multiple comparison. 
3.4.4 Discussion 
Clinical trials investigating the efficacy of RIC in myocardial IRI have had mixed 
results.173, 178 This meta-analysis of pre-clinical in vivo studies of myocardial IRI is the 
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first to confirm an overall large beneficial effect of RIC on IS, based on data from 34 
studies and over 700 animals. This is an important finding in the context of recent 
pessimism regarding RIC as a genuine cardioprotective phenomenon.309, 310 
Interestingly, there was high heterogeneity between studies and resolving this may 
be the key to understanding the mixed results in clinical studies. 
To facilitate the investigation of any factors that might impair clinical translation and 
to be as clinically relevant as possible, only in vivo models were included in this study. 
The impact of experimental variables on effect size is important as any over-
estimation of effect size might justify recent neutral clinical studies of RIC. This 
approach has been successfully applied to several promising pre-clinical 
interventions to date.102, 146 For example, the finding that ciclosporin was less 
effective in large compared to small animal models might be important in the context 
of a subsequent neutral clinical study of ciclosporin before reperfusion in patients 
with STEMI.311 In their meta-analysis, Lim et al. point to the similarity between swine 
and human hearts in terms of coronary anatomy, collateralisation and myocardial 
mass. Therefore, finding the parameters responsible for heterogeneity can guide pre-
clinical and clinical study design. 
However, the meta-regression analyses did not identify any cause for the observed 
heterogeneity. Unlike the meta-analysis of ciclosporin described above, RIC was well 
conserved between species. Interestingly, there was no difference in effect size 
according to the number and duration of cycles. This is consistent with the 
description from Johnsen et al. described in section 3.3.4, who reported that four and 
six, but not eight, cycles of RIC were protective in mice, notwithstanding their 
application of ex vivo IRI,302 as studies using eight cycles were not represented in the 
present sample. Similarly, this analysis supports their finding of no association with 
the number of limbs conditioned. Johnsen et al. further reported that 2 and 5 min, in 
contrast to 10 min, cycles were beneficial in mice.302 This analysis demonstrated 10 
min cycles to be equally effective, albeit only in larger species as no studies included 
in the meta-regression used 10 min cycles in mice. Pre-, per- and post-conditioning 
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were also statistically equally effective (WMD 21.5, 21.6 and 14.5, respectively) 
despite observing an apparently smaller effect in studies of postconditioning. 
The use of supplementary oxygen in acute MI is controversial,312 but the potential 
role of supplementary oxygen in RIC has not been investigated. If RIC is driven by 
cellular hypoxia in the conditioned limb, the role of supplementary oxygen could be 
central to the efficacy of the stimulus. However, this meta-analysis found 
conditioning of animals with and without oxygen to be equally effective. Similarly, 
there was not a difference between limbs occluded by femoral artery (or aortic) 
clamping versus external compression via a cuff, which was considered potentially 
important due to the possible involvement of limb collaterals and in relation to the 
putative effect of shear stress in RIC,189 which might be greater with direct arterial 
clamping compared to external cuff inflation. Finally, RIC was equally effective in 
animals treated with and without heparin, which was included as a variable in light 
of reports that heparin is cardioprotective in the context of IRI.242-246 
In studies of preconditioning only, there was no relationship between effect size and 
the interval between the preconditioning stimulus and index ischaemia, although the 
included range of intervals was small (0-10 min) and studies with an interval ≥1 h 
were excluded as the so-called second window of cardioprotection is believed to have 
a different mechanism.313 
In an exploratory analysis of the effect of index ischaemia duration, comparisons 
were stratified according to species as identical durations of index ischaemia can 
return dissimilar IS/AAR in different species due to, for example, variable 
collateralisation. There was no statistical effect of index ischaemic time; however, 
there was a pattern of increased efficacy of RIC at longer ischaemic durations that 
appeared to weaken at the longest durations, especially in small animals. This might 
suggest an important role for the timing of intervention, but should be interpreted 
with caution in view of the limited number of comparisons available after 
stratification. 
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There were several experimental variables that were of considerable interest but that 
lacked sufficient power for statistical analysis. For example, the potential importance 
of anaesthetic agent was discussed in section 3.3.4. In particular, the potential of 
propofol to abrogate RIC is highly topical.298 Interestingly, we observed studies where 
propofol (together with either opioid analgesia ± pancuronium) was administered to 
have effect sizes above the mean, although no trends were observed with other 
anaesthetic agents. Furthermore, studies reporting the use of either female or mixed 
gender experimental groups reported apparently smaller effect sizes. These 
qualitative data require further testing in formal, well-designed studies. 
No statistical relationship was found between study quality and effect size using 
meta-regression. However, there were some interesting observations. In particular, 
it is noteworthy that there was generally poor observation of the ARRIVE guidelines, 
particularly in relationship to blinding and statistics. These facets are clearly essential 
to ensure good quality research and increase the likelihood of successful clinical 
translation, and were a central tenet of a recent position paper on improving the pre-
clinical assessment of novel cardioprotective therapies.237 However, aspects of the 
report relating to the experimental procedure, including control of temperature and 
recording of the ECG, were generally well reported. Each quality criterion was not 
analysed independently to avoid false positive findings due to multiple comparisons. 
Finally, an assessment of publication bias by visual analysis of the funnel plot 
suggested that small, neutral studies may be under-represented; however, this did 
not statistically impact on the overall effect size, which is reassuring. 
Meta-analysis has several limitations. The validity of this meta-analysis is contingent 
upon the quality of reporting of the included studies. Unpublished studies and those 
with missing data could not be included in the meta-analysis, and others did not meet 
important quality criteria including poor information regarding statistical analysis and 
blinding. However, the absence of a statistical impact from study quality or 
publication bias is reassuring in this regard. Being unable to consider manuscripts not 
available in English was a further limitation and it is acknowledged that a systematic 
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review of the literature to determine which experimental variables to include in the 
meta-regressions was not performed, which might therefore be subject to selection 
bias. A relatively small number of studies were included in the meta-analysis, thereby 
limiting the power of the study, which was further affected by multiple comparisons 
within individual studies; however, all comparisons were included to avoid selection 
bias. Meta-regression is inherently limited; however, to ensure this was as robust as 
possible a stratified meta-analysis by subgroup was performed and yielded similar 
results including a highly significant overall effect of RIC, significant heterogeneity, 
and no effect of any of the experimental variables included in the model. 
3.5 Summary 
This systematic review and meta-analysis of pre-clinical in vivo studies of myocardial 
IRI demonstrates a significant and highly reproducible beneficial effect of RIC, which 
is encouraging. This effect was highly heterogeneous, which could not be explained 
by any of the experimental variables tested. This heterogeneity may be due to un-
measurable, multifactorial differences between individual experimenters and 
laboratories. However, importantly, in vivo studies to date suggest the optimal RIC 
stimulus has not yet been identified. Therefore, this meta-analysis provides little 
guidance regarding the establishment of an in vivo IRI protocol, but does reinforce 
the importance of adhering to the ARRIVE guidelines. 
It also does not explain the neutral findings of ERICCA and RIP-HEART in CABG 
patients. The results suggest that the discrepancy between RIC in in vivo animal 
experiments and large outcome studies of RIC in CABG surgery might be better 
explained by failure of translation to humans rather than a type I error in pre-clinical 
studies. Furthermore, it is possible that RIC in animals more accurately models STEMI. 
While pilot trials in this setting have been promising, a large randomised outcome 
study is only now underway.180 If this is positive, it might be explained by a difference 
between STEMI and CABG patients with respect to the extent of ischaemia 
reperfusion injury, co-morbidities, or by adjunctive medications and techniques. 
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Chapter 4 Establishment and verification of murine in vivo models of 
myocardial ischaemia-reperfusion injury 
4.1 Introduction 
Following STEMI, early reperfusion by PPCI or pharmacological thrombolysis is a 
priority for reducing IS and improving clinical outcome.2, 3 Nonetheless, despite the 
widespread uptake of PPCI as the default strategy for STEMI in the UK (60% of centres 
offered 24/7 PPCI for STEMI in 2014 compared to 5% in 2004) there remains a 
significant burden of heart failure following MI.314 For example, in 2010, heart failure 
hospitalisations within 1 year of MI reached 14.2%, with unadjusted 1-year mortality 
of 45.5%.315 It is recognised that outcome following STEMI is related to IS,316 and as 
lethal IRI contributes to final IS it constitutes an important, and thus far unfulfilled, 
potential target for conferring better outcomes to these patients.5, 6, 9, 157  
Investigating IRI in human patients is complicated by the difficulty in measuring the 
AAR, that is, the portion of myocardium that is rendered ischaemic by an obstructed 
epicardial coronary artery and stands to be salvaged by reducing IRI. AAR can be 
calculated from angiographic jeopardy scores, including the Alberta Provincial 
PRoject for Outcome Assessment in Coronary Heart disease (APPROACH) score.317 
However, although such scores have been prospectively validated, they require 
invasive angiography with its associated cost and procedural risk. CMR techniques 
using T2-weighted imaging of myocardial oedema have been validated as a measure 
of AAR by comparison to histology in animals, angiographic jeopardy scores, 
myocardial single photon emission CT (SPECT) and, recently, hybrid positron emission 
tomography and magnetic resonance (PET-MR).318 
However, although the use of CMR to evaluate AAR and IS has been described and 
validated in rodents,319 it is limited by financial constraints. Therefore, an 
experimental model of IRI that permits the direct measurement of injury is required. 
Several are available, including simulated IRI (hypoxia-reoxygenation) of in vitro 
cultured cells, ex vivo isolated cardiomyocytes, ex vivo hearts on a Langendorff 
apparatus, and ex vivo human atrial trabeculae. However, an in vivo model of 
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myocardial IRI is preferred here as this project aims to investigate cardioprotective 
mechanisms that are remote from the heart and therefore require intact organ 
systems. 
Myocardial IRI in humans most commonly occurs as a result of atheromatous plaque 
rupture, thrombus formation and subsequent mechanical or pharmacological 
reperfusion. To replicate this in an animal model is time-consuming, expensive and 
unpredictable, and therefore alternative approaches are necessary. Surgical 
induction of myocardial ischaemia has the advantages of being under the spatial and 
temporal control of the experimenter.292 A surgical model of IRI was first described 
in dogs in 1967, in a study of the haemodynamic effects of isoproterenol, but was 
complicated by high mortality due to ventricular tachycardias and small IS due to 
collateral circulation.320 Rats and mice lack an extensive collateral circulation, and 
although rodent hearts are less similar to human hearts than those of large animals, 
they are cheaper, easier to breed and less time-consuming than large animal 
models.292 
This chapter therefore aims to describe the establishment of an in vivo model of 
myocardial IRI in both rats and mice. 
4.2 Research aims and objectives 
The main objective of this chapter was to establish a murine in vivo model of 
myocardial IRI. The research aims for this objective were: 
1. Establish and verify a rat in vivo model of myocardial IRI; 
2. Establish and verify a mouse in vivo model of myocardial IRI. 
4.3 Aim 1: Establish and verify a rat in vivo model of myocardial ischaemia-reperfusion 
injury 
4.3.1 Background 
The first rat model of permanent left coronary artery occlusion was described in 
1979.321 Since then, the rat model of myocardial IRI has been established and widely 
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used in our laboratory and others to investigate potential therapeutic interventions 
and has been extensively described in the literature (reviewed by Klocke et al.).292 
This includes confirmation of its suitability for demonstrating cardioprotection by IPC 
and RIC (validation).283, 322 Once established by any individual researcher, it is 
necessary to verify the model. This requires demonstrating that the application of a 
valid method is effective. Here, this mandates demonstrating a reduction of IS in 
response to known cardioprotective interventions. Furthermore, the model should 
be reliable, meaning it produces consistent results. This is important as good 
reliability (low variance) reduces the sample size necessary to demonstrate a 
statistically significant effect, which is an important reductionist concept. Therefore, 
it is necessary to develop a model that is reproducible enough to permit the detection 
of cardioprotection (reduction of IS) upon application of an established 
cardioprotective intervention. 
As discussed in 0, several cardioprotective interventions are available, including both 
pharmacological and mechanical strategies. IPC has been confirmed in a large meta-
analysis to substantially (mean difference of 24.6% in this particular study) reduce IS 
in pre-clinical models,102 and is therefore a suitable cardioprotective intervention to 
verify this model. It is equally important to demonstrate cardioprotection by RIC, as 
the subject of this project. Cardioprotection by RIC in an in vivo rat model of IRI is less 
well described and, in studies published to date, has been shown to confer less 
marked (WMD 20.9%) and more variable protection, as demonstrated by the 
significant heterogeneity in the meta-analysis described in Chapter 2 (I2 99.4% 
compared to 94.7% in the meta-analysis of IPC, described above).102 Nonetheless, in 
order to investigate the mechanism it is essential to first successfully reduce IS using 
RIC, which is the main aim of this section. 
4.3.2 Methods 
Rats were randomly assigned to control, IPC or RIC groups. To confirm the cessation 
of blood flow during cuff inflation, non-invasive, two-dimensional blood flow 
assessment was undertaken using a high resolution laser Doppler imager (Moor 
Instruments, Devon, UK). Briefly, an infra-red (785 nm) laser was used to sequentially 
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scan the whole hind limb. The incident beam undergoes Doppler shift when it is 
reflected by moving erythrocytes, and the magnitude and frequency of the 
backscattered signal is converted by photodiodes to an electrical signal representing 
the number and velocity of erythrocytes.323, 324 These signals are digitally transformed 
into a colour-coded map indicating the spatial distribution of flow in the hind limb, 
whereby low or absent flow is blue and areas of highest flow are red. A Sprague 
Dawley rat was anaesthetised and subjected to the RIC protocol described in section 
2.4.3. Laser Doppler images were taken at baseline, during ischaemia and during 
reperfusion. 
In addition, in an exploratory analysis, skeletal muscle oxygen tension (tPO2) was 
measured during cuff inflation. This relied on a 650 µm diameter large-area-surface 
(LAS) sensor connected to an OxyLite dissolved oxygen monitor (Oxford Optronix, 
Oxon, UK). Oxygenation is measured along the shaft of the LAS sensor, resulting in a 
sampling area of 8 mm2, which allows averaging of local tPO2 fluctuations caused by 
placement and movement. Measurements are accurate in the physiological range 
and oxygen is not consumed during recording.325 
To insert the probe, a skin incision was made over the left lateral thigh. A 10 mm deep 
puncture was made in the vastus intermedius muscle with a 21G x 5/8” Microlance 
needle (BD, Oxon, UK), and the LAS sensor was immediately passed into the track. 
The probe was withdrawn by 1 mm prior to recording to negate the confounding 
effect of local haematoma. tPO2 measurements were continuously recorded using 
PowerLab 4/25 coupled to Chart 7 (AD Instruments, Oxon, UK). 
Sample size was not calculated a priori for any experiments in rats, in which six 
animals per group were used in line with convention. 
4.3.3 Results 
During the establishment of this in vivo rat model of myocardial IRI, a number of 
problems were identified that largely resulted from surgical inexperience. The major 
challenges were: (1) successful intubation; (2) surgically-induced haemorrhage; and 
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(3) inadequate staining with Evans blue. These were mainly resolved by experiential 
learning, but some specific refinements are considered here. Firstly, initial attempts 
to intubate were complicated by an inadequate view of the vocal cords and trans-
illuminated trachea, caused by failure to move the epiglottis out of the line of vision. 
Failed intubation typically causes respiratory arrest, usually resulting in death. The 
intubation technique was modified by using angled dissecting forceps with a longer 
blade (200 mm; B. Braun, PA, USA) to ensure apposition of the epiglottis to the 
posterior tongue and an unobstructed view of the vocal cords. Secondly, it was 
apparent that myocardial puncture in order to under-run the LAD caused significant 
surgical bleeding, which was another major cause of animal loss. To rectify this, the 
needle shape was changed from 1/2 circle to 3/8 circle, and its size from 13 mm to 
9.3 mm. This facilitated more precise placement of the LAD suture, resulted in less 
surgical trauma, and consequently less haemorrhage and animal loss. 
Early results are not described here due to the variability in IS, survival and surgical 
technique. However, subsequent experiments were conducted after completion of 
this process, to maximise their validity. During this experiment, reasons for 
experiment failure were documented, audited and discussed with experienced 
operators, and a training log was maintained throughout. A summary is given in 
Figure 4-1. Whenever possible, hearts were removed from animals that died 
prematurely to check correct placement of the LAD suture by Evans blue staining to 
guide future technical refinement. 
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Figure 4-1: Experimental success during establishment of a rat in vivo model of myocardial 
ischaemia-reperfusion injury 
47 animals were used during the course of the experiment. 18 were included in the analysis 
(38%). Excluded animals were defined as operator-dependent (72% of exclusions) or 
operator-independent (28%). The former related to surgical inexperience and most 
frequently included haemorrhage and inadequate staining with Evans blue. The latter were 
predominantly due to unexplained mortality or due to their AAR falling outside the pre-
defined range. 
Doppler images of the lower limb demonstrated cessations of blood flow during cuff 
inflation to 200 mmHg and return of blood flow to the distal tissues upon cuff 
deflation. Representative images are shown in Figure 4-2. 
 
Figure 4-2: Laser Doppler blood flow assessment demonstrating rat hind limb ischaemia 
during remote ischaemic conditioning 
A rat was anaesthetised and subjected to three cycles of 5 min hind limb ischaemia and 5 min 
reperfusion. A representative image from each step is shown here, alongside a plain 
photograph of the subject (A). Low or absent flow is blue and areas of highest flow are red 
(scale bar shown in Panel A). 
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Skeletal muscle tPO2 measurement confirmed reduced oxygen tension, but 
interestingly showed that the rate of decline is longer in animals anaesthetised with 
supplementary oxygen (Figure 4-3). Consequently, oxygenated animals spend less of 
the RIC cycle with tPO2 at hypoxic levels. This will be discussed in more detail in 
section 4.4.1. 
 
Figure 4-3: Representative rat skeletal muscle tPO2 assessment during remote ischaemic 
conditioning with and without supplementary oxygen 
Sprague Dawley rats were anaesthetised and stabilised without supplementary oxygen prior 
to the following interventions: (A) Supplementary oxygen started; (B) Hind limb cuff inflated 
to 200 mmHg; (C) Cuff deflated; (D) Supplementary oxygen stopped; (E) Cuff inflated; (F) Cuff 
deflated; (G) Cuff removed. The dashed red line gives an approximate ‘hypoxic’ tPO2 (6 
mmHg). During RIC on supplementary oxygen, skeletal muscle tPO2 spends less time below 
this line than during RIC without supplementary oxygen. 
This experiment measured IS as a proportion of AAR in Sprague Dawley rats following 
in vivo IRI. Six animals were included per group and analysis of their respective areas 
at risk, to ensure surgical consistency, revealed no significant differences (control 
45.0±3.6% vs. IPC 38.9±1.0% vs. RIC 47.1±2.9%, n=6, P=NS, Figure 4-4). 
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Figure 4-4: Comparison of area at risk between control, ischaemic preconditioning and 
remote ischaemic conditioning groups 
Sprague Dawley rats were anaesthetised and treated with either IPC (5 min LAD occlusion 
and 5 min reperfusion) or RIC (three cycles of 5 min hind limb ischaemia and 5 min 
reperfusion) prior to 30 min ischaemia and 2 h reperfusion in vivo. Analysis of their respective 
areas at risk, to ensure surgical consistency, revealed no statistically significant differences. 
Statistical significance was assessed using one-way ANOVA and Tukey’s multiple comparison 
test, n=6, P=NS for all comparisons. Data presented as mean ± SEM. 
Subsequent analysis of IS as a proportion of AAR revealed that the application of IRI, 
as described, resulted in an IS of 51.1±4.0 (Figure 4-5), which is broadly consistent 
with IS described in Chapter 2. As expected, IPC significantly reduced IS/AAR 
(17.9±1.5%, n=6, P<0.001 vs. control). IS were smaller after the application of RIC, 
although this effect was less marked and more variable than IPC, as predicted 
(37.6±4.2%, n=6, P<0.05 vs. control). Representative transverse heart sections are 
shown in Figure 4-5. This study confirms that it is feasible to investigate IRI and RIC in 
this rat in vivo model of IRI. 
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Figure 4-5: Infarct size following ischaemic preconditioning and remote ischaemic 
conditioning prior to myocardial ischaemia-reperfusion injury in vivo 
Sprague Dawley rats were anaesthetised and treated with either IPC (5 min LAD occlusion 
and 5 min reperfusion) or RIC (three cycles of 5 min hind limb ischaemia and 5 min 
reperfusion) prior to 30 min ischaemia and 2 h reperfusion in vivo. IS as a proportion of AAR 
was analysed using Evans Blue and TTC staining. (A) Both IPC and RIC significantly reduced IS 
compared to control. Statistical significance was assessed using one-way ANOVA and Tukey’s 
multiple comparison test, n=6, ***P<0.001, *P<0.05. Data presented as mean ± SEM; (B) 
Representative scanned transverse heart sections demonstrating Evans Blue area (blue), area 
at risk (pink) and infarct (white). 
4.3.4 Discussion 
Initial surgical experiments were complicated by a range of issues, as described in 
section 4.3.3. However, by making the refinements outlined above, it was possible to 
develop a robust and reproducible in vivo model of myocardial IRI. 
The protocol described here, which is used as standard in our laboratory, applies 30 
min of ischaemia followed by 2 h of reperfusion. This generated an IS of 
approximately 50%, which was broadly similar to the IS described in Chapter 2. 
Furthermore, the mean IS and SEM in this group were sufficient to be amenable to 
cardioprotection from known cardioprotective interventions, namely IPC and RIC, 
without being large enough to cause premature complications and death. 
Previous studies have examined the impact of time of surgery on IS, and found 
significantly larger infarcts on animals undergoing surgery in the early morning.326 
This is of particular interest with reference to SDF-1α, which is known to exhibit 
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circadian rhythm in its expression in bone marrow.327 To control for this potentially 
confounding effect, control and intervention groups were distributed evenly 
between morning and afternoon operating sessions, and no surgeries were 
conducted out of hours. 
Furthermore, AAR exclusion criteria are a potential confounder as AAR is variable 
depending upon the exact position of the LAD suture and variable LAD anatomy, 
especially in Sprague Dawley rats that are reported to have variable IS and cardiac 
dysfunction after IRI due to variable LAD branching.203  As discussed in section 3.3.2, 
IS has a strong positive correlation with AAR and, therefore, it is essential to evaluate 
both the AAR and absolute IS. Only then can IS be interpreted in context, as a 
percentage of AAR. This corrects, in part, for subtle variations in the position of the 
LAD suture and murine cardiac vessel anatomy. However, at the extremes of AAR the 
linear relationship with IS fails.216, 258 This can confound results and, for this reason, 
hearts were excluded from analysis if the AAR was outside a pre-defined range (based 
on precedent within the laboratory) of 35-70%. The present study found no 
significant difference in AAR between the groups, and exclusions were evenly 
distributed between groups. 
While MI clearly affects, thereby mandating basic research in, both genders, this was 
not specifically examined in experiments involving rats, which used male animals 
throughout. This experimental variable is discussed in more detail in section 4.4.4. All 
rats were anesthetised with pentobarbitone in view of our laboratory’s experience 
with this agent, and the well-described cardioprotective effects of volatile 
anaesthetics such as isoflurane.241 Furthermore, no impact of pentobarbitone on 
effect size was identified in Chapter 2. As discussed in 0, it is hypothesised that SDF-
1α affects cardioprotection by activating the RISK pathway at the time of reperfusion. 
A remote ischaemic pre-conditioning protocol was applied here, and throughout this 
thesis, to allow sufficient time for circulating SDF-1α levels to reach their peak. This 
is discussed in more detail in section 7.4. Finally, all rats were ventilated with 
supplementary oxygen. Despite finding no difference between ventilation with room 
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air and supplementary oxygen in Chapter 2, the use of supplementary oxygen is 
routine in our laboratory. This is discussed in more detail in section 4.4.1. 
4.4 Aim 2: Establish and verify a mouse in vivo model of myocardial ischaemia-reperfusion 
injury 
Dr D. Bromage conceived and co-designed the oxygenation experiments described in 
this section. The experiments were performed by Dr D. He from the Hatter 
Cardiovascular Institute (UCL,UK). 
4.4.1 Background 
This non-recovery mouse model of myocardial IRI was first described in 1995.328 It 
has since been used to investigate myriad interventions including IPC and RIC, both 
of which are well validated in this model.181, 329 Prior to instituting this technique, it is 
necessary to consider important experimental variables. Although none apparently 
affected efficacy in the meta-analysis described in Chapter 2, there is interesting 
recent data from our laboratory that is apposite in this context. 
Firstly, while the analysis in Chapter 2 found no significant difference in the efficacy 
of RIC in animals ventilated with oxygen versus those with room air, this may still be 
important in view of the finding of slower skeletal muscle de-oxygenation during RIC 
in the limbs of rats ventilated with supplementary oxygen in section 4.3.3. Therefore, 
a comparison of the efficacy of RIC in oxygenated versus un-oxygenated animals was 
performed in our laboratory by Dr D. He. This demonstrated a reduction in control IS 
in mice ventilated with oxygen and, importantly, cardioprotection by RIC was 
abrogated in these mice (Figure 4-6). To investigate whether this was a function of 
limb oxygenation or the lower control IS, further mice were treated with vehicle or 
40 µg/kg bradykinin (a pharmacological cardioprotective agent), in addition to 
supplementary oxygen, prior to IRI.218 Bradykinin conferred cardioprotection in these 
mice, despite oxygenation, suggesting that the development of IPC and RIC might be 
related to limb oxygenation. 
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Figure 4-6: Infarct size following remote ischaemic conditioning with and without 
supplementary oxygen in vivo 
(A) Comparison of IS/AAR in C57BL/6 mice subjected to IRI with and without preceding RIC 
(three cycles of 5 min hind limb ischaemia and 5 min reperfusion) in animals ventilated with 
and without supplementary oxygen. RIC significantly reduced IS compared to control in mice 
ventilated with room air, but not in mice ventilated with 100% oxygen. Statistical significance 
was assessed using a two-way ANOVA with Bonferroni correction, n=6, **P<0.01; (B) In a 
separate experiment, bradykinin significantly reduced IS/AAR in mice ventilated with oxygen. 
Statistical significance was assessed using an unpaired t-test, n=4-6, *P<0.05. Data obtained 
by Dr D. He. 
An alternative explanation might be that bradykinin is simply a more powerful 
cardioprotective intervention than RIC and, therefore, is able to protect over and 
above the diminished IS in oxygenated animals. Furthermore, oxygen clearly did not 
abrogate RIC in rats, due to the findings discussed in section 4.3.3. Nonetheless, 
based on the finding described here, mice used in this section were ventilated 
without supplementary oxygen. 
Dr D. He also performed a similar assessment of blood flow during cuff inflation using 
high resolution laser Doppler imaging to that described in section 4.3.2. Interestingly, 
this demonstrated incomplete cessation of blood flow at a cuff pressure of 200 mmHg 
that was rectified by inflating the cuff to 250 mmHg (Figure 4-7). Therefore, a higher 
pressure of 250 mmHg was used specifically for the mouse in vivo model of RIC 
described in this thesis. Finally, in his further characterisation, Dr D. He found 30 min 
of ischaemia to be insufficient in the generation of a control IS amenable to 
cardioprotection, and instead applied 40 min of ischaemia (data not shown). This was 
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applied to the mouse in vivo model of IRI described in this thesis without further 
enquiry. 
 
Figure 4-7: Laser Doppler blood flow assessment demonstrating hind limb ischaemia during 
cuff inflation 
A mouse was anaesthetised and subjected to RIC (three cycles of 5 min hind limb ischaemia 
and 5 min reperfusion). A representative image from each step is shown here, alongside a 
plain photograph of the subject (A). During cuff inflation to 200 mmHg residual flow was 
apparent (Panel C, arrowed) compared to baseline (Panel B). This was abrogated by cuff 
inflation to 250 mmHg (Panel D). Data obtained by Dr D. He. 
It was then necessary to both verify the ability of this model to demonstrate 
cardioprotection following the application of known cardioprotective interventions, 
and to confirm its reliability. In these experiments in mice, cardioprotection was 
validated using hypothermia and RIC. 
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4.4.2 Methods 
Excess CXCR4flox/flox Cre+/+, un-injected mice (wild type) were used in this experiment. 
LoxP sites were not expected to interfere with the generation of MI, and this is 
discussed further in section 4.4.4. All mice underwent 5 min of stabilisation, 30 min 
of (index) LAD ischaemia and 2 h of reperfusion, as described above. Heart sections 
were fixed in formalin for 24 h compared to 2 h in rats, as this was found to improve 
demarcation of infarcted and viable myocardium without significantly impacting on 
mean AAR or IS. This is discussed further in section 5.2.3. 
During the characterisation of the model, it became apparent that the temperature 
probe was not calibrated and was overestimating core body temperature by 2⁰C. 
Consequently, the homeothermic heat mat (Kent Scientific, CT, USA) was not hot 
enough, resulting in hypothermic animals (approximately 35±0.5⁰C) for the duration 
of the experiment. Temperature regulation was subsequently managed manually 
using a rectal temperature probe, which was calibrated prior to each experiment, and 
adjustment of a heated veterinary operating mat. 
Heart rate was recorded throughout using PowerLab 4/25 and Animal Bio Amp 
coupled to Chart 7 (AD Instruments, Oxon, UK). Mean heart rate over 5 min was 
specifically documented at the following time points: (1) baseline; (2) after the onset 
of ischaemia; (3) after the onset of reperfusion; (4) after 1 h reperfusion; and (5) prior 
to extraction of the heart. 
Mice were subsequently randomly assigned to control or RIC groups and RIC was 
applied as described in section 2.4.3. The necessary sample size for the evaluation of 
RIC was calculated using a two-sided test for the comparison of two means. A 20% 
estimate of effect size was applied, based on the meta-analysis described in Chapter 
3 and the following assumptions made: a control IS of 60%, a SD of 10%, a significance 
level of 5% (α=0.05) and 80% power (β=0.2). This required a minimum sample size of 
four animals per group. 
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4.4.3 Results 
During this experiment, reasons for failure were documented, audited and discussed 
with experienced operators, and a training log was maintained throughout. A 
summary is given in Figure 4-8. 
 
Figure 4-8: Experimental success during characterisations of a mouse in vivo model of 
myocardial IRI 
22 animals were used during the course of the experiment. 17 were included in the analysis 
(77%). Excluded animals were defined as operator-dependent (60% of exclusions) or 
operator-independent (40%). The former related to surgical inexperience and included 
trauma to the LAD and inadequate staining with Evans blue. The latter were due to 
unexplained mortality, anaesthetic complications or due to their AAR falling outside the pre-
defined range. 
Overall, the treatment group (control, hypothermia or RIC) had a significant effect on 
heart rate throughout the experiment (n=4-7, P for effect of heart rate <0.05, Figure 
4-9). Interestingly, mice treated with RIC had significantly lower heart rates at 
baseline compared to control animals (P<0.05), although hypothermic animals were 
generally more bradycardic throughout. 
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Figure 4-9: Comparison of heart rate according to treatment group in mice 
C57BL/6 mice were anaesthetised and treated with either RIC (three cycles of 5 min hind limb 
ischaemia and 5 min reperfusion) or hypothermia prior to 40 min ischaemia and 2 h 
reperfusion in vivo. Mean heart rate was recorded over 5 min at each of the following time 
points: Baseline (BL); Immediately after the onset of ischaemia (I); Immediately following 
reperfusion (R) and at 60 and 120 min into reperfusion. Hypothermic animals had 
significantly lower heart rates than either normothermic (control) or RIC groups. Statistical 
significance was assessed using repeated measures ANOVA and Tukey’s multiple comparison 
test, n=4-7, P<0.05. 
This experiment measured IS as a proportion of AAR in mice following in vivo IRI. Six 
animals were included in the control group, four in the RIC group and seven in the 
hypothermia group. Analysis of their respective areas at risk revealed no significant 
differences (control 56±6% vs. RIC 59±5 vs. hypothermia 58±4%, n=6, P=NS, Figure 
4-10). 
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Figure 4-10: Comparison of area at risk between control (normothermia), remote ischaemic 
conditioning and hypothermia groups 
C57BL/6 mice were anaesthetised and treated with either RIC (three cycles of 5 min hind limb 
ischaemia and 5 min reperfusion) or hypothermia prior to 40 min ischaemia and 2 h 
reperfusion in vivo. Analysis of their respective areas at risk, to ensure surgical consistency, 
revealed no statistically significant differences. Black points indicate male mice and red 
points indicate female mice. Statistical significance was assessed using one-way ANOVA and 
Tukey’s multiple comparison test, n=4-7, P=NS for all comparisons. Data presented as mean 
± SEM. 
Subsequent analysis of IS as a proportion of AAR revealed that the application of IRI, 
as described, resulted in an IS of 43±3% (n=6, Figure 4-11), which is consistent with 
IS generated using standard protocols within our laboratory (data not shown). RIC 
significantly reduced IS/AAR compared to control (23±4%, n=4, P<0.0001 vs. control). 
Furthermore, hypothermia reduced IS/AAR compared to control to an even greater 
degree (14±1%, n=7, P<0.0001 vs. control, P<0.05 vs. RIC). Representative transverse 
heart sections are shown in Figure 4-11. This study confirms that it is feasible to 
investigate cardioprotection in this mouse in vivo model of IRI. 
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Figure 4-11: Infarct size following remote ischaemic conditioning and hypothermia in vivo 
C57BL/6 mice were anaesthetised and treated with either RIC (three cycles of 5 min hind limb 
ischaemia and 5 min reperfusion) or hypothermia prior to 40 min ischaemia and 2 h 
reperfusion in vivo. IS as a proportion of AAR was analysed using Evans Blue and TTC staining. 
(A) Both RIC and hypothermia significantly reduced IS compared to control. Black points 
indicate male mice and red points indicate female mice. Statistical significance was assessed 
using one-way ANOVA and Tukey’s multiple comparison test, n=4-7, ***P<0.0001, *P<0.05. 
Data presented as mean ± SEM; (B) Representative scanned transverse heart sections 
demonstrating Evans Blue area (blue), area at risk (pink) and infarct (white). 
Echocardiogram measurements were successfully obtained in 100% of control and 
RIC animals, and 74% of hypothermic animals, with the remainder attributable to 
poor image quality. Echocardiography revealed a pattern of reduced fractional 
shortening, stroke volume and cardiac output between scans performed before and 
after IRI, which reached significance with respect to stroke volume (P<0.001). 
Importantly, however, there was no discernible difference in any parameter between 
treatment groups (Figure 4-12). 
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Figure 4-12: A comparison of echocardiographic parameters according to treatment group 
C57BL/6 mice were anaesthetised and treated with either RIC (three cycles of 5 min hind limb 
ischaemia and 5 min reperfusion) or hypothermia prior to 40 min ischaemia and 2 h 
reperfusion in vivo. Echocardiography was performed prior to the onset of ischaemia 
(baseline) and prior to heart extraction (end). Stroke volume, but not fractional shortening 
or cardiac output, was significantly reduced after IRI. Treatment group (control, RIC and 
hypothermia) made no detectable difference to any of these parameters, either at baseline 
or after IRI. Statistical significance was assessed using two-way ANOVA and Bonferroni 
correction for multiple comparisons, n=4-6, ***P<0.001 between baseline and end. 
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As discussed in section 2.4.5, mouse heart sections were fixed in formalin for 24 h, in 
contrast to 1 h for rat heart sections. To exclude this as a source of bias, comparison 
was made between sections fixed for 1h and the same sections fixed for 24 h using 
the control group described above. Analysis of the areas at risk revealed no significant 
differences (1 h 56±4% vs. 24 h 56±6%, n=6, P=NS, Figure 4-13). IS as a proportion of 
AAR similarly revealed no significant difference (1 h 42±4% vs. 24 h 43±3%, n=6, P=NS, 
Figure 4-13). 
 
Figure 4-13: Comparison of 1 h versus 24 h fixation time on area at risk and infarct size as 
a proportion of area at risk 
C57BL/6 mice were anaesthetised and subjected to 40 min ischaemia and 2 h reperfusion in 
vivo. IS as a proportion of AAR was analysed using Evans Blue and TTC staining, before either 
1 h or 24 h fixation in formalin. Neither AAR (A) or IS/AAR (B) were significantly altered by a 
longer duration of fixation. Black points indicate male mice and red points indicate female 
mice. Statistical significance was assessed using paired t-tests, n=6, P=NS. Data presented as 
mean ± SEM. 
To further investigate the effect of duration of fixation in formalin, a single sample 
was scanned daily for analysis of the AAR and IS (Figure 4-14). AAR remained stable 
up to day 9 while IS/AAR seemed to enlarge beyond 5 days of fixation. Representative 
images are given in Figure 4-14. 
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Figure 4-14: Effect of formalin fixation time on area at risk and infarct size as a proportion 
of area at risk 
C57BL/6 mice were anaesthetised and subjected to 40 min ischaemia and 2 h reperfusion in 
vivo. IS as a proportion of AAR was analysed using Evans Blue and TTC staining, before fixation 
in formalin and daily analysis until day 9. (A) Effect of fixation in formalin on AAR (black line) 
and IS/AAR (red line); (B) Representative transverse heart sections scanned at 1 h and 9 days 
demonstrating Evans Blue area (blue), area at risk (pink) and infarct (white). 
4.4.4 Discussion 
This protocol conferred an IS of approximately 40%, which was consistent with the IS 
described in Chapter 3. Furthermore, this in vivo model of myocardial IRI was robust 
and reproducible; specifically, the mean IS and SEM in this group was sufficient to be 
amenable to cardioprotection from known cardioprotective interventions, namely 
RIC and hypothermia. 
The C57BL/6 background strain was used throughout. This is the most widely 
investigated inbred general purpose strain and has the advantage of breeding well. 
C57BL/6 mice also tolerate the generation of most transgenic strains and are the 
background strain to the CXCR4flox/flox mice described above and used for this 
experiment. Specifically, all mice used here were un-injected, CXCR4flox/flox Cre+/+ 
mice.  As LoxP sites do not alter gene expression per se, they were not expected to 
affect IS or the ability to confer cardioprotection. 
Mice of both genders were used in this study for several reasons: (1) both male and 
female humans suffer MI and it is therefore important that this is reflected in pre-
clinical studies; (2) using both gender animals avoids animal wastage and is an 
important reductionist concept; and (3) no difference in the efficacy of RIC or IPC 
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according to gender was observed in the meta-analysis described in Chapter 3 or the 
study by Wever et al., respectively.102 While the numbers of each gender included in 
each group in the present study were too small for statistical comparison, there were 
no obvious trends and both male and female mice were included in mouse in vivo 
infarction studies throughout this thesis. 
Mice were anaesthetised with pentobarbitone in view of our laboratory’s experience 
with this agent, the lack of effect on WMD seen in Chapter 2, and the well-described 
cardioprotective effects of volatile anaesthetics such as isoflurane.241 Similar studies 
have used a combination of ketamine, xylazine and atropine.330 Although this 
reportedly has comparable haemodynamic effects to isoflurane and 
pentobarbitone,296 all these agents adversely affect cardiovascular functional indices 
compared to tiletamine and zolazepam.296 Nonetheless, in the absence of any 
experience in our laboratory of tiletamine and zolazepam, and to be consistent with 
the rat model, pentobarbitone was used throughout. 
As discussed, mice were ventilated without supplementary oxygen. This factor was 
not specifically examined in this thesis, but it would be fascinating to investigate 
further as the effect of oxygenation on the development of RIC might have important 
implications for both pre-clinical and clinical study design. 
In the present study, 40 min of ischaemia and 2 h of reperfusion were applied, and 
these durations were closely controlled. All experiments were distributed evenly 
between morning and afternoon operating sessions, and no surgeries were 
conducted out of hours. To correct for variations in the position of the LAD suture 
and murine cardiac vessel anatomy, IS was expressed as a percentage of AAR. To 
avoid confounding by areas at risk at either extreme, hearts were excluded from 
analysis if the AAR was outside a pre-defined range of 35-75%. This varied from the 
exclusion criteria used in rats due to different precedents in our laboratory. However, 
provided the exclusion criteria are applied consistently to all groups, this should not 
impact on experimental outcomes. The present results found no significant 
 139 
 
difference in AAR between the groups, and exclusions were equally distributed 
between groups. 
Although the initial intention was not to investigate hypothermia, it was decided to 
exploit the experiments in which mice were maintained at a lower temperature and 
examine its effects. Mild hypothermia is known to significantly reduce myocardial IS. 
For example, Hamamoto et al. demonstrated cardioprotection in sheep subjected to 
myocardial IRI after systemic cooling to 35.5⁰C for the duration of ischaemia and 
reperfusion (IS/AAR 21.7±2.2% vs. 49.4±1.4% at 37.5⁰C, P<0.05).331 A similar effect 
has been demonstrated in several species, including 60-80 kg pigs, using several 
techniques, including endovascular, topical and intracoronary cooling.332-337 These 
studies have applied hypothermia at various time-points during the ischaemia-
reperfusion protocol, although Kanemoto et al. reported the temperature at 
reperfusion to correlate most strongly with reduction in IS.333 All studies reduced core 
temperature between 2-5⁰C and one study, by Chien et al., reported a reduction in 
IS of approximately 10% for each 1⁰C reduction in core body temperature.338 This is 
broadly consistent with the present data that demonstrated a 25% reduction in IS 
with a 2⁰C reduction in core body temperature (Figure 4-11). 
The mechanism of hypothermia-induced cardioprotection has been less well 
investigated, but has been attributed to moderation of oxidative stress,335 
attenuation of the no-reflow phenomenon (whereby coronary microvasculature 
disruption during ischaemia impedes successful reperfusion),339 inhibition of p53-
mediated apoptosis and up-regulation of Akt,340 increased NO synthesis and PKC 
activation.341 
Interestingly, hypothermia apparently synergises with preconditioning, suggesting 
the mechanisms of protection are distinct. Van den Doel et al. reported that the 
combination of IPC and hypothermia applied in the setting of IRI in the in vivo rat 
heart reduced IS more than either intervention alone,342 and a similar phenomenon 
has been demonstrated in rabbits.334 However, this was not tested in the present 
study. 
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This study found a significantly reduced mean heart rate in hypothermic mice, which 
is caused by a non-vagal reduction in spontaneous sinoatrial node depolarisation. 
However, the advantages of hypothermia in IRI described above are apparently 
independent of this bradycardia (and consequent reduced myocardial oxygen 
demand and preservation of aerobic metabolism), as evidenced by studies that have 
maintained heart rate during hypothermia by electrical pacing and still observed a 
benefit with hypothermia.337, 338 
Based on this pre-clinical evidence, there is significant interest regarding the potential 
benefit of therapeutic hypothermia in STEMI, and there have been several 
randomised controlled trials to date. These were recently subject to systematic 
review and meta-analysis which demonstrated that, despite being safe with regard 
to bleeding, ventricular arrhythmias and bradycardia, therapeutic hypothermia in 
STEMI did not benefit any clinical end-points.343 The only significant benefit was seen 
with regard to IS, as measured by CMR or SPECT, in patients with anterior wall 
involvement. Interestingly, this is precisely the scenario in the present study where 
hypothermia mitigated IS in mice subject to LAD territory (anterior wall) IRI. 
Therefore, it is unclear how generally applicable the present results are. 
In the RIC group there was significant bradycardia at baseline, measured prior to the 
onset of ischaemia and during the last cycle of RIC. This is interesting in the context 
of studies investigating the role of vagus nerve activation during RIC (reviewed by 
Gourine et al.195). Increased parasympathetic tone as a result of RIC may be 
responsible for the observed relative bradycardia. However, in a retrospective 
analysis of heart rates in the rat characterisation experiment described in section 4.3 
there was no difference between control and RIC groups (P=NS, data not shown). 
Furthermore, a study investigating humoral and neural mechanisms of RIC likewise 
reported no effect of either pathway on heart rate.181 This finding may therefore 
represent a chance statistical finding and was not pursued further. 
Regarding the echocardiographic assessment of mice, it is known that the degree of 
LV impairment is directly proportional to IS,223, 321 and the use of echocardiographic 
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parameters might therefore increase the reliability and validity of the results. The 
present study demonstrated a fractional shortening at baseline of 45.7±4.8%, which 
is consistent with published values that range from 34-45% for C57BL/6 mice of a 
similar age and weight.223, 225, 344 However, cardiac output at baseline was 10.3±1.0 
ml/min, which is lower than estimates in the literature of 14-21 ml/min, depending 
on the method used.225 This is most likely to be attributable to underestimation of 
aortic root Doppler parameters due to an angle of incidence >15⁰ or error associated 
with calculating the aortic root CSA.224, 225 However, any error should not vary 
between experimental groups. 
The broad pattern of deteriorating echocardiographic parameters over the course of 
the experiment, which reached significance with respect to stroke volume, might be 
attributable to infarction. However, in view of the lack of difference between injured 
and protected experimental groups, it seems more likely that this was a consequence 
of prolonged anaesthesia. As discussed, pentobarbitone adversely affects 
cardiovascular functional indices, which include heart rate, cardiac output, blood 
pressure and LV dimensions, compared to tiletamine/zolazepam.296 This may explain 
the present results, although the relationship between duration of anaesthesia and 
LV impairment is unknown. Nonetheless, all groups were anaesthetised with 
pentobarbitone so, despite its negative inotropic and chronotropic effects, 
comparisons between experimental groups should remain valid. 
Furthermore, the absence of any measurable difference in echocardiographic 
parameters between infarcted and protected groups is consistent with previously 
published reports that differences are only apparent after at least 1 week. Gao et al. 
subjected C57 mice to coronary artery ligation and only identified significant 
differences in LVIDd, LVIDs and FS after 3 weeks.223 
4.5 Summary 
This chapter describes the development and refinement of rat and mouse in vivo 
models of myocardial IRI. In vivo models of myocardial IRI have some important 
limitations. Firstly, as described above, several animals died prematurely in these 
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studies. It was not appropriate to measure IS in these animals due to the confounding 
effects of cardiopulmonary arrest. However, it is possible that this introduced bias 
towards animals with smaller infarcts and better survival. Nonetheless, survival was 
not different between experimental groups. Secondly, the application of IRI in an 
open-chest model has important differences to MI in humans. These include surgical 
trauma, including a profound inflammatory response, and the effect of anaesthesia 
on IS and autonomic tone, all of which can affect IS.345 To this end, several groups 
have developed closed-chest, conscious, unrestrained models of in vivo IRI (reviewed 
by Lujan et al).345 Thirdly, although staining with TTC is considered the gold standard 
for histological assessment of IS, its utility is impaired by: (1) difficulty in 
distinguishing cell types, including red blood cells in haemorrhagic infarcts; (2) 
subjectivity in defining infarct and AAR by planimetry; (3) ‘stunning’ of living cells, 
impairing their ability to reduce TTC; and (4) difficulty in identifying cells in the 
ischaemic penumbra that will die, particularly after short periods of reperfusion. 
Fourthly, it is important to acknowledge that ligating the LAD of young, healthy, drug 
naive animals does not necessarily reflect clinical experience with MI patients, and 
thereby limits the translational utility of this model.238, 239 
Nonetheless, the key findings are that the IS conferred by IRI is consistent with 
previous data from our laboratory, and IS and variability were amenable to 
cardioprotection. The models were subsequently verified by demonstrating 
significant cardioprotection with the application of cardioprotective interventions, 
and are suitable for ongoing use in this thesis.  
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Chapter 5 Is exogenous SDF-1α cardioprotective? 
5.1 Introduction 
The Working Group of Cellular Biology of the Heart of the European Society of 
Cardiology published criteria that must be satisfied to define a molecule as an 
endogenous mediator of IPostC.103 These criteria apply equally to the 
characterisation of a molecule as an endogenous mediator of RIC and are (adapted 
from Ovize et al.103): 
 Induction of a pharmacological cardioprotective effect by exogenous 
administration of the mediator at the time of reperfusion; 
 Abolition of the effect by specific receptor blockade or by inhibition of the 
mediator’s production; 
 Increased production or maintenance of extracellular concentrations of the 
mediator(s) as a direct effect of RIC and 
 Absence of cardioprotection in animals, tissues or cells with genetic disruption 
of the mediator’s production or its receptor(s). 
These criteria form the basis of subsequent chapters, and the limited number of 
studies that have investigated whether SDF-1α-CXCR4 meets any of these criteria are 
discussed therein. The first of these criteria is to investigate whether a 
pharmacological cardioprotective effect could be induced by exogenous administration 
of the mediator (SDF-1α) at the time of reperfusion. 
5.2 Research aims and objectives 
The objective of this chapter was to investigate whether exogenous administration 
of SDF-1α at the time of reperfusion mediates a pharmacological cardioprotective 
effect. 
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Aim 1: Investigate whether exogenous administration of SDF-1α at the time of 
reperfusion mediates a pharmacological cardioprotective effect  
5.2.1 Background 
The evidence for exogenous SDF-1α being cardioprotective in the context of 
myocardial IRI is considered in detail in section 1.4.2. As discussed, in data from our 
laboratory from a model of simulated IRI applied to ex vivo rat papillary muscle, SDF-
1α administered prior to hypoxia significantly increased recovery of contractile 
function (Figure 5-1).31 
 
Figure 5-1: The effect of SDF-1α in the recovery of developed force in isolated rat heart 
papillary muscle after simulated ischaemia reperfusion injury 
SDF-1α prior to ischaemia improves contractile recovery of rat heart papillary muscle that is 
isolated and subject to 30 min hypoxia and 2 h reoxygenation, compared to untreated 
(control) muscle. Before hypoxia, the rat papillary muscle was perfused with (1) SDF-1α for 
10 min; or (2) AMD3100 for 5 min then AMD3100 plus SDF-1α for 10 min; or (3) AMD3100 
alone for 15 min. Statistical significance was assessed using two-way ANOVA and Fisher’s 
protected least significant difference test for multiple comparisons, n=6, *P<0.05. Figure 
from 31. 
Similarly, SDF-1α has been shown to mimic the cardioprotection conferred by hypoxic 
preconditioning in a model of simulated IRI using isolated human atrial trabeculae 
muscle (Figure 5-2).151 
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Figure 5-2: The effect of SDF-1α in the recovery of developed force in human right atrial 
trabeculae after simulated ischaemia-reperfusion injury 
Recovery of contractile function during 60 min hypoxia and 1 h reoxygenation of isolated 
human atrial trabeculae is improved by pre-treatment with exogenous SDF-1α to a level 
similar to that conferred by hypoxic preconditioning. Statistical significance was assessed 
using two-way ANOVA and Fisher’s protected least significant difference test for multiple 
comparisons, n=11 atrial trabeculae in the control and SDF-1α pre-treatment groups, 10 in 
the hypoxic preconditioning and AMD3100 + SDF-1α pre-treatment groups and 5 in the 
AMD3100 pre-treatment group, *SDF-1α vs. control, †AMD + SDF-1α vs. SDF-1α. Figure from 
151. 
Other laboratories have reported similar findings in a variety of settings. Huang et al. 
demonstrated better functional recovery after administering SDF-1α prior to the 
onset of ischaemia in an isolated mouse heart model of simulated IRI.149 Jang et al. 
used a similar Langendorff model in rats and demonstrated a significant benefit on IS 
after the infusion of SDF-1α around the time of reperfusion.150 In the only in vivo 
model investigating the potential acute efficacy of SDF-1α to date, Hu et al. 
demonstrated significantly reduced IS after infusing SDF-1α into the LV cavity of 
C57BL/6 mice prior to myocardial IRI.46 Saxena et al. also administered intra-cardiac 
SDF-1α, albeit in a mouse model of permanent LAD ligation, and found better long-
term recovery of function and less adverse remodelling.20 
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However, despite the promising results of Hu et al., the direct translational potential 
of their approach is limited by both the necessity to administer SDF-1α before the 
onset of ischaemia, which is impossible to predict in MI, and the impracticality of 
infusing SDF-1α into the LV cavity. Furthermore, the paradigm for RIC defined in this 
thesis requires demonstrating an effect at the time of reperfusion. Therefore, the aim 
of this section was to investigate whether exogenous SDF-1α, administered 
peripherally during ischaemia and prior to reperfusion, can reduce the injury 
conferred by myocardial IRI. 
5.2.2 Methods 
CXCR4flox/flox Cre+/+ mice that were neither injected with tamoxifen nor vehicle 
(phenotypically wild type) were used in this experiment. First, male mice were 
treated with either 0.9% saline (control) or 80 µg/kg SDF-1α (100 µl of 20 µg/ml stock 
for a 25 g animal, for example) by tail vein injection 10 min prior to blood sampling 
and analysis for SDF-1α as described in section 2.4.4. This served to demonstrate the 
efficacy of tail vein injection as well as ensuring that the administered dose of SDF-
1α, chosen based on the studies described in section 5.2.1, resulted in plasma 
concentrations at the time of reperfusion at least as high as those described as being 
protective after RIC in the literature. For example, Jiang et al. demonstrated serum 
SDF-1α after RIC of approximately 7000 pg/ml,29 and Kamota et al. measured peak 
levels in unfractionated plasma of approximately 3000 pg/ml.30 
To test the protective utility of SDF-1α mice underwent 5 min of stabilisation, 40 min 
of (index) LAD ischaemia and 2 h of reperfusion, as described above. 80 µg/kg rhSDF-
1α was administered by tail vein injection 10 min prior to reperfusion. Importantly, 
both male and female mice were used in this and subsequent experiments in mice. 
Sample size was calculated using a two-sided test for the comparison of two means. 
Based on the results described in section 4.4.3, the following assumptions were 
made: a 20% estimate of effect size (which is more conservative than the benefit seen 
by Hu et al. which exceeded 30%46), a control IS of 40%, an SD of 10%, a significance 
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level of 5% (α=0.05) and 80% power (β=0.2). This required a minimum sample size of 
four animals per group. 
5.2.3 Results 
The surgical complications encountered in this experiment were similar to those 
described in section 4.4.3, although it is reassuring that the proportion of operator-
dependent exclusions was reduced and there were no operator-independent 
exclusions. A summary is given in Figure 5-3. 
 
Figure 5-3: Experimental success during investigation of whether SDF-1α is 
cardioprotective when given before reperfusion 
35 animals were used during the course of the experiment.  31 were included in the analysis 
(89%). All exclusions were defined as operator-dependent, and included three cases of 
accidental anaesthetic overdose and one case of missed tail vein injection. 
This study confirmed that treatment with 80 µg/kg SDF-1α prior to reperfusion 
elevates the serum level of SDF-1α to 32,000 pg/ml (32 ng/ml), giving an approximate 
percentage recovery of 3% (Figure 5-4). 
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Figure 5-4: Effect of tail vein injection of SDF-1α on concentration in platelet-free plasma 
in mice 
80 µg/kg rhSDF-1α or saline vehicle was administered by tail vein injection 10 min prior to 
blood sampling and analysis of PFP with ELISA. Statistical significance was assessed using an 
unpaired t-test, n=7-9, **P<0.01. 
IS was measured as a proportion of AAR in C57BL/6 mice following in vivo IRI with 
injection of SDF-1α into the tail vein. Interim analysis revealed mean AAR of 65±5% 
and mean IS/AAR of 47±2% (n=3). This experiment was terminated prematurely 
(without a control group) as tail vein injection proved technically more difficult than 
in the characterisation experiment, possibly due to sympathetic activation during 
myocardial ischaemia. Therefore, RV administration was chosen to mimic peripheral 
administration as closely as possible. Furthermore, the apparent lack of 
cardioprotection (mean IS was similar to that described in section 4.4) in the present 
experiment may have been consequent upon an inadequate dose, which was 
subsequently increased to 200 µg/kg. 
RV injection was well tolerated with no excess mortality. In the subsequent 
experiment, six animals were included per group and analysis of their respective 
areas at risk, to ensure surgical consistency, revealed no significant differences 
(control + vehicle 56±2% vs. control + SDF-1α 58±4%, n=6, P=NS, Figure 5-5). 
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Furthermore, the areas at risk in this experiment were very similar to those described 
in the characterisation experiment (section 4.4.3). 
 
Figure 5-5: Comparison of area at risk between control and SDF-1α groups 
C57BL/6 mice were anaesthetised and treated with either 200 µg/kg SDF-1α or 0.9% saline 
(control) by RV puncture prior to 40 min ischaemia and 2 h reperfusion in vivo. Analysis of 
their respective AAR revealed no statistically significant differences. Black points indicate 
male mice and red points indicate female mice. Statistical significance was assessed using an 
unpaired t-test, n=6, P=NS. Data presented as mean ± SEM. 
Analysis of IS demonstrated that SDF-1α significantly reduced IS as a proportion of 
AAR (19±4%) compared to saline vehicle control (57±5%, n=6, P<0.001, Figure 5-6). 
The control group excluded a cardioprotective effect of RV puncture. In fact, the 
mean control IS in this experiment was greater than that described in section 4.4.3 
(57±5% vs. 43±2%), suggesting a possible injurious effect of RV puncture per se, 
despite being ostensibly well tolerated. Representative transverse heart sections are 
shown in Figure 5-6. 
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Figure 5-6: Infarct size following the administration of SDF-1α prior to reperfusion in vivo 
C57BL/6 mice were anaesthetised and treated with either 200 µg/kg SDF-1α or 0.9% saline 
(vehicle control) by RV punture 40 min prior to ischaemia and 2 h after reperfusion in vivo. IS 
as a proportion of AAR was analysed using Evans Blue and TTC staining. (A) SDF-1α 
administered by RV puncture 10 min prior to reperfusion significantly reduced IS compared 
to control + vehicle. Black points indicate male mice and red points indicate female mice. 
Statistical significance was assessed using an unpaired t-test, n=6, ***P<0.001. Data 
presented as mean ± SEM; (B) Representative scanned transverse heart sections 
demonstrating Evans Blue area (blue), area at risk (pink) and infarct (white). 
5.2.4 Discussion 
This study demonstrated that SDF-1α, delivered prior to reperfusion, is acutely 
cardioprotective in a mouse in vivo model of myocardial IRI. Importantly, it is the first 
time SDF-1α has been shown to protect when administered during ischaemia, 
thereby improving its translational potential. 
SDF-1α was administered prior to reperfusion for several reasons: (1) as discussed in 
0, SDF-1α has an estimated plasma half-life of 25.8±4.6 min, due to proteolysis by 
DPP4 and other peptidases.53 In the present study, percentage recovery of injected 
SDF-1α from plasma using an ELISA specific for the active form was only 3%. 
Therefore, if SDF-1α was administered prior to ischaemia (to correlate with the 
application of RIC) almost complete degradation would be expected by the time of 
reperfusion. This is important because, as discussed in section 1.4.4, SDF-1α is 
posited to confer cardioprotection by activating the protective RISK pathway at the 
time of reperfusion. This degradation could be prevented by the co-administration of 
a DPP4 inhibitor. However, this would confound the present result due to 
preservation of GLP-1, which is also postulated to be cardioprotective in myocardial 
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IRI (reviewed by Clarke et al.346); (2) studies have suggested that SDF-1α takes up to 
1 h to reach peak levels after the application of RIC.29, 30 If correct, this further 
supports the hypothesis that if SDF-1α mediates remote ischaemic pre-conditioning 
it does so via an effect at the time of reperfusion. This is discussed in detail in Chapter 
7; and (3) although not directly related to the present hypothesis, administering a 
pharmacological conditioning mimetic prior to reperfusion is more clinically relevant 
than administration prior to ischaemia, which is impossible to predict in humans. Hu 
et al. infused SDF-1α into the LV cavity followed by 10 min washout before the 
induction of ischaemia.46 Therefore, the SDF-1α would have reached, and potentially 
affected, effector cells in the heart prior to ischaemia. This is not feasible in human 
patients suffering MI who, by definition, do not present until after the onset of 
ischaemia. The present study therefore confirms an effect specifically on reperfusion 
injury. 
The initial absence of benefit from SDF-1α could either be due to inadequate delivery 
via the tail vein or an insufficient dose. The in vivo studies described above 
administered SDF-1α in concentrations of 12-175 µg/kg.20, 46 In the absence of 
protection with the initial dose of 80 µg/kg, the dose was successfully increased to 
200 µg/kg. Although Jang et al. have demonstrated dose-dependent cardioprotection 
with SDF-1α using an ex vivo Langendorff model of myocardial IRI,150 it is not possible 
to comment on possible dose-dependent cardioprotection in the present study as 
the tested doses were administered via different routes. Nonetheless, control mice 
treated with saline vehicle via RV puncture remained significantly more injured than 
SDF-1α-treated groups. 
Hu et al. identified CXCR4 on cardiomyocytes and cardiac fibroblasts, and induced 
SDF-1α release from in vitro cardiomyocytes using hypoxia.46 This engendered the 
hypothesis that exogenous SDF-1α is cardioprotective by augmenting endogenous 
autocrine/paracrine signalling. The present experiment does not specifically 
implicate CXCR4 as the mediator of protection conferred by SDF-1α. Instead, SDF-1α 
could exert its effects via CXCR7, an alternative chemokine receptor for SDF-1α that 
is discussed in more detail in section 6.3.4, or via another mechanism entirely. It 
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would be possible to confirm this by addition of AMD3100, in a similar manner to the 
experiment described in Chapter 6. However, this was beyond the scope of this 
thesis, which specifically aimed to investigate a putative mechanism of RIC. Nor does 
the present finding identify the organ or cell type upon which SDF-1α is acting, which 
is discussed further in Chapter 8. 
Finally, the specific intracellular mechanism of SDF-1α that affects cardioprotection 
is unknown and remains controversial. As discussed in 0, several mechanisms by 
which SDF-1α exerts acute cardioprotection have been proposed. For example, 
Huang et al. identified activation of STAT3 without concomitant phosphorylation of 
Akt or Erk1/2 and no loss of protection with LY294002.149 Importantly, however, the 
inhibitors were given prior to ischaemia and not prior to reperfusion (the time-point 
at which the RISK kinases are defined to act), and hence it may be that Akt is still 
integral to mitigating reperfusion injury specifically. Others have implicated a role for 
Akt and Erk1/2 when SDF-1α is administered around the time of reperfusion.150 The 
intracellular mechanism of SDF-1α-mediated cardioprotection is not specifically 
investigated in this thesis but is an important target for subsequent clarification. 
5.3 Summary 
This chapter provides the first description of cardioprotection as a result of the 
administration of exogenous SDF-1α prior to reperfusion in a murine model of 
myocardial IRI. The use of SDF-1α during ischaemia builds upon previous in vivo 
studies that reduced IS using SDF-1α prior to the onset of ischaemia, thereby 
improving its therapeutic relevance. The present study does not indicate a target cell-
type or potential mechanism of action of SDF-1α, but does satisfy the first criteria 
necessary to define a molecule as a mediator of RIC. 
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Chapter 6 Does the SDF-1ɑ receptor blocker, AMD3100 abrogate the 
cardioprotective effect of remote ischaemic conditioning? 
6.1 Introduction 
The second condition that must be satisfied to define a molecule as an endogenous 
mediator of cardioprotection, according to The Working Group of Cellular Biology of 
the Heart of the European Society of Cardiology,103  is abolition of the effect by specific 
receptor blockade. 
AMD3100 (Plerixafor) is a specific inhibitor of CXCR4 that retains its specificity 
independent of the cell type carrying the receptor, although it should be noted that 
allosteric agonism of CXCR7 has recently been reported.32, 347 No selectivity data 
comparing different CXC receptors has been published but AMD3100 is known to 
have a Ki of 100-650 nM for CXCR4.348, 349 Numerous studies have demonstrated a loss 
of effect of SDF-1α when given with or after AMD3100 in a variety of settings and 
models including in the in vivo model of myocardial IRI employed by Hu et al.46 It was 
therefore essential to the present study to examine the effect of AMD3100 on 
cardioprotection conferred by RIC in vivo. 
6.2 Research aims and objectives 
The main objective of this chapter was to investigate whether the SDF-1ɑ receptor 
blocker AMD3100 abrogates the cardioprotective effect of RIC. The research aims for 
this objective were: 
1. Investigate whether the SDF-1ɑ receptor blocker AMD3100 abrogates the 
cardioprotective effect of RIC; 
2. Identify CXCR4 on rat and human cardiomyocytes. 
6.3 Aim 1: Investigate whether the SDF-1ɑ receptor blocker AMD3100 abrogates the 
cardioprotective effect of remote ischaemic conditioning 
Rat cardiomyocytes used in this section were isolated and donated by Dr O. Ziff, 
Hatter Cardiovascular Institute (UCL, UK). 
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6.3.1 Background 
As discussed in Chapter 1 and section 5.2.1, numerous studies have abrogated beneficial 
effects of SDF-1α with AMD3100, thereby implicating CXCR4 in the mechanism. This has 
also been shown in the context of RIC, albeit in an isolated cardiac papillary muscle 
model.31 Davidson et al. demonstrated that RIC applied in vivo to a rat, prior to 
isolation of papillary muscle and simulated IRI, significantly improved functional 
recovery (Figure 6-1).31 This effect was blocked by AMD3100. Likewise, AMD3100 
abrogated the benefit conferred by the addition of SDF-1α in the same model, as 
discussed in section 5.2.1 (Figure 5-1). 
 
Figure 6-1: The effect of AMD3100 on the improvement of developed force after remote 
ischaemic conditioning in isolated rat heart papillary muscle 
In vivo RIC (three cycles of 5 min hind limb ischaemia and 5 min reperfusion) prior to isolation 
of rat heart papillary muscle and simulated IRI (30 min hypoxia and 2h reoxygenation) 
improved contractile recovery. Before hypoxia, the rat papillary muscle was perfused with 
AMD3100 for 15 min. Control papillary muscle was untreated. The functional recovery of 
muscle treated with RIC was significantly improved, an effect that was abrogated by 
AMD3100. Statistical significance was assessed using two-way ANOVA and Fisher’s protected 
least significant difference test for multiple comparisons, n=6, *P<0.05, **P<0.01. Figure 
taken from 31. 
Similarly, in the model of simulated IRI using isolated human atrial trabeculae, 
AMD3100 abrogated the beneficial effect of SDF-1α in terms of recovery of 
contractile function.151 Therefore, the aim of this section was to investigate whether 
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AMD3100, administered peripherally prior to IRI, can abrogate the beneficial effect 
of RIC on myocardial IRI in vivo. 
6.3.2 Methods 
Rats were randomly assigned to control plus vehicle, control plus AMD3100, RIC plus 
vehicle or RIC plus AMD3100 groups. 10 µg/kg (250 µl of 10µg/ml stock for a 250 g 
animal, for example) AMD3100 (Tocris Bioscience, C of Bris, UK) was administered to 
a rat by intravenous tail vein injection 5 min prior to the first cycle of cuff inflation 
(Figure 6-2). This dose was chosen based on previous experience in our laboratory.31 
 
Figure 6-2: Remote ischaemic conditioning and ischaemia-reperfusion injury protocols, and 
AMD3100 administration 
(A) Control: 35 min stabilisation, 30 min ischaemia and 2 h reperfusion; (B) RIC: 5 min 
stabilisation, three cycles of 5 min hind limb ischaemia and 5 min reperfusion, 30 min 
ischaemia and 2 h reperfusion. AMD3100 or vehicle was administered by tail vein injection 
at the beginning of the stabilisation period. Figure not to scale. 
Sample size was not calculated a priori for any experiments in rats, in which six 
animals were used per group in line with convention. 
6.3.3 Results 
The surgical complications encountered in this experiment were similar to those 
described in section 4.3, although it is reassuring that the number of operator-
dependent exclusions and total number of included animals were improved in 
comparison. None were excluded due to missed tail vein injection, although it was 
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occasionally necessary to attempt tail vein injection up to three times. A summary is 
given in Figure 6-3. 
 
Figure 6-3: Experimental success during investigation of whether AMD3100 abrogates the 
cardioprotective effect of remote ischaemic conditioning 
52 animals were used during the course of the experiment. 24 were included in the analysis 
(46%). Excluded animals were defined as operator-dependent (57% of exclusions) or 
operator-independent (43% of exclusions). Surgically-induced haemorrhage was eliminated 
by the refinements described in section 4.3 and the subsequent predominant reason for 
operator-dependent exclusions was inadequate staining with Evans blue. Reasons for 
operator-independent exclusions were similar to those described in section 4.3. 
This experiment measured IS as a proportion of AAR in Sprague Dawley rats following 
in vivo IRI. Six animals were included per group and analysis of their respective areas 
at risk, to ensure surgical consistency, revealed no significant differences (control + 
vehicle 55±2% vs. control + AMD 55±4% vs. RIC + vehicle 61±4% vs. RIC + AMD 53±5%, 
n=6, P=NS, Figure 6-4). 
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Figure 6-4: Comparison of area at risk in rat hearts between control and remote ischaemic 
conditioning groups, treated with or without AMD3100  
Sprague Dawley rats were anaesthetised and treated with RIC (three cycles of 5 min hind 
limb ischaemia and 5 min reperfusion) or acted as sham controls. Rats were treated in vivo 
with or without 10 µg/kg AMD3100 (AMD) or 0.9% saline (vehicle control) 35 mins prior to 
30 min of ischaemia and 2 h of reperfusion. Data presented as mean ± SEM. Statistical 
significance was assessed using one-way ANOVA and Tukey’s multiple comparison test, n=6, 
P=NS. Analysis of their respective areas at risk (AAR), to ensure surgical consistency, revealed 
no statistically significant differences. Data presented as mean ± SEM. 
Subsequent analysis of IS as a proportion of AAR repeated the finding in section 4.3 
that RIC significantly reduced IS as a proportion of AAR (31±3%, n=6) compared to 
either control (57±3%, n=6, P<0.001 vs. RIC + vehicle) or the administration of 
AMD3100 alone (62±2%, n=6, P<0.001 vs. RIC + vehicle, Figure 6-5). In support of the 
hypothesis, pre-treatment with AMD3100 abrogated the beneficial effect of RIC 
(56±4%, n=6, P<0.01 vs. RIC + vehicle, Figure 6-5). Representative transverse heart 
sections are shown in Figure 6-5. 
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Figure 6-5: Infarct size following myocardial ischaemia-reperfusion injury (control) with 
remote ischaemic conditioning in vivo, with or without AMD3100 
Sprague Dawley rats were anaesthetised and treated with RIC (three cycles of 5 min hind 
limb ischaemia and 5 min reperfusion) or sham, with or without AMD3100 or 0.9% saline 
control, prior to 30 min ischaemia and 2 h reperfusion in vivo. IS as a proportion of AAR was 
analysed using Evans Blue and TTC staining. (A) RIC + vehicle significantly reduced IS 
compared to control + vehicle, which was abrogated by the addition of AMD3100. AMD3100 
alone (control + AMD) did not alter IS. Statistical significance was assessed using one-way 
ANOVA and Tukey’s multiple comparison test, n=6, ***P<0.001. Data presented as mean ± 
SEM; (B) Representative scanned transverse heart sections demonstrating Evans Blue area 
(blue), area at risk (pink) and infarct (white). 
As discussed, parametric tests cannot correctly be applied to non-Gaussian data; 
however, statistical tests of normality are precluded by small sample sizes, and non-
parametric statistical tests have significantly lower power. Therefore, the control 
data from both this experiment and the characterisation experiment described in 
section 4.3 were retrospectively combined to test the assumption made in section 
2.10 that animal data in this thesis is normally distributed. The D’Agostino-Pearson 
omnibus test confirmed a Gaussian distribution (P=0.9969), which will continue to be 
assumed throughout this thesis. 
6.3.4 Discussion 
This experiment investigated the effect of pre-treatment with AMD3100 on the 
efficacy of RIC in a rat in vivo model of myocardial IRI. Rats were used for this 
experiment in view of the difficulty with SDF-1α administration described in section 
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5.2.3. Here, the larger size of rats compared to mice facilitated tail vein injection. 
While it would be preferable to investigate all aspects of this project in the same 
species, visual inspection of the funnel plot in Chapter 3 revealed no difference in the 
efficacy of RIC between rats and mice. Furthermore, if SDF-1α is central to the 
mechanism of RIC, it is known to be highly conserved between species.28, 38 
AMD3100 was given prior to RIC to facilitate CXCR4 antagonism prior to possible SDF-
1α up-regulation during RIC. Of note, AMD3100 was expected to continue blocking 
CXCR4 at the time of reperfusion, evidenced by binding assays showing it to be 
selective, tight-binding and slowly reversible (taking up to 48 h in one study).348 As 
expected, pre-treatment with AMD3100 abrogated the beneficial effect of RIC in this 
model. Although this strongly implicates SDF-1α in the mechanism of RIC, it does not 
necessarily prove it as other potential ligands for CXCR4 have been identified, 
including MIF and ubiquitin.350 351 
MIF, like SDF-1α, is a chemokine that plays a role in monocyte recruitment and has 
attracted attention in the context of IRI.350 It is known to be immobilised on the 
endothelial surface and mediate the arrest of rolling macrophages in inflammation 
via CXCR2.350 MIF has also been implicated in cardioprotection from myocardial IRI, 
via AMP-activated protein kinase signalling, inhibition of apoptosis and the reduction 
of oxidative stress,352 effects that are enhanced by post-translational S-nitrosation of 
MIF.353 These findings have begun to be translated to clinical studies, with the 
majority of studies to date noting a significant increase in MIF after a cardiac insult, 
including MI, PPCI, cardiac surgery and cardiopulmonary resuscitation (reviewed by 
Rassaf et al.).352 In clinical studies, high levels of MIF have been associated with 
improved outcome after cardiac surgery.354 There is, however, no published pre-
clinical or clinical data on MIF-mediated RIC to date, although the RIPHeart group 
examined MIF levels at several time points before and after RIC and IRI and found no 
significant differences (personal communication). 
Ubiquitin is a small intracellular protein that is involved in post-translational 
modification (so-called ubiquination). However, they have also been reported to be 
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extracellular and to agonise CXCR4, but not CXCR7.351 Saini et al. report that unlike 
SDF-1α, ubiquitin binds independently of the CXCR4 N-terminal receptor domain.351 
However, they found it to cause a similar G protein-coupled up-regulation of 
intracellular Akt and Erk phosphorylation, albeit much more transiently than by SDF-
1α. The impact of ubiquitin, if any, on IRI has not been investigated. 
Other limitations of this experiment include that AMD3100 is a partial agonist of 
CXCR7, the role of which was not investigated here.  However, as AMD3100 is a 
partial agonist of CXCR7, any effect on CXCR7 in the context of myocardial IRI should 
be evident in the group treated with AMD3100 alone. This group was statistically 
indistinct from the group pre-treated with saline vehicle and it is therefore unlikely 
that CXCR7 is important in the context of this experiment. 
Finally, it should be considered that AMD3100 might have other ‘off-target’ effects. 
Although AMD3100 is thought to be highly specific, without interaction with either 
CXC or CC receptor subtypes (apart from CXCR7, as described),32 it is impossible to 
definitively exclude alternative actions. However, an alternative approach is to 
confirm the role of CXCR4 by using CXCR4 null mice, which is addressed in Chapter 8. 
6.4 Identify CXCR4 on rat and human cardiomyocytes 
6.4.1 Background 
The experiments described in sections 5.2.1 demonstrate a protective effect of SDF-
1α in ex vivo isolated rat papillary muscle and isolated human atrial trabeculae 
subjected to simulated IRI.31, 151 Moreover, AMD3100 has also been found to 
abrogate the protective utility of exogenous SDF-1α in both of these models.31, 151 In 
the absence of other organs and tissues, these findings engender the hypothesis that 
SDF-1α protects the myocardium from (simulated) IRI via its action(s) on one or more 
cardiac cell types. 
As discussed in 0, CXCR4 is reported to be expressed by a range of cardiac cell types. 
Its expression by cardiomyocytes, which account for 25-35% of all cells in the heart,355 
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is well documented but it has also been identified in vascular smooth muscle cells,47 
endothelial cells,44 and fibroblasts.46 In the context of acute cardioprotection, only 
cardiomyocytes and fibroblasts have been investigated to date. Hu et al. isolated 
ventricular cardiomyocytes and cardiac fibroblasts from adult male C57BL/6 mice and 
found both cell types to express CXCR4 and SDF-1α.46 Hypoxia and reoxygenation 
resulted in significantly increased SDF-1α release from cardiomyocytes but not from 
cardiac fibroblasts. They next administered exogenous SDF-1α to isolated 
cardiomyocytes and found increased phosphorylation of both Erk1/2 and Akt, less 
lactate dehydrogenase release and less apoptosis, thereby implicating 
cardiomyocyte-expressed CXCR4 in the mechanism of protection. 
Aside from the limited literature on SDF-1α-CXCR4 in the context of acute 
cardioprotection, cardiomyocytes are also implicated in the wider field of SDF-1α-
CXCR4 in chronic cardioprotection. Most notably, Dong et al. described loss of the 
beneficial effect of MSC infusion after permanent ligation of the LAD in 
cardiomyocyte-specific CXCR4 null mice.75 
To support the hypothesis that SDF-1α protects the myocardium from IRI via its 
action on cardiomyocytes, it is necessary to demonstrate the expression of CXCR4 by 
cardiomyocytes. The aim of this section was therefore to confirm that CXCR4 is 
present in rat and human cardiomyocytes, to support the preliminary data discussed 
above and the finding reported in section 6.3. 
6.4.2 Methods 
Isolated cardiomyocytes obtained from male Sprague Dawley rats weighing 200-250 
g were prepared and stained for immunofluorescence as described in section 2.6. The 
primary antibody was rabbit monoclonal anti-CXCR4 (ab124824), which was used at 
a dilution of 1:100. Alexa Fluor 488 anti-rabbit secondary antibody was diluted 1:400. 
Control samples were incubated in Alexa Fluor 488 in the absence of primary 
antibody, to exclude non-specific staining with secondary antibody. 
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In a separate series of experiments, isolated human atrial trabeculae were obtained 
and processed as described in section 2.6, and labelled as above. To investigate the 
spatial distribution of CXCR4, immunofluorescent co-staining of CXCR4 and 
cardiomyocytes was performed using mouse 1:10 anti-cardiac troponin T (ab8295) 
and anti-mouse Alexa Fluor 555 secondary antibody. A sample incubated in 
secondary antibody alone was included as a control. 
6.4.3 Results 
Immunofluorescent staining of isolated rat cardiomyocytes appeared to demonstrate 
the presence of CXCR4 (Figure 6-6). However, control samples that were stained with 
secondary antibody alone demonstrated similar fluorescence intensity. It is therefore 
unlikely that the signal in these images represents the true distribution of CXCR4 but 
instead may represent non-specific binding of the secondary antibody. 
 
 Figure 6-6: Immunofluorescent staining of isolated rat cardiomyocytes 
Immunofluorescent staining for CXCR4 using a monoclonal antibody (ab124824) and Alexa 
Fluor 488 anti-rabbit secondary antibody (green) in an isolated rat cardiomyocyte. Equal 
intensity was found using primary and secondary antibodies (left panel) compared to 
secondary alone (right panel). Representative images, 50 µm scale bar. 
Similar immunofluorescent staining in isolated human atrial trabeculae suggested the 
presence of CXCR4 on cardiomyocytes and endothelial cells (Figure 6-7). Importantly, 
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this staining appeared to be specific due to its absence in secondary-only control 
samples. 
 
Figure 6-7: Immunofluorescent staining of isolated human atrial trabeculae 
Row (A) Immunofluorescent staining demonstrates the distribution of CXCR4 (ab124824, 
green) in relation to troponin (ab8295, red). Hoechst nuclear stain shown in blue; Row (B) 
Immunofluorescent staining using secondary antibody in the absence of primary antibody. 
Representative images from n=2 independent experiments, 50 µm scale bar. 
6.4.4 Discussion 
The isolated rat cardiomyocyte immunohistochemistry demonstrated non-specific 
fluorescence suggestive of non-specific binding of the fluorescent secondary 
antibody, therefore precluding any conclusions about the presence and distribution 
of CXCR4. This was possibly a result of over-fixation of the sample but was not 
investigated any further in rats. The distribution of CXCR4 on mouse cardiomyocytes 
is discussed in more detail in section 8.3. In contrast, the secondary antibody-only 
staining of isolated human atrial trabeculae sections demonstrated minimal 
fluorescence, suggesting that the observed signal represents the true distribution of 
CXCR4.  
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Of course, SDF-1α (and AMD3100) may be exerting effects on several other cell types 
in the heart, including vascular smooth muscle cells, endothelial cells and fibroblasts. 
Whilst cardiomyocyte CXCR4 is the most described and investigated, it does not 
preclude a (central) role for other cell types that express CXCR4. For example, 
endothelial cells are of particular interest due to their abundance in the heart.355, 356 
Although these were not specifically investigated here, they should be considered 
when attempting to resolve the mechanism for SDF-1α-mediated cardioprotection. 
Finally, it is important to acknowledge that, in contrast to the ex vivo experiments 
described, the in vivo experiments presented in this thesis do not necessarily 
implicate an action of SDF-1α (or AMD3100) in the heart. The study of simulated IRI 
in isolated rat papillary muscle by Davidson et al. administered AMD3100 in vivo, 
prior to RIC and surgical removal of the heart for placement on a Langendorff 
apparatus.31 Consequently, SDF-1α (and AMD3100) could be exerting an effect in the 
limb or elsewhere and exerting cardioprotection via either a secondary messenger or 
neural pathway. It has been demonstrated that transient limb ischaemia liberates a 
protective dialysable factor(s) with a molecular weight below 15 kDa.28 The role of 
SDF-1α in signal transduction in RIC could be elucidated by subjecting an animal to 
RIC in vivo, with and without pre-treatment with AMD3100, and isolating plasma 
dialysate which could subsequently be exposed to a naïve heart on a Langendorff 
apparatus (which itself could be pre-treated with AMD3100 or vehicle). This plasma 
dialysate model has been well described and is valuable for distinguishing processes 
occurring in the limb from those in the heart. This was not specifically investigated 
here but is an interesting avenue for future enquiry. 
Furthermore, CXCR4 is also present on circulating cells that are sequestered by the 
heart following IRI. For example, Xu et al. reported an influx of platelets to the area 
at risk in early reperfusion in a murine model of myocardial IRI.357 They demonstrated 
an important role for platelet activation in the pathophysiology of myocardial IRI, 
which is interesting when considering that platelets constitutively express CXCR4 and 
release SDF-1α from their α-granules when activated.358, 359 The potential role of 
platelets in relation to RIC is explored in section 7.6 but, suffice to say that, the 
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apparent presence of cardiomyocyte CXCR4 described in the present experiment 
does not confirm cardiomyocytes to be the target of SDF-1α or AMD3100 in the 
studies described in Chapter 5 and section 6.3, respectively. However, it is possible 
to investigate the importance of cardiomyocytes by using cardiomyocyte-specific 
CXCR4 null mice. Both this and the demonstration of cardiomyocyte CXCR4 in mice is 
described in detail in Chapter 8. 
6.5 Summary 
This chapter describes the use of AMD3100, a highly specific inhibitor of CXCR4, to 
abolish the beneficial effect of RIC in a rat in vivo model of myocardial IRI. This is the 
second condition that must be satisfied to define a molecule as a mediator of 
cardioprotection and, when considered alongside the finding in Chapter 5 that 
exogenous SDF-1α is cardioprotective when administered prior to reperfusion, remains 
supportive of the hypothesis that SDF-1α is central to the mechanism of RIC. 
Furthermore, immunofluorescent staining of isolated human atrial trabeculae indicated 
the presence of CXCR4 on cardiomyocytes, which is likewise consistent with the 
paradigm defined in Chapter 5. As discussed, the present findings do not confirm the 
importance of cardiomyocyte CXCR4 (or indeed any cardiac cell type) in the mechanism 
of RIC, which will be considered in detail in Chapter 8. 
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Chapter 7 Does remote ischaemic conditioning increase the production of 
SDF-1α? 
7.1 Introduction 
The third condition, according to The Working Group of Cellular Biology of the Heart 
of the European Society of Cardiology,103  that must be satisfied to define a molecule 
as an endogenous mediator of cardioprotection is increased production or 
maintenance of extracellular concentrations of the mediator(s) as a direct effect of RIC. 
The current humoral paradigm for RIC asserts that a factor, between 3.5 kDa and 15 
kDa in size,27, 28 is released from the remote organ or tissue that is subject to cyclical, 
non-lethal ischaemia and reperfusion, and is carried by the blood to exert a protective 
effect on cardiac cells following lethal IRI. Investigation of SDF-1α as the potential 
mediator of RIC is complicated by its relatively short half-life due to cleavage and 
inactivation by DPP4.52, 201 No convenient method exists to specifically quantify full-
length SDF-1α in plasma, as all known antibodies recognize both the intact and 
cleaved forms. This chapter aims to investigate the acute role of SDF-1α in RIC but to 
do this it was first necessary to develop and characterise a novel recombinant 
antibody for use in an ELISA for full-length SDF-1α. 
7.2 Research aims and objectives 
The main objective of this chapter was to investigate the acute role of SDF-1ɑ in RIC. 
The research aims for this objective were: 
1. Validate and characterise an ELISA to the active (full-length) form of SDF-1α; 
2. Investigate whether the ligands of CXCR4 are increased in the blood of rats 
and humans subjected to RIC; 
3. Investigate the contribution of DPP4 to SDF-1α dynamics after RIC; 
4. Investigate the role of platelets in SDF-1α dynamics after RIC. 
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7.3 Aim 1: Validate and characterise an ELISA to the active (full-length) form of SDF-1α 
7.3.1 Background 
SDF-1α is described by the primary sequence KPVSLSYRC PCRFFESHVA RANVKHLKIL 
NTPNCALQIV ARLKNNNRQV CIDPKLKWIQ EYLEKALNK and is cleaved by DPP4 at its 
proline residue (position 2) and by MMP-2/9 position 4,51 although DPP4 is 
responsible for the majority of SDF-1α cleavage and is the focus here.52 Currently, no 
method exists to specifically quantify full-length SDF-1α in plasma as all known 
antibodies recognize both intact SDF-1α and SDF-1α after cleavage (Figure 7-1). 
 
Figure 7-1: Representation of binding sites of commercially available antibodies to SDF-1α  
Dipeptidyl peptidase-4 (DPP4) is an extracellular peptidase that cleaves SDF-1α at its N-
terminus. Commercially available antibodies recognise both intact and cleaved forms of SDF-
1α, whereas the aim of this section was to characterise an antibody to the N-terminus, which 
is specific to the intact from. 
Most commonly, polyclonal antibodies are made by inoculating the antigen of 
interest into a mammal. This results in the production of specific IgG 
immunoglobulins by B lymphocytes of different lineages, each of which recognise a 
different epitope. It was hypothesised here that the reason for the lack of an antibody 
specific to full-length SDF-1α was its short in vivo half-life and its very high 
interspecies homology. To overcome these hurdles, an in vitro screening method was 
utilised in order to obtain a specific recombinant antibody for a single epitope. This 
approach has the additional advantages of being automated, rapid, animal-free and 
flexible, insofar as a number of antibody formats can be generated.360, 361 
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A custom human IgG1 bivalent mini-antibody against the N-terminus of SDF-1α was 
identified by screening the HuCAL® (Human Combinatorial Antibody Library) phage-
display library containing several billion, distinct, fully human antibodies.360, 361 In this 
method a random cDNA library encoding each distinct human antibody is inserted 
into a bacteriophage coat protein gene, causing the phage to display a variable 
peptide (antibody) on its outside while containing the gene encoding that specific 
antibody inside the same phage. The library was screened using positive selection for 
binding to the peptide KPVSLSYR-Ttds-C derived from full-length SDF-1α and negative 
selection for binding to the peptide VSLSYR-Ttds-C derived from cleaved SDF-1α (AbD 
Serotec, Oxon, UK). This approach has the advantage of defining the antibody’s 
antigenicity. 
The HuCAL® antibodies are initially produced as human IgG1 monovalent or bivalent 
mini-antibodies, which have greater sensitivity due to having more binding sites 
(Figure 7-2). AbD Serotec (Oxon, UK) are able to convert these into full-length IgG1 if 
the Fc domain is required. However, this was not necessary since the HuCAL® 
antibodies are supplied with two embedded epitope tags, a FLAG octapeptide tag 
and a polyhistidine (His6) tag, facilitating the use of anti-FLAG and anti-His6 
secondary antibodies, as well as anti-human Fab secondary antibodies. 
 
Figure 7-2: HuCAL® antibody format 
(A) Representative image of full size IgG; (B) Bivalent mini-antibody structure used in this 
thesis. Each Fab fragment consists of the first two domains of the antibody heavy chain (VH 
and CH1) plus the complete light chain (from either the κ or λ family) and contains two 
epitope tags. Figure adapted from 362. 
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Fourteen candidate antibodies, labelled A-N, were provided by AbD Serotec after 
their initial screening, which determined that they detected full-length but not 
cleaved SDF-1α. These screening reactions had been performed using SDF protein 
conjugated to human transferrin (TRF). Therefore, the first aim of this chapter was to 
validate and characterise the binding of these custom antibodies to unbound, active, 
full-length SDF-1α using an ELISA format. The terms ‘full-length’, ‘intact’ and ‘active’ 
are used interchangeably in this section, as are the terms ‘cleaved’ and ‘inactive’. 
7.3.2 Methods  
The initial step was to validate these antibodies in a direct ELISA using the standard 
protocol provided by AbD Serotec, which is as follows: 100 µl of full-length and 
cleaved SDF-1α-TRF at 5 µg/ml, as well as full-length rhSDF-1α (Miltenyi Biotec, CA, 
USA), in Hispec buffer (AbD Serotec, Oxon, UK) were incubated on a black, flat 
bottom, MaxiSorp, 96-well ELISA plate (Thermo Fisher Scientific, MA, USA) at 4⁰C 
overnight. Wells were washed three times for 5 min with 0.05% PBS-T before blocking 
with 300 µl of 5% non-fat dry milk in PBS-T for 1 h at RT. After three further 5 min 
washes with PBS-T, 100 µl of primary anti-Fab antibody (HuCAL® A-N) at 2 µg/ml in 
Hispec buffer was added per well and incubated for 1 h at RT. After five 5 min washes 
with PBS-T, 100 µl of alkaline phosphatase conjugated polyclonal goat anti-human 
Fab secondary antibody (STAR126A, AbD Serotec, Oxon, UK) diluted in Hispec at a 
concentration of 1:5000 was added to each well and incubated for a further 1 h at 
RT. Following incubation, wells were washed a further three 5 min with PBS-T. 
Detection was performed using AttoPhos® AP Fluorescent Substrate System 
(AttoPhos, Roche, Sussex, UK). This provides a highly sensitive fluorescent substrate 
for the alkaline phosphatase contained within the anti-human Fab secondary 
antibody described above. Specifically, the substrate (2’-[2-benzothiazoyl]-6’-
hydroxybenzothiazole phosphate (BBTP)) is cleaved by alkaline phosphatase to 
produce inorganic phosphate and 2’-[2-benzothiazoyl]-6’-hydroxybenzothiazole 
(BBT), which has enhanced fluorescence compared to the substrate.363 100 µl of 
AttoPhos® substrate diluted to 1:10 with distilled water was added to each well. In 
each experiment, separate wells were prepared containing Hispec buffer (zero 
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control or blank) and AttoPhos® Calibration Solution (500±50 ng/ml BBT in 2.4 M 
dienthanolamine buffer), to which AttoPhos® Substrate Solution was added. 
Fluorescence was recorded using a FLUOstar Omega microplate reader. An excitation 
wavelength of 440±10 nm and an emission wavelength of 550±10 nm were selected, 
as per AttoPhos® recommendations. Sample measurements were calibrated using 
the AttoPhos® Calibration Solution well, and blank-corrected using the zero control 
well. All analyses, including samples and standards, were performed in duplicate and 
readings were averaged to minimise intra-assay variability. 
7.3.3 Results 
Initial results are shown in Figure 7-3, Panel A. This demonstrated greater signal than 
noise for full-length SDF-1α-TRF (green bars) and rhSDF-1α (red bars) for five of the 
candidate antibodies: C, G, H, M and N. The protocol described above was 
subsequently optimised in a series of steps in order to maximise the sensitivity of the 
assay. Variations tested were: concentration (1:10 vs. 1:2 dilutions in distilled water) 
and duration of exposure (0, 1 and 2 h) to AttoPhos® Substrate Solution; number of 
excitation flashes emitted by the FLUOstar Omega microplate reader per well (10 vs. 
50); fluorescence emission filter (550±10 nm vs. 560±40 nm); and well orbital 
averaging versus central measurement. The 560±40 nm filter was chosen for 
comparison to encompass the peak emission wavelength cited in the AttoPhos® 
literature. 
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Figure 7-3: Validation of HuCAL® antibodies against full-length and cleaved SDF-1α 
HuCAL® antibodies A-N were tested against full-length and cleaved SDF-1α-TRF, and full-
length rhSDF-1ɑ. (A) Initial results using standard protocols. HuCAL® antibodies C, G, H, M 
and N (arrowed) detected full-length forms of SDF-1α (red and green bars) but not cleaved 
forms (blue bars); (B) Following optimisation of the ELISA protocol, there was improved 
signal:noise. Again, HuCAL® antibodies C, G, H, M and N demonstrated a favourable profile 
(arrowed). The remaining HuCAL® antibodies were excluded from further characterisation. 
The results of this optimisation are displayed in Figure 7-3, Panel B, and were: orbital 
averaging with 50 flashes per well immediately after addition of 1:10 AttoPhos® 
Substrate Solution, using a 560±40 nm filter. Again, HuCAL® antibodies C, G, H, M and 
N displayed a favourable profile. The remaining HuCAL® antibodies were excluded 
from further characterisation. In control experiments, GLP-1, another incretin that is 
proteolysed by DPP4, and cleaved rhSDF-1α were also tested (data not shown) and 
found not to have any signal above background. Henceforth, only rhSDF-1α unbound 
to transferrin was used for characterisation. 
The five candidate HuCAL® antibodies were then tested for their ability to detect full-
length rhSDF-1α in human plasma. As a negative control, cleaved rhSDF-1α was 
prepared by incubating 20 µg full-length rhSDF-1α (2.4 nmol) with 0.1 µg 
recombinant human DPP4 (R&D Systems, Oxon, UK) in 25 mM Tris buffer, pH 8.0, 
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which cleaves 2.5 nmol SDF-1α per min per µg of DPP4, at 37⁰C for 60 min. Human 
plasma was collected on ice in citrated tubes (BD, Oxon, UK), then centrifuged at 
1,600 x g for 20 min then 10,000 x g for 30 min to remove platelets. Full-length and 
cleaved rhSDF-1α were diluted in human plasma spiked with 10 µM Sitagliptin per 
well to inhibit DPP4 and prevent proteolysis of full-length rhSDF-1α by endogenous 
DPP4. Unfortunately, the direct ELISA configuration described was unable to detect 
signal above noise for any tested quantity of full-length rhSDF-1α in plasma, 
indicating a need to further increase sensitivity (data not shown). 
To increase sensitivity, the ELISA was changed to a ‘sandwich’ configuration (Figure 
7-4), and several combinations of capture antibody, blocking agent, detection 
antibody, secondary antibody and detection reagent were tested (see Table 7-1).  
 
Figure 7-4: Comparison of direct and ‘sandwich’ ELISA configurations 
(A) Direct ELISA configuration, whereby the antigen (Ag) is adsorbed onto the plate prior to 
addition of the primary antibody; (B) A ‘sandwich’ ELISA configuration, whereby a capture 
antibody is adsorbed to the plate surface prior to addition of the sample. In both cases, 
detection may be direct (via an enzyme (E)-conjugated primary antibody) or indirect (via a 
conjugated secondary antibody). Figure adapted from 364. 
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Capture 
antibody 
Blocking agent Detection 
antibody 
Secondary Reagent 
MAB350 5% milk HuCAL® C STAR126A Attophos 
AF310NA 5% milk HuCAL® C STAR126A Attophos 
HuCAL® G 2% BSA/PBS-T AF310NA ab97102 Attophos 
AF310NA 2% BSA/PBS-T HuCAL® G STAR126A Attophos 
AF310NA 5% BSA/PBS-T HuCAL® A-N STAR126B Streptavidin-
HRP  
MAB350 5% BSA/PBS-T HuCAL® A-N STAR126B Streptavidin-
HRP  
AF310NA 5% BSA/PBS-T HuCAL® 
C,G,H,M,N 
STAR126B Streptavidin-
HRP  
HuCAL® 
C,G,H,M,N 
5% BSA/PBS-T BAF310 - Streptavidin-
HRP  
HuCAL® C 5% BSA/PBS-T BAF310 - Streptavidin-
HRP  
Table 7-1: Sandwich ELISA configurations tested during ELISA characterisation 
The working configuration is highlighted in grey. MAB350 (R&D Systems, Oxon, UK) is a 
monoclonal mouse IgG against mouse and human SDF-1α. STAR126A (AbD Serotec, Oxon, 
UK) is a polyclonal goat anti-human IgG F(ab’)2:Alk.Phos. AF310NA (R&D Systems, Oxon, UK) 
is a polyclonal goat IgG against total human SDF-1α. Ab97102 is a polyclonal rabbit anti-goat 
IgG H&L (Alkaline Phosphatase). STAR126B (AbD Serotec, Oxon, UK) is a polyclonal goat anti-
human IgG F(ab’)2:Biotin. BAF310 (R&D Systems, Oxon, UK) is a polyclonal goat IgG against 
total human and mouse SDF-1ɑ. 
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The principle problem with the sandwich ELISA, and reasons for testing several 
configurations, was cross-reactivity between components of the ELISA, resulting in 
signal even in the absence of full-length SDF-1α. Examples of two ELISA 
configurations that exhibit this substrate-independent signal are shown in Figure 7-5 
(compare Panel A in the presence of SDF-1α to Panel B in the absence of SDF-1α for 
AF310NA, and Panel C with Panel D for MAB350). 
 
Figure 7-5: Effect of cross-reactivity when HuCAL® antibody used for detection 
Panels A and C demonstrate an apparently appropriate diminution of signal with lower 
concentrations of capture (AF310NA and MAB350) and detection (HuCAL® G) antibody. 
However, when the antigen (full-length rhSDF-1α) was absent from the assay similar results 
were seen (Panels B and D). 
The successful configuration, highlighted in grey in Table 7-1, utilised the HuCAL® Fab 
fragment as the capture, rather than the detection, antibody. The capture HuCAL® 
antibody was diluted in 0.2M anhydrous sodium carbonate-sodium bicarbonate 
buffer to improve binding conditions and incubated in MaxiSorp, 96-well ELISA plates 
at 4⁰C overnight. A biotinylated polyclonal goat IgG against human and mouse SDF-
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1ɑ (BAF310), diluted in Hispec buffer, was used as the detection antibody. The biotin 
tag permitted a streptavidin protein detection step, owing to the high affinity of 
streptavidin for biotin. Substrate Solution, composed of a 1:1 mix of hydrogen 
peroxide and tetramethylbenzidine, was added because in the presence of HRP, 
tetramethylbenzidine donates hydrogen ions for the reduction of hydrogen peroxide 
to water, forming tetramethylbenzidine diimine. The latter causes the solution to 
turn blue and the colour intensity develops in proportion to the amount of 
streptavidin-HRP, and therefore the amount of full-length rhSDF-1α. After stop 
solution was added, the optical density of each well was immediately measured as 
described in section 2.8. Prior to reading, 5 sec of double orbital shaking at 500 rpm 
were applied, to ensure the solution was thoroughly mixed. 
Following these adjustments, antibodies C, H and N were found to have an 
appropriate full-length rhSDF-1α concentration-signal curve in the absence of plasma 
(Figure 7-6). Antibodies G and M were excluded from further characterisation as they 
failed to show any signal above background (indicated by the 0 pg/ml rhSDF-1α 
column). 
HuCAL® antibodies C, G and M were subsequently tested against full-length rhSDF-
1α at physiological concentrations in plasma (estimated as 2000 pg/ml, see Table 
7-2), to ensure the assay would have utility for experimental samples. In addition, to 
permit comparison with commercially available assays MAB350, a monoclonal mouse 
IgG against mouse and human SDF-1α, was tested as the detection antibody using 
the same assay protocol. This antibody was selected based on the capture antibody 
used in a commercially available ELISA for total SDF-1α (Quantikine® ELISA for Human 
CXCL12, R&D Systems, Oxon, UK). Similarly, MAB350 was tested with estimated 
physiological concentrations of SDF-1α in plasma. Figure 7-7 demonstrates that 
HuCAL® antibody C and MAB350 continued to generate highly sensitive and quantity-
dependent SDF-1α concentration-signal curves, and were therefore selected for use 
in the final configuration of the assay. HuCAL® antibody C was subsequently 
designated HCI.SDF1α, and this name is used henceforth.  
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Figure 7-6: Concentration-signal curves with HuCAL® capture antibody and a streptavidin 
amplification step 
HuCAL® C, G, H, M and N antibodies were used in the capture step together with a 
biotinylated detection antibody (BAF310) and streptavidin amplification. This reduced false 
positive signal and generated an appropriate concentration curve for HuCAL® antibodies C, 
H and N. HuCAL® antibodies G and M were excluded from further characterisation. 
9  
Figure 7-7: HuCAL® C, H and N antibodies and MAB350 against rhSDF-1α were tested in 
plasma 
At physiological concentrations of SDF-1α, HuCAL® antibody C and MAB350 continued to 
generate appropriate concentration-response curves. HuCAL® antibodies H and N did not 
and were excluded from further characterisation. 
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Following selection of the optimal primary antibodies, it was necessary to optimise 
the concentrations of both detection and capture antibody to maximise signal:noise. 
The approach to this was twofold. Firstly, varying concentrations of capture and 
detection antibody were tested against a fixed concentration of rhSDF-1α (5000 
pg/ml) to estimate the optimum combination of tested antibody concentrations 
(Figure 7-8, Panels A and C). Concentrations tried were based on a technical guide to 
ELISA available from Thermo Fisher Scientific (MA, USA).365 Secondly, a low and a high 
concentration of capture and detection antibody were tested in the absence of SDF-
1α in order to estimate their relative contribution to assay noise (Figure 7-8, Panels 
B and D). This process was applied to both HCI.SDF1α (Figure 7-8, Panels A and B) and 
MAB350 (Figure 7-8, Panels C and D). In both assays, higher concentrations of BAF310 
made a larger contribution to assay noise than higher concentrations of capture 
antibody and, with this in mind, the working antibody concentrations were chosen as 
5 µg/ml HCI.SDF1α and 0.4 µg/ml BAF310 (arrowed in Figure 7-8, Panel A), and 9 
µg/ml MAB310 and 0.4 µg/ml BAF310 (arrowed in Figure 7-8, Panel C). 
Further modifications to the protocol included testing different ELISA plates, based 
on which flat bottom clear polystyrene microplates (R&D Systems, Oxon, UK) were 
selected (data not shown). The effect of shaking the plate during incubation steps 
and diluting the sample to improve analyte recovery were also investigated, neither 
of which increased assay signal (data not shown). 
Sample SDF-1α values were interpolated from a standard curve generated using 
known concentrations of full-length rhSDF-1α (R&D Systems, Oxon, UK). The effect 
of different standard diluents on the interpolated SDF-1α value was investigated and 
found to have a significant effect, due to variable target analyte recovery (Figure 7-9, 
Panel A). Full-length rhSDF-1α standards in plasma and in Hispec buffer were 
compared and demonstrated over-estimation of the quantity of SDF-1α with Hispec 
buffer (blue line), particularly at the lowest concentrations of SDF-1α, compared to 
plasma (green line, Figure 7-9, Panel B). The effect of using Hispec buffer to dilute 
standards, therefore, was underestimation of SDF-1α in experimental plasma 
samples interpolated from this curve. This was corrected by using BUF037A, a 
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commercially available diluent with mammalian serum proteins, designed to mimic 
the recovery profile of human plasma (AbD Serotec, Oxon, UK). The standard profile 
of BUF037A is shown in Figure 7-9 (Panel B, red line). Averaged samples were baseline 
corrected using duplicate BUF037A wells without SDF-1α to account for any SDF-1α 
in the mammalian serum proteins included with this diluent. A sensitivity analysis was 
performed by multiple serial dilutions of standard samples in BUF037A, and a limit of 
detection (LOD) of 300 pg/ml was ascertained (Figure 7-9, Panel C). Limit of 
quantification (LOQ) was not calculated for this assay but was expected to be 
satisfactory as the typical concentration range of SDF-1α in biological samples is well 
above the LOD (see Table 7-2). 
 
Figure 7-8: Optimising signal:noise for HCI.SDF1α and MAB350 ELISA 
Concentrations of capture and detection antibody were optimised for both assays. (A) Signal 
produced by 5000 pg/ml full-length rhSDF-1α at variable concentrations of both HCI.SDF1α 
(capture) and BAF310 (detection) antibodies; (B) Assay noise at variable concentrations of 
both antibodies when no SDF-1α was added. The working antibody concentrations were 
chosen as 5 µg/ml HCI.SDF1α and 0.4 µg/ml BAF310 (arrowed in Panel A); (C) Signal produced 
by 5000 pg/ml full-length rhSDF-1α at variable concentrations of both MAB310 (capture) and 
BAF310 (detection) antibodies; (D) Assay noise at variable concentrations of both antibodies 
when no SDF-1α was added. The working antibody concentrations were chosen as 9 µg/ml 
MAB310 and 0.4 µg/ml BAF310 (arrowed in Panel C). 
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Figure 7-9: Optimising the standard sample diluent for SDF-1α value interpolation 
(A) Effect of the standard sample diluent on the interpolated value for full-length SDF-1α 
samples. The same raw sample data, from a full-length SDF-1α assay, was used for each 
regression analysis using a standard curve in either Hispec or plasma. Statistical significance 
was assessed using an unpaired t-test, n=4, P<0.001; (B) Difference in Hispec and plasma 
standard curves at lower values of full-length SDF-1α, which represents the concentration 
range of interest in this chapter. BUF037A mimicked plasma at lower concentrations of SDF-
1α and prevented underestimation of sample values; (C) Sensitivity assay using BUF037A, 
which indicated a LOD of 300 pg/ml (arrowed). 
To ascertain the effect of freezing on target analyte recovery, rat plasma samples 
spiked with 2500 pg/ml full-length rhSDF-1α were subjected to repeated freeze-thaw 
cycles (Figure 7-10). There was an unexpected difference between the absolute value 
of SDF-1α as measured by HCI.SDF1α and MAB350, which may be a consequence of 
sample processing by proteases in the rat plasma or may be statistical chance in view 
of the small sample size. Nonetheless, there was no evidence of SDF-1α degradation 
as measured with either HCI.SDF1α or MAB350, albeit with a sample size of one. 
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Figure 7-10: Effect of freeze-thaw cycles on SDF-1α recovery 
Rat plasma was spiked with 2500 pg/ml full-length rhSDF-1α and divided into 500 µl aliquots. 
Each aliquot was frozen and thawed a different number of times to ascertain whether this 
would degrade the sample (n=1). 
Finally, the percentage intra- and inter-assay coefficients of variation were calculated 
as [mean of SD x 100 / mean] and [SD of mean x 100 / mean], respectively. For 
HCI.SDF1α these values were 2.7% and 7.1%, and for MAB350 they were 3.4% and 
4.5%. All values were below the recommended maximum threshold of 10%. 
Once this ELISA for full-length SDF-1α was validated and characterised, it was 
necessary to compare the specificity against existing commercial antibodies. By 
assaying different proportions of intact and cleaved SDF-1α it was possible to 
demonstrate that HCI.SDF1α is specific for full-length SDF-1α, whereas commercial 
assays report a combination of intact and cleaved SDF-1α (Figure 7-11), making the 
results with the commercial antibody difficult to interpret in terms of SDF-1α activity. 
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Figure 7-11: Specificity of HCI.SDF1α and MAB350 for full-length and cleaved rhSDF-1α 
HCI.SDF1α is specific for active SDF-1α, with very low signal in the absence of intact SDF-1α, 
whereas there is substantial residual signal in the absence of intact SDF-1α in the case of 
MAB350. 
7.3.4 Discussion 
This section reports the successful characterisation and validation of a novel antibody 
(HCI.SDF1α), specific for the N-terminus of SDF-1α, and the development and 
optimisation of an immunoassay using this antibody that is specific for intact, active 
SDF-1α. HCI.SDF1α was identified as having specific and robust binding to full-length 
SDF-1α without any binding to cleaved SDF-1α or to GLP-1, an unrelated protein that 
is also cleaved by DPP4. It should be acknowledged that this approach does not 
preclude cross-reaction with other proteins, although a Basic Local Alignment Search 
Tool (BLAST) search for the sequence of interest in a human protein database 
revealed only protocadherin Fat 1 precursor as a potential match.366 Fat 1 is a 50 kDa 
protein that is expressed in epithelial and endothelial smooth muscle cells and, 
although its precise role remains poorly defined, it may have a role in promoting 
vascular remodelling after arterial injury.367 Western blotting would be an 
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appropriate method to exclude this as an important target of HCI.SDF1α in the 
samples used in this study. Although this was not done, it is unlikely to be present in 
plasma samples as, unlike SDF-1α, it is not secreted by cells.368 Furthermore, it should 
be noted that all isoforms of SDF-1α share the same N-terminal sequence. However, 
SDF-1α is the most prevalent and HCI.SDF1α is described in these terms to be 
consistent with the literature and commercially available antibodies.40 The relative 
quantities of each isoform in samples relevant to this study could be assessed by 
Western blotting, but was not pursued here because of time limitations. 
Cleavage reduces the affinity of SDF-1α for CXCR4, rendering it inactive. This is 
evidenced by the significant reduction in bio-reactivity in response to cleavage by 
DPP4.52, 201 Furthermore, studies using bioengineered SDF-1 that is resistant to 
cleavage by DPP4 have demonstrated improved stem cell homing, angiogenesis and 
EF.51, 369 
Baerts et al. described a significant reduction in immunoreactivity after they 
measured DPP4-cleaved rhSDF-1α using several different commercial ELISA kits 
(including R&D Systems, Raybiotech and Peprotech).151 They also determined that 
DPP4 was predominant in mediating cleavage of SDF-1α. However, despite currently 
available commercial antibodies having different affinities towards intact and DPP4-
truncated SDF-1α,52, 53 this section describes incomplete loss of signal in an ELISA 
using MAB350 following complete cleavage of SDF-1α with DPP4. This may 
potentially be explained by the fact that binding of MAB350 to an internal sequence 
in SDF-1α would leave a decreased number of SDF-1α binding sites available to the 
polyclonal detection antibody used in this sandwich ELISA format, despite loss of the 
N-terminus. As loss of the N-terminal Lys1 confers a complete loss of bio-reactivity, 
this observation confounds interpretation of both basic and clinical studies of SDF-1α 
that have used commercially available ELISA assays. Accurate measurement is crucial 
given the growing interest in SDF-1α as a potential biomarker 370-375 and therapy for 
ischaemic cardiomyopathy.93, 100, 200, 369, 376 
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ELISAs depend on the assembly of a large immune complex, and failure of any of its 
component parts can result in a failure of signal. A number of these problems were 
encountered, and remedied, in this study. The most problematic of these were low 
signal:noise in plasma samples and poorly representative standard curves, and these 
are discussed in turn. However, extensive refinement and incremental improvements 
to the assay have resulted in a robust and reliable assay for full-length SDF-1α. 
There were a number of possible reasons for initial poor signal:noise in plasma, 
related to either low signal or excessive background noise. Here, the biggest benefit 
was gained by switching from direct detection to a sandwich ELISA. Full-length SDF-
1α is expected to be present at low levels in the plasma and by immobilising SDF-1α 
using a specific antibody, rather than the spectrum of proteins present in plasma 
using a non-specific plate, the sensitivity of the assay was increased. This was 
augmented by optimising each individual component of the assay to ensure none was 
present at a limiting concentration. The optimisation of the capture and detection 
antibodies, for example, is demonstrated in Figure 7-8. Another important 
consideration was selecting pairs of antibodies that work in combination. This was 
challenging, as indicated by Figure 7-5, primarily due to cross-reactivity between 
antibodies. Specifically, initial attempts with a secondary antibody to the biotin tag 
in the HuCAL® antibodies cross-reacted with the biotin tag in the polyclonal goat IgG 
capture antibody (AF310NA; R&D Systems, Oxon, UK). Other cross-reactions were 
less easy to define and were solved by testing a number of combinations (see Table 
7-1). 
Secondly, optimising the standard diluent posed significant difficulty. Initially, a 
general ELISA diluent (Hispec, AbD Serotec, Oxon, UK) was used, as per the protocol 
provided by AbD Serotec (Oxon, UK). However, this led to relative over-estimation of 
the quantity of SDF-1α in standard samples resulting in under-estimation of sample 
values, particularly at the lowest concentrations of SDF-1α. As the concentration of 
full-length SDF-1α in actual samples was expected to be low it was important to 
address this issue. Initial attempts used a human or rat plasma standard diluent, 
which were successful but not sustainable. Furthermore, this approach complicated 
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analysis due to the SDF-1α naturally present in plasma. The issue was resolved by 
identifying a commercially available diluent that includes goat serum proteins that 
mimic the constitution and target analyte recovery profile of plasma samples without 
interfering with the assay (BUF037A, AbD Serotec, Oxon, UK). Once baseline SDF-1α 
was corrected for, this diluent had a good dynamic range and linearity-of-dilution. 
7.4 Aim 2: Investigate whether levels of CXCR4 ligands are increased in the blood of rats 
and humans subjected to remote ischaemic conditioning 
7.4.1 Background 
Several studies have correlated increased SDF-1α following RIC, as measured with 
commercially available ELISA kits (R&D Systems, Oxon, UK), with a range of protective 
phenomena. Jiang et al. demonstrated increased serum and myocardial SDF-1α after 
a remote IPostC protocol consisting of clamping the infra-renal abdominal aorta for 
four cycles of 5 min ischaemia and 5 min reperfusion. SDF-1ɑ levels peaked at 1 h, 
with an 80±5% increase (P<0.001) compared to control (sham surgery) animals. The 
authors associated this with improved retention of intravenously administered MSCs 
in a murine model of MI.29 In a similar experiment, Kamota et al. conferred RIC using 
repetitive occlusion of the abdominal aorta in mice prior to IRI of the LAD territory.30 
Using a standard ELISA, they measured 4-fold levels of SDF-1α after 1 h in 
unfractionated plasma samples. Finally, Davidson et al. confirmed that circulating 
SDF-1α levels were altered in rats subjected to three cycles of 5 min hind limb 
ischaemia and reperfusion, increasing by 50% in PFP samples to a peak of 890±70 
pg/ml.31 
However, all of these studies used the monoclonal mouse IgG, MAB350. As discussed 
in section 7.3, MAB350 reports a combination of intact and cleaved SDF-1α and any 
effect of RIC on full-length SDF-1α has not been documented. Furthermore, published 
results using commercially available assays for SDF-1α are also highly variable (see 
Table 7-2). Examination of the methods used in these studies revealed variable 
protocols, particularly with reference to sample type, and the effect of sample 
collection and preparation is considered in this section.  
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Reference Species 
SDF-1α 
(pg/ml) 
Serum 
377 Human 1264±251* 
67 Human 2500** 
65 Mouse 1700** 
Plasma 
378 Human 2447 
379 Human 
2565 (1322-
4174) 
373 Human 
1508 (1102-
2016) 
375 Human 
1894 (742–
17,633) 
30 Mouse 800** 
374 Human 3400** 
380 Human 1869 
381 Human 2000 
370 Human 
2420 (2070-
2810) 
65 Mouse 1700** 
382 Mouse 1879±1417 
383 Rat 1200±100 
31 Rat 590 ± 50 
Sample type not stated 
384 Human 2166±489 
Table 7-2: Control SDF-1ɑ levels from 
published studies 
All studies used an SDF-1α Quantikine 
ELISA Kit (R&D Systems, Oxon, UK) or 
equivalent reagents. Value given is 
mean±SD or median (interquartile range) 
SDF-1ɑ from the control group. *Study 
methods do not match stated sample 
type. **Value estimated from study 
figure. 
 
Unfractionated plasma describes the fraction of whole blood that holds blood cells in 
suspension. It is obtained after collection in citrated or heparinised tubes (to prevent 
clotting) and centrifugation (to remove red and white blood cells). Unfractionated 
plasma contains platelets as well as proteins, clotting factors, and several other 
dissolved substances. PFP is the residual supernatant after further centrifugation to 
aggregate platelets. Finally, serum describes the blood fraction obtained after 
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activation of clotting cascades and removal of the clot by centrifugation. It contains 
neither blood cells nor clotting factors. 
Therefore, the aim of this section was to investigate whether levels of active SDF-1α 
are increased in the blood of rats and humans subjected to RIC. As discussed in 
section 6.3.4, the inhibition of RIC by AMD3100 strongly implicates CXCR4, but not 
necessarily SDF-1α. The most attractive alternative ligand for CXCR4 in the context of 
cardioprotection is MIF, and its kinetics in response to RIC are also examined in this 
section. Finally, this section aims to ascertain the effect of sample preparation on 
SDF-1α measurement. 
7.4.2 Methods 
Sprague Dawley rats were used for all animal experiments in this section due to their 
greater blood volume compared to mice, and were randomly assigned to control or 
RIC groups. RIC was conducted using three cycles of 5 min cuff inflation and 5 min 
deflation. Samples were collected either immediately after RIC or 1 h later (Figure 
7-12). 
 
Figure 7-12: Remote ischaemic conditioning and blood sampling protocol 
(A) Control: 35 min stabilisation; (B) RIC: 5 min stabilisation, three cycles of 5 min hind limb 
ischaemia and 5 min reperfusion. Animals were exsanguinated by cardiac puncture either 
immediately after RIC (sample 1) or 60 min thereafter (sample 2). Figure not to scale. 
Samples were prepared and assayed as described in Chapter 2. Rat samples were 
assayed for MIF using a custom sandwich ELISA protocol provided by Professor 
Bernhagen (Aachen, Germany). This was the same as the SDF-1α assay described in 
A. Control
B. RIC
0 5
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section 2.8, with the following differences: clear, flat bottom, 96-well MaxiSorp ELISA 
plates (Thermo Fisher Scientific, MA, USA) were coated with 7.5 µg/ml anti-MIF 
monoclonal antibody (MAb XIV.14.3, courtesy of Professor Bernhagen) in PBS 
overnight at RT. Wells were blocked with a buffer containing 1% BSA and 5% sucrose 
in PBS for 1 h at RT. 100 µl of sample diluted 1:10 in Tris-buffered saline (TBS, 
consisting of 0.05 M Tris and 0.15 M sodium chloride at pH 7.6) with 0.1% BSA and 
0.05% Tween® 20 was added to each well. Standard samples were prepared using 
purified rat MIF (BioTrend, Köln, Germany) starting at 200 ng/ml with twofold dilution 
steps (range 4-200 ng/ml) in TBS with 0.1% BSA and 0.05% Tween® 20. Biotinylated 
polyclonal goat anti-human and mouse MIF secondary antibody (BAF289, R&D 
Systems, Oxon, UK) diluted in TBS with 0.1% BSA and 0.05% Tween® 20 to 200 ng/ml 
was added to each well for a further 1 h at RT. All analyses, including samples and 
standards, were performed in duplicate and readings were averaged to minimise 
intra-assay variability. 
No exclusion criteria were defined beyond those described in section 4.3.2. To ensure 
the correct curve fit was used in the SDF-1α assay, standard curves of values from 
fourteen assays were plotted using both linear and non-linear methods. Next, 
standards were treated as unknown values and interpolated from each standard 
curve. The resultant values were compared with the expected values using the 
Pearson product-moment correlation coefficient (r) and the curve fit yielding the best 
correlation was used. Consequently, full-length SDF-1α values were interpolated 
from linear regression of the HCI.SDF1α standard curve (r=0.9996, P<0.001), whereas 
the commercially available MAB350 standard curve was evaluated with nonlinear 
regression using log(agonist) versus response (r=0.9993, P<0.001). 
Sample size for rat experiments was calculated using a two-sided test for the 
comparison of two means. Based on the most conservative increase in SDF-1α, 
reported by Davidson et al. from our laboratory,31 the following assumptions were 
made: a 50% estimate of effect size, a control value of 600 pg/ml, an SD of 150 pg/ml, 
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a significance level of 5% (α=0.05) and 80% power (β=0.2). This required a minimum 
sample size of four animals per group. 
Six healthy male subjects volunteered to participate in the human arm of the study. 
None were taking any regular medication and no heparin was administered. Each 
volunteer was subjected to RIC as described in section 2.9 and samples were again 
collected either immediately after RIC or 1 h later. Experiments were all conducted 
at the same time of day. Platelet count and waist circumference was measured in all 
participants. The samples were assayed for full-length SDF-1α, as described above, 
and for MIF using the R&D ELISA (R&D Systems, Oxon, UK) according to the 
manufacturers’ instructions. 
7.4.3 Results 
The surgical complications encountered in this experiment were negligible compared 
to in vivo myocardial ischaemia-reperfusion experiments as, apart from intubation 
and exsanguination, no invasive surgical procedures were applied. 48 animals were 
included in the analysis, with only two exclusions due to anaesthetic-related cardio-
respiratory arrest and ventilation complications. 
This experiment measured intact and cleaved SDF-1α after RIC in Sprague Dawley rats 
subjected to a standard RIC protocol. The main difficulty during this study was 
successfully aspirating blood for analysis. This was initially done by transecting a 
major vessel and allowing the animal to exsanguinate into its chest cavity, before 
aspirating blood into a syringe. However, this method activated clotting, which was a 
potential source of confounding. To test this, PFP prepared by the differential 
centrifugation protocol described in section 7.4.2 was compared to serum. To 
prepare serum, blood was collected into tubes with DPP4 inhibitor as before but 
without citrate. Blood was allowed to clot at RT for 20 min before centrifuging at 
1,600 g for 10 min. This removes red and white blood cells, clotting factors, and 
causes the activation of platelets.385 SDF-1α measured with both HCI.SDF1α and 
MAB350 were significantly higher in serum than in PFP samples (HCI.SDF1α PFP 
1200±200 pg/ml vs. serum 5000±200 pg/ml, n=3-7, P<0.001; MAB350 PFP 490±30 
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pg/ml vs. serum 4400±300 pg/ml, n=3-7, P<0.001, Figure 7-13). For completeness, 
separate samples were taken from the same animals for the measurement of 
unfractionated plasma. Blood was taken into citrated tubes containing DPP4 inhibitor 
and immediately centrifuged at 1,600 g for 20 min, without subsequent 
centrifugation at 10,000 g. Likewise, SDF-1α measured with either antibody was 
significantly higher in serum than in unfractionated plasma samples (HCI.SDF1α 
unfractionated plasma 1100±200 pg/ml vs. serum 5000±200 pg/ml, n=3-4, P<0.001; 
MAB350 unfractionated plasma 1200±100 pg/ml vs. serum 4400±300 pg/ml, n=3-4, 
P<0.001, Figure 7-13). In order to limit the number of animals used, samples for 
unfractionated plasma and serum were collected from the same animals using 
separate RV punctures whenever possible. 
 
Figure 7-13: Effect of sample preparation on SDF-1α concentration in rat blood 
Sprague Dawley rats were anaesthetised and exsanguinated via RV puncture for analysis of 
SDF-1α in different blood fractions. Serum samples had significantly more SDF-1α using 
either HCI.SDF1α or MAB350 assays than PFP or unfractionated plasma samples. Statistical 
significance was assessed using one-way ANOVA and Tukey’s multiple comparison test for 
each assay, n=3-7, ***P<0.001. 
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In view of the high concentration of SDF-1α in serum samples and the potential 
confounding effect of platelets in unfractionated plasma, PFP samples were used in 
all subsequent experiments. Additionally, blood was collected via cardiac puncture, 
and further incremental improvements were made by reducing needle length and 
increasing needle gauge to reduce activation of clotting. 
An ELISA of PFP samples using MAB350 replicated the published finding of 
significantly higher SDF-1α after RIC,29-31 and this difference was still present 1 h after 
the RIC protocol (0 min control 490±20 pg/ml vs. RIC 760±60 pg/ml, n=3, P<0.05; 60 
min control 500±100 pg/ml vs. RIC 740±20 pg/ml, n=4, P<0.05, Figure 7-14). However, 
when measured using HCI.SDF1α, levels of full-length SDF-1α unexpectedly 
decreased immediately after RIC (700±100 pg/ml vs. 1200±200 pg/ml, n=7-9, P<0.05, 
Figure 7-14) and normalised by 1 h (900±100 pg/ml vs. 950±90 pg/ml, n=4, P=NS, 
Figure 7-14). Samples were taken at 0 and 60 min after RIC to reflect reports in the 
literature that total SDF-1α significantly increased only after 60 min.29, 30 
These findings suggest increased cleavage of SDF-1α after RIC, at least in the 
circulation, which is discussed further in section 7.5. However, it is known that 
endothelial sulphated glycoasaminoglycans, including heparan sulfate (HS), 
sequester SDF-1α from the circulation,386, 387 promoting its oligomerization and 
competitively inhibit its interaction with CXCR4.388 It was therefore necessary to test 
for any change in the quantity of sequestered SDF-1α in response to RIC. 
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Figure 7-14: Rat PFP SDF-1α measured using HCI.SDF1α and MAB350 immediately and 1 h 
after remote ischaemic conditioning 
Sprague Dawley rats were anaesthetised and treated with either RIC (three cycles of 5 min 
hind limb ischaemia and 5 min reperfusion) or sham procedure. Blood was taken by RV 
puncture at either 0 min or 60 min and processed to obtain PFP. ELISA using MAB350 
detected an increase in plasma SDF-1α levels whereas HCI.SDF1α, which is more specific for 
full-length SDF-1α, measured a decrease immediately after RIC that returned to baseline by 
1 h. Statistical significance was assessed with unpaired t-tests, n=3-9, *P<0.05. 
To investigate the significance of the association between SDF-1α and cell surface HS 
rats were pre-treated with either intraperitoneal heparin oligosaccharides (heparin 
sodium 500 IU combined with usual anaesthetic), which competitively displaces 
sequestered pools of SDF-1α and increase circulating levels,386 or saline vehicle 
control. As expected, heparin treatment significantly increased SDF-1α in control 
animals from 490±20 pg/ml to 1100±100 pg/ml (n=4, P<0.01, Figure 7-15) when 
assayed using MAB350. However, it did not significantly increase PFP full-length SDF-
1α (no heparin 1200±200 pg/ml vs. heparin 1400±200 pg/ml, n=3-7, P=NS, Figure 
7-15). 
 192 
 
 
Figure 7-15: Rat platelet-free plasma SDF-1α measured using HCI.SDF1α and MAB350 after 
pre-treatment with intraperitoneal heparin 
Sprague Dawley rats were anaesthetised with either intraperitoneal pentobarbitone alone 
or in combination with 500 IU heparin. Blood was taken by RV puncture and processed to 
obtain PFP. Animals that were pre-treated with heparin had significantly more full-length 
SDF-1α than un-heparinised controls. Statistical significance was assessed using unpaired t-
tests, n=3-7, **P<0.01. 
Next, the RIC experiments were repeated to determine whether a significant 
elevation in active SDF-1α levels after RIC could be unmasked by the addition of 
heparin. Rats were randomly allocated to either the control or RIC arm of the study. 
Blood was taken both immediately and 1 h after RIC, and SDF-1α was measured using 
HCI.SDF1α. Interestingly, rather than reveal an increase in active SDF-1α, pre-
treatment of animals with heparin prior to RIC increased overall levels of PFP SDF-1α 
and abolished the significant reduction in SDF-1α seen immediately after RIC in Figure 
7-14 (0 min control 1400±200 pg/ml vs. RIC 1230±50 pg/ml, n=4, P=NS; 60 min control 
1500±400 pg/ml vs. RIC 1200±300 pg/ml, n=4, P=NS, Figure 7-16). 
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Figure 7-16: Rat SDF-1α measured in platelet-free plasma using HCI.SDF1α immediately and 
1 h after remote ischaemic conditioning in animals pre-treated with heparin  
Sprague Dawley rats were anaesthetised with intraperitoneal pentobarbitone in combination 
with 500 IU heparin prior to RIC (three cycles of 5 min hind limb ischaemia and 5 min 
reperfusion) or sham procedure. Blood was taken by RV puncture at 0 min and 60 min and 
processed to obtain PFP. In rats pre-treatment with heparin, RIC did not significantly increase 
active SDF-1α at either 0 or 60 min. Statistical significance was assessed using unpaired t-
tests, n=4, P=NS. 
In the absence of a detectable increase in active SDF-1α, it may be another ligand of 
CXCR4 that increases in response to RIC. To test this MIF was assayed in the same 
samples as above. There was no detectable change in MIF concentration after RIC in 
PFP (Panel A: 0 min control 24±6 ng/ml vs. RIC 18±7 ng/ml, n=4, P=NS; 60 min control 
24±8 ng/ml vs. RIC 45±27 ng/ml, n=4, P=NS, Figure 7-17) or serum samples (Panel B: 
0 min control 300 ng/ml vs. RIC 290±11 ng/ml, n=1-3, P=NS; 60 min control 290±25 
ng/ml vs. 340±20 ng/ml, n=3-4, P=NS, Figure 7-17). 
To confirm the surprising finding that RIC resulted in a reduction of full-length SDF-
1α, the RIC protocol was repeated on the upper limb of six healthy human volunteers. 
Despite significant inter-individual variability and exclusion of a haemolysed sample 
(because haemolysis is known to interfere with the assay), a small but significant 
decrease in active SDF-1α was observed (pre-RIC 380.0±154.9 pg/ml vs. 0 min 
337.5±148.3 pg/ml vs. 60 min 329.8±148.7 pg/ml, n=5, P<0.05, Figure 7-18). There 
was no correlation with waist circumference, which has previously been associated 
with SDF-1α, albeit using commercially available antibodies (Pearson’s r -0.04, 
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P=NS),389 nor was any association with platelet count observed (Pearson’s r -0.41, 
P=NS). 
 
Figure 7-17: MIF measured in rat platelet-free plasma (Panel A) and serum (Panel B) 
immediately and 1 h after remote ischaemic conditioning 
Sprague Dawley rats were anaesthetised and subjected to RIC (three cycles of 5 min hind 
limb ischaemia and 5 min reperfusion) or sham procedure. Blood was taken by RV puncture 
at 0 min and 60 min and processed to obtain PFP. RIC did not significantly increase MIF at 
either 0 or 60 min in either blood fraction. Statistical significance was assessed using unpaired 
t-tests, n=1-4, P=NS. 
 
Figure 7-18: PFP SDF-1α measured in healthy male volunteers using HCI.SDF1α at baseline, 
and immediately and 1 h after remote ischaemic conditioning 
RIC consisting of three cycles of 5 min right upper limb ischaemia and 5 min reperfusion was 
applied by inflation of a manual sphygmomanometer to a pressure of 200 mmHg. Blood 
samples were collected into citrated tubes at baseline and after the final 5 min of reperfusion. 
Samples were immediately prepared to obtain PFP. Despite marked baseline variation, there 
was a decrease in plasma full-length SDF-1α levels after RIC. Statistical significance was 
assessed using one-way ANOVA and Tukey’s multiple comparison test, n=5, *P<0.05. 
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The same samples were assayed for MIF with a commercial ELISA as MIF was 
undetectable in human samples when using the same custom ELISA used in rats. A 
haemolysed sample was excluded from the human volunteer baseline group. The 
remaining samples indicated there was no significant difference either immediately 
or 1 h after RIC (baseline 16±1 ng/ml vs. 0 min 15±3 ng/ml vs. 60 min 18±4 ng/ml, 
n=5-6, P=NS, Figure 7-19). 
 
Figure 7-19: Platelet-free plasma MIF measured in healthy male volunteers at baseline, and 
immediately and 1 h after remote ischaemic conditioning 
RIC consisting of three cycles of 5 min right upper limb ischaemia and 5 min reperfusion was 
applied by inflation of a manual sphygmomanometer to a pressure of 200 mmHg. Blood 
samples were collected into citrated tubes at baseline and after the final 5 min of reperfusion. 
Samples were immediately prepared to obtain PFP. MIF in the PFP of healthy human 
volunteers was unaffected by RIC. Statistical significance was assessed using one-way ANOVA 
and Tukey’s multiple comparison test, n=5-6, P=NS. 
7.4.4 Discussion 
The main finding reported in this section is that, surprisingly, full-length SDF-1α 
significantly decreased immediately after RIC, in both rats and humans. In rats, this 
had returned to baseline by 60 min. Combined with the observation here and in the 
literature that SDF-1α levels appear to increase when measured with commercial 
assays, this suggests that there is, in fact, an increase in cleaved, inactive SDF-1α. 
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It is unclear how increased cleavage can relate to acute cardioprotection given the 
existing paradigm that anticipates increased production or maintenance of 
extracellular concentrations of SDF-1α as a direct effect of RIC.103 There are several 
hypotheses for this finding in the context of this thesis, that include: (1) RIC-mediated 
increases in SDF-1α expression are limited to a specific circulating cell type such as 
platelets or inflammatory cells; (2) RIC-mediated increases in SDF-1α expression are 
predominantly sequestered by endothelial sulphated proteoglycans; (3) an 
alternative ligand for CXCR4 is responsible for the cardioprotection conferred by RIC; 
(4) SDF-1α is important in either the trigger or effector phases of RIC, but is not the 
humoral factor; and (5) cardioprotection in response to RIC is related to altered 
receptor dynamics, rather than up-regulation of SDF-1α. These hypotheses will be 
discussed in turn. 
Firstly, regarding the hypothesis that RIC-mediated increases in SDF-1α expression 
are limited to a specific circulating cell type, platelets are of particular interest. 
Activated platelets are known to express SDF-1α and adhere to injured endothelium 
via inflammatory cell adhesion molecules in MI.358, 390 Furthermore, platelets are 
removed during the preparation of PFP and any such up-regulation may not be 
detectable in the ELISA described here. With this in mind, it was further hypothesised 
that platelets may be central to SDF-1α dynamics after RIC, and this is examined 
further in section 7.6. The potential role of inflammatory cells is discussed in section 
8.4.4. 
Secondly, RIC-mediated increases in SDF-1α expression may be predominantly 
sequestered by endothelial sulphated proteoglycans.386, 387 Any change in SDF-1α 
conferred by RIC may be undetectable by ELISA if SDF-1α is absent from the 
circulation. Exogenous heparin can be useful in this regard as it is known to liberate 
HS-bound SDF-1α and increase circulating levels.386 Interestingly, it has been 
reported that heparin is cardioprotective in the context of IRI,242-246 although it is not 
known whether this is related to altered SDF-1α dynamics. This seems unlikely given 
that glycosaminoglycans (including heparin) promote dimerisation of SDF-1α, which 
abrogates the cardioprotection conferred by SDF-1α in an isolated rat heart model of 
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IRI by impairing the ability of SDF-1α to bind to CXCR4.388 However, this finding may 
further contribute to elevated circulating SDF-1α after heparin administration. It is 
notable that studies that demonstrate increased SDF-1α after RIC use variable 
protocols, however only one (Davidson et al.31) specifically documents the use of 
intraperitoneal heparin sodium prior to RIC. 
In the present study, only circulating SDF-1α measured using MAB350 was 
significantly increased after the administration of heparin, suggesting it was the 
cleaved fraction. It is unclear then exactly what form (full-length or cleaved) of SDF-
1α binds to cell-surface HS, but to investigate this further was beyond the scope of 
this project. Importantly, pre-treatment with exogenous heparin did not unmask any 
change after RIC but instead abrogated the significant reduction in SDF-1α seen 
immediately after RIC in experiments performed without heparin. This may relate to 
the finding by Ziarek et al. that HS- and heparin-induced SDF-1α dimerisation also 
inhibits its proteolytic degradation by DPP4 by shielding DPP4 from its binding 
sites,388 rather than altered activity per se,391 although this hypothesis was not 
specifically tested here. 
Thirdly, an alternative ligand for CXCR4 may be responsible for RIC-induced 
cardioprotection. This justifies both the failure of the present study to demonstrate 
increased SDF-1α in the plasma of rats subjected to RIC and the finding that the 
CXCR4 receptor antagonist AMD3100 abrogates the cardioprotective effect of RIC. To 
this end, MIF was assayed after RIC in rat PFP and serum without any detectable 
increase. MIF values were generally higher in serum samples, although the inclusion 
of only one sample in the 0 min control group precluded statistical comparison. Like 
SDF-1α, this may relate to its expression by platelets although, unlike SDF-1α, its 
release from activated platelets is delayed for up to 2 h.392, 393 Furthermore, it is not 
clear whether MAb XIV.14.3 measures intact or cleaved MIF. Nonetheless, there was 
no indication from these experiments that this is an important consideration and it 
was not investigated further. In addition to MIF, ubiquitin is a recognised ligand for 
CXCR4. As discussed in section 6.3.4, it has not yet been investigated in 
cardioprotection and this was not specifically addressed here. 
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Fourthly, it is possible that SDF-1α increases locally to the limb stimulus or remotely 
in the effector organ, perhaps via a neural or humoral intermediary.181 To be certain 
it would be necessary to demonstrate increased extracellular concentrations of 
active SDF-1α at these locations. This was not possible during the course of this 
project, but could be investigated using immunofluorescence with standard anti-
CXCR4 antibodies or by exploiting a molecule called Ac-TZ14011-FITC, which is a 
validated, fluorescent CXCR4-binding peptide.394 
Fifthly, it may be the case that, rather than fluctuations in SDF-1α concentration that 
are important for acute cardioprotection, it is alterations in CXCR4 expression that 
are central to the mechanism of RIC. This is discussed in more detail in Chapter 8. 
To confirm the unanticipated finding that full-length SDF-1α is degraded by RIC, the 
study was repeated in healthy human volunteers. A similar decrease in SDF-1α levels 
after RIC was seen, despite there being significant variability in baseline SDF-1α 
measurements. Previously, variability in circulating SDF-1α has been associated with 
waist circumference,389 time of day and acute stress.327 In this study, there was no 
association between waist circumference and baseline SDF-1α, all experiments were 
performed at the same time of day to account for SDF-1α circadian rhythm, and no 
major differences in stress levels of the subjects were apparent, although this was 
not specifically controlled for. Platelet count was measured in each subject but no 
significant correlation was found. 
The experiments in this section measured SDF-1α in different blood fractions, 
including unfractionated plasma, PFP and serum. SDF-1α levels were found to be 
dramatically increased in serum, compared to platelet-free and unfractionated 
plasma samples. As discussed, SDF-1α is known to be contained in platelet α-granules 
and be expressed upon platelet activation and degranulation,358 as occurs during the 
preparation of serum samples. The present finding therefore emphasises the 
importance of correct sample preparation when measuring SDF-1α. Interestingly, the 
methods described in published studies investigating SDF-1α are highly variable and 
often include the analysis of serum samples, for example the study by Jiang et al. 
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described above, which complicates interpretation of the existing literature and 
suggests that some published results may be anomalous. 29, 65, 67, 377 
Overall, it seems likely that the apparent increased cleavage of SDF-1α in response to 
RIC does not relate to acute cardioprotection. Instead, this finding may relate to the 
gradient-guided homing, reparative properties of the SDF-1α-CXCR4 axis in response 
to tissue ischaemia. The precise mechanism is not clear, and is beyond the scope of 
this project, but it is intriguing to consider a possible role of SDF-1α in relation to 
recent large randomised control trials of DPP4 inhibitors, which are described in more 
detail in section 7.5.1. Specifically, SAVOR-TIMI 53 compared Saxagliptin and placebo 
in 16,492 patients with a history of, or at risk for, cardiovascular events.395 It 
unexpectedly reported an increased risk of hospitalisation for heart failure (hazard 
ratio 1.27, 95% CI 1.07-1.51, P=0.007), which a subsequent sub-study found to be 
highest in patients with elevated natriuretic peptides, previous heart failure or 
chronic kidney disease.396 Combined with mixed results from observational studies, 
the relationship between DPP4 inhibitors and heart failure is controversial. A recent 
systematic review and meta-analysis concluded that, despite an abundance of low-
quality evidence, DPP4 inhibitors ‘may increase the risk of hospital admission for 
heart failure in those patients with existing cardiovascular diseases or multiple risk 
factors for vascular diseases, compared with no use’.397 Although SDF-1α has not 
been investigated in this context, it may be speculated that increased cleavage of 
SDF-1α after tissue injury (MI, for example) is part of a reparative mechanism that, if 
interrupted by DPP4 inhibitors, results in worse outcomes. It is anticipated that 
resolving the role of SDF-1α and DPP4 in response to ischaemia would yield important 
and timely information in this area of clinical uncertainty. 
7.5 Aim 3: Investigate the contribution of DPP4 to SDF-1α dynamics after remote ischaemic 
conditioning 
7.5.1 Background 
DPP4 is an extracellular peptidase that cleaves SDF-1α at its position 2 proline 
residue. It is present on many of the same cell types as CXCR4, including B and T 
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lymphocytes, endothelial cells and CD34+ haematopoietic progenitor cells, as well as 
being present in plasma.17, 398 Several studies have attempted to interfere with SDF-
1α proteolysis by DPP4. For example, bioengineered SDF-1 that is resistant to 
cleavage by DPP4 and MMP-2 has been associated with improved stem cell homing, 
angiogenesis and EF.51, 369 With regard to DPP4 inhibitors, Christopherson et al. first 
showed that DPP4 inhibition increased stem cell homing to bone marrow,399 
following which Zaruba et al. combined DPP4 inhibition with G-CSF-mediated stem 
cell mobilisation in a murine model of MI.200 They found increased CXCR4+ EPC 
homing (an effect that was abrogated by administration of AMD3100), reduced 
cardiac remodelling and apoptosis, and improved EF and survival. This approach was 
recently tested in a phase III clinical trial using Sitagliptin (Safety and efficacy of 
SITAgliptin plus Granulocyte-colony-stimulating factor in patients suffering from 
Acute Myocardial Infarction, SITAGRAMI).400 They randomised 174 patients to either 
G-CSF and Sitagliptin or placebo after PPCI for MI in a multi-centre, double-blind 
design. The primary endpoint of improved combined global LV and RV EF as assessed 
by magnetic resonance imaging at 6 months was not met and while there was a trend 
towards reduced major adverse cardiac events, it was not significant. This may be 
explained by the inclusion of only 21% of patients with LV EF below 50%, thereby 
obfuscating any potential benefit of this therapy. 
Similarly, three large multicentre clinical trials have recently failed to demonstrate a 
benefit of DPP4 inhibitors on cardiovascular outcomes in patients with type 2 
diabetes at high risk for cardiovascular events. SAVOR-TIMI 53, described above, 
found no significant difference in the primary endpoint of cardiovascular death, MI 
or stroke between Saxagliptin and placebo.395 Similarly, EXAMINE compared 
Alogliptin with placebo in 5380 patients with type 2 diabetes and recent acute 
coronary syndrome over median follow-up of 18 months and found no significant 
difference in the primary endpoint of cardiovascular death, non-fatal MI or non-fatal 
stroke.401 In a post-hoc analysis, there was no evidence of excess admissions for heart 
failure.402 Most recently, TECOS compared Sitagliptin to placebo in 14,671 patients 
with type 2 diabetes and cardiovascular disease, and found no difference with 
respect to the composite primary outcome of cardiovascular death, nonfatal MI, 
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nonfatal stroke, or hospitalization for unstable angina.403 In a subgroup analysis, 
there was no difference in the rate of hospitalisation for heart failure. 
However, none of the aforementioned studies elucidated the contribution, if any, of 
DPP4 inhibitors in the acute phase of MI. In the context of RIC, Davidson et al. found 
no increase in plasma DPP4 activity after RIC in rats.31 However, it is not known if the 
expression or activity of membrane-bound DPP4 changes following RIC and whether 
this impacts on SDF-1α dynamics. It was therefore hypothesised that the increased 
cleavage of SDF-1α described in section 7.4 was consequent upon increased 
membrane-bound DPP4 activity in response to RIC. 
7.5.2 Methods 
To confirm the absence of increased circulating DPP4 activity as the cause of SDF-1α 
cleavage, rats were randomly assigned to control or RIC groups. Soluble DPP4 activity 
was measured using the DPPIV-GloTM Protease Assay (Promega, Essex, UK) according 
to the manufacturer’s instructions. Briefly, plasma samples were added to an equal 
volume of DPPIV-GloTM reagent, mixed using a plate shaker and incubated at RT for 2 
h. Luminescence was measured on a 96 well microplate reader (FLUOstar Omega, 
BMG Labtech, Germany). All samples were measured in duplicate. As a significant 
increase in circulating DPP4 activity after RIC has not been reported in the literature, 
a pragmatic decision was made to test a minimum of four animals per group. 
Assuming a control value and SD of 1.2 LU and 0.3 LU, respectively, based on the 
report by Davidson et al.,31 a significance level of 5% (α=0.05) and 80% power (β=0.2), 
this sample size would detect an effect size of 50% 
Endothelium membrane-bound DPP4 activity was investigated using human 
umbilical vein endothelial cells (HUVECs). 5 x 104 cells were seeded per well of a 96-
well flat-bottomed plate in 200 µl of the endothelial cell growth medium EGM-2 
supplemented with 2% foetal bovine serum (Lonza, Berks, UK) until confluence was 
achieved. To apply oxidative stress, medium was removed and replaced with PBS 
containing 1 mM H2O2 at RT. After 5 min this was removed and replaced with 200 µl 
EGM-2 medium for 150 min, after which the supernatant was removed and replaced 
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with 50 µl EGM-2 medium and 50µl DPPIV-GloTM reagent. All groups were performed 
in triplicate. 
7.5.3 Results 
Circulating plasma DPP4 activity was not significantly altered when assayed 
immediately after RIC, and activity actually decreased by 1 h post RIC (0 min control 
440±30 LU vs. RIC 360±60 LU, n=4, P=NS; 60 min control 440±10 LU vs. RIC 380±20 
LU, n=4, P<0.05, Figure 7-20). No surgical complications were encountered in this 
experiment. 
 
Figure 7-20: Dipeptidyl peptidase 4 activity measured in rats immediately and 1 h after 
remote ischaemic conditioning 
Sprague Dawley rats were anaesthetised and treated with either RIC (three cycles of 5 min 
hind limb ischaemia and 5 min reperfusion) or sham procedure prior to exsanguination via 
RV puncture for analysis of DPP4 activity at 0 min and 60 min. Levels of circulating DPP4 were 
unchanged immediately after RIC but significantly decreased by 1 h. Statistical significance 
was assessed using unpaired t-tests, n=4, *P<0.05. 
To investigate the possibility that the activity of membrane-bound DPP4 on 
endothelial cells could be specifically altered, cultured HUVECs were stimulated with 
transient (5 min) H2O2 to simulate the oxidative stress conferred by IPC.404 This 
resulted in a significant increase in DPP4 activity in stressed cells (140±7 vs. 120±4, 
n=4, P<0.05, Figure 7-21). 
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Figure 7-21: Effect of heparin on DPP4 activity HUVECs stimulated with to H2O2 
To simulate RIC in primary endothelial cells, HUVECs were briefly (5 min) exposed to 100 μM 
H2O2. There was a significant increase in DPP4 activity in stressed cells. Statistical significance 
was assessed using an unpaired t-test, n=4, *P<0.05. 
7.5.4 Discussion 
The finding of increased cleavage of SDF-1α immediately after RIC could not be 
explained by increased circulating DPP4, which is consistent with the finding of 
Davidson et al.31 However, DPP4 is known to be predominantly active on 
endothelium,391 and this experiment provides the first description of the activity of 
membrane-bound DPP4 being increased in response to oxidative stress, which was 
used to mimic RIC in HUVECs. 
This experiment provides some justification for the unexpected finding of increased 
SDF-1α cleavage in response to RIC.  However, it is unclear if this mechanism relates 
to acute cardioprotection. In the context of the hypothesis that SDF-1α mediates RIC 
it might instead be expected that acute DPP4 inhibition, to increase the half-life of 
SDF-1α by preventing its degradation, would be advantageous. Only a relatively small 
number of pre-clinical studies have investigated whether DPP4 inhibitors confer 
acute cardioprotection after IRI in non-diabetic animals.405-409 For example, Chinda et 
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al. found that Vildagliptin significantly reduced IS in an in vivo rat model of IRI.406 This 
was associated with reduced mitochondrial ROS, mitochondrial swelling, and 
increased markers of cardiomyocyte apoptosis, including Bcl-2 and pro-caspase 3. Ye 
et al. reported a similar result with Sitagliptin, via cAMP dependent PKA activation,408 
and Sauve et al. demonstrated smaller IS following IRI in isolated hearts from DPP4 
null mice.407 The involvement of SDF-1α in these studies was not tested. 
No study to date has examined whether pre-treatment with a DPP4 inhibitor can 
augment RIC-induced cardioprotection. This was not addressed here in view of the 
absence of a detectable increase in full-length SDF-1α after RIC. Furthermore, as 
discussed in section 7.4, it is not clear whether DPP4 inhibition would compromise 
the beneficial effects of the SDF-1α-CXCR4 axis with respect to ventricular 
remodelling. 
7.6 Aim 4: Investigate the role of platelets in SDF-1α dynamics after remote ischaemic 
conditioning 
7.6.1 Background 
As discussed, a possible reason for the unexpected absence of an increase in PFP SDF-
1α after RIC might relate to the role of platelets in SDF-1α kinetics. As presented in 
Figure 7-13, serum samples, that contain activated platelets, have significantly more 
SDF-1α than PFP samples. This leads to the hypothesis that RIC might activate 
platelets, by hypoxia for example,410 triggering  the release and expression of SDF-1α. 
It is well established that platelets contain SDF-1α within α-granules and express 
CXCR4 on their surface.358 Furthermore, Chatterjee et al. have shown that stimulating 
platelets using protease-activated receptor (PAR)-1-activating peptide, ADP (via 
P2Y12 receptors) or glycoprotein VI-targeting collagen-related peptide induces SDF-
1α release and surface expression.358 As platelets are activated in the preparation of 
serum samples as part of a general activation of clotting pathways, this is the likely 
mechanism of SDF-1α release described in Figure 7-13. 
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Interestingly, it has been hypothesised that RIC activates platelets, albeit without 
specific reference to SDF-1α. Oberkofler et al. applied RIC to the femoral vascular 
bundle prior to hepatic IRI in mice.411 As well as hepatic protection, RIC caused 
platelet activation as evidenced by a 40% reduction in platelet numbers and an 
associated increase in serum P-selectin, which is ubiquitous in α-granules.412 
Furthermore, RIC was abolished when platelet activation was inhibited using a 
platelet-activating factor (PAF) receptor antagonist. 
Taken together, these findings engender the hypothesis that RIC is mediated by 
platelet activation and the release of proteins contained within α-granules, including 
SDF-1α. This is consistent with the finding of diminished full-length SDF-1α in PFP 
samples described in section 7.3.4 if it is hypothesised that SDF-1α interacts with 
platelet-expressed CXCR4 and is then removed along with platelets during 
centrifugation. In this case, an increase in SDF-1α might only be detectable in serum 
samples or directly on platelets. This is supported by the use of serum by Jiang et al. 
in their report of increased SDF-1α following RIC,29 and its investigation is the next 
aim of this chapter. 
7.6.2 Methods 
For rat experiments, animals were randomly assigned to control or RIC groups. 
Anaesthetised rats were subjected to RIC consisting of three cycles of 5 min cuff 
inflation and 5 min deflation. Blood was taken via ventricular puncture immediately 
and 1 h after the RIC protocol (Figure 7-12). Blood was centrifuged to obtain serum, 
which was subsequently assayed for levels of intact SDF-1α. 
Sample size was calculated using a two-sided test for the comparison of two means. 
Based on the increase in SDF-1α after RIC in serum reported by Jiang et al., the 
following assumptions were made: an 80% estimate of effect size, a control value of 
3.5 ng/ml, an SD of 1 ng/ml, a significance level of 5% (α=0.05) and 80% power 
(β=0.2). This required a minimum sample size of two animals per group. 
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The methods used for human experiments were based on those described in section 
2.9, with details specific to this experiment described here. Three healthy male 
volunteers participated in the study after giving informed consent. None were taking 
any regular medication and no heparin was administered. Experiments were all 
conducted at the same time of day. 
Samples were taken at baseline and immediately after RIC. No 1 h sample was taken 
in this experiment as SDF-1α is known to be released within minutes of platelet 
activation.392 Whole blood was either immediately fixed in 1% PFA or diluted with 
PBS containing 0.1% BSA and treated with 10 µM ADP for 20 min at RT, then 1% PFA 
added for 10 min at RT to a final dilution of 1:20. Blood samples taken after RIC were 
prepared in the same way and both groups were subsequently prepared and 
analysed as described in section 2.9. 
7.6.3 Results 
The aim of this section was to investigate the hypothesis that RIC activates platelets, 
triggering the release and expression of SDF-1ɑ. The surgical complications 
encountered in this experiment were negligible. 24 animals were included in the 
analysis, with no exclusions. 
In the first experiment, serum samples were measured to determine whether there 
was any difference in SDF-1α between control and RIC groups. Any such difference 
would suggest that RIC potentiates SDF-1α release and expression by platelets that 
are activated in the preparation of serum. However, despite finding high levels of 
SDF-1α, no difference was observed between the control and RIC group either 
immediately or 1 h after RIC (0 min control 4300±300 pg/ml vs. RIC 4300±300 pg/ml, 
n=5-6, P=NS; 60 min control 5000±200 pg/ml vs. RIC 4900±300 pg/ml, n=4, P=NS, 
Figure 7-22). 
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Figure 7-22: Full-length SDF-1α measured in rat serum immediately and 1 h after remote 
ischaemic conditioning 
Sprague Dawley rats were anaesthetised and treated with either RIC (three cycles of 5 min 
hind limb ischaemia and 5 min reperfusion) or sham procedure. Blood was taken by RV 
puncture at either 0 min or 60 min and processed to obtain serum. Serum samples were 
prepared by allowing whole blood to clot for 10 min prior to removing the clot by 
centrifugation and analysis for full-length SDF-1α. Samples prepared in this way had high 
levels of SDF-1α but there were no significant differences between control and RIC groups at 
either time point. Statistical significance was assessed using unpaired t-tests, n=4-6, P=NS. 
This finding remains consistent with the hypothesis that RIC stimulates the release of 
SDF-1α from α-granules because the massive SDF-1α release from activated serum 
samples might obscure any change conferred by RIC. Therefore, the presence of an 
interaction between SDF-1α and platelet-expressed CXCR4 was investigated, instead, 
using unfractionated plasma samples that are expected to retain a platelet 
population. These were incubated with 5 µg/ml of AMD3100, a competitive 
antagonist of CXCR4, for 1 h prior to measuring full-length SDF-1α. This demonstrated 
a significant increase in detectable SDF-1α versus Hispec buffer control (AMD3100 
640±60 pg/ml vs. control 460±70 pg/ml, n=3, P<0.01, Figure 7-23), suggesting a 
reversible association of SDF-1α with CXCR4 on platelets. 
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Figure 7-23: SDF-1α levels in rat unfractionated plasma samples after incubation with 
AMD3100 
Unfractionated plasma samples obtained from Sprague Dawley rats via RV puncture were 
incubated with 5 µg/ml AMD3100 (AMD) for 1 h prior to measurement of full-length SDF-1α. 
There was significantly more SDF-1α in the AMD3100 group. Statistical significance was 
assessed using a paired t-test, n=3, **P<0.01. 
To ascertain whether there was any difference in platelet-expression of SDF-1α 
between control and RIC groups, healthy male volunteers were subjected to RIC and 
whole blood samples were fixed and analysed by flow cytometry using HCI.SDF1α. As 
a positive control, whole blood was fixed and treated with 10 µM ADP, which has 
been shown to cause α-degranulation and the increased expression of SDF-1α.358 
There was a marked, albeit not statistically significant, increase in the numbers of 
platelets expressing SDF-1α in the ADP group (control 12±4% vs. RIC 8±2%, n=3, P=NS, 
Figure 7-24) but no increased expression in the RIC group (control 12±4% vs. ADP 
25±8%, n=3, P=NS, Figure 7-24), indicating that platelet-derived SDF-1α is an unlikely 
mediator of RIC. 
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Figure 7-24: Effect of ADP and remote ischaemic conditioning on platelet surface 
expression of SDF-1α in humans 
RIC consisting of three cycles of 5 min right upper limb ischaemia and 5 min reperfusion was 
applied by inflation of a manual sphygmomanometer to a pressure of 200 mmHg. Human 
whole blood samples were fixed and a positive control group immediately treated with 10 
µM ADP prior to flow cytometry analysis of full-length SDF-1α expression. (A) Representative 
image demonstrating an obvious rightward shift in fluorescence in the ADP group (black line) 
versus control (blue line) that was absent in the RIC group (Panel B); (C) This was not 
significant when assessed using one-way ANOVA and Tukey’s multiple comparison test, n=3, 
P=NS. 
7.6.4 Discussion 
In view of the absence of a detectable increase in SDF-1α in PFP, described in section 
7.3.4, this section aimed to ascertain what role, if any, platelets contribute to putative 
SDF-1α-mediated cardioprotection, predicated on the observation that platelets 
contain large amounts of SDF-1α that they release after activation. Unsurprisingly, no 
difference in SDF-1α was detected between control and RIC groups when serum 
samples were assayed because extensive degranulation during serum preparation 
results in large increases in SDF-1α levels, which is likely to obscure subtler changes 
in SDF-1α in vivo. This is interesting when considering that three of the studies in 
Table 7-2 report SDF-1α levels measured in serum samples and might, therefore, be 
anomalous. 
It remained possible that there was a difference in platelet-expression of SDF-1α after 
RIC. To confirm an interaction between SDF-1α and platelet-expressed CXCR4, 
AMD3100 was incubated with unfractionated plasma samples and found to increase 
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SDF-1α. To investigate the role of platelet-expressed SDF-1α in RIC, flow cytometry 
was used to measure platelet surface SDF-1α and similarly found no increase in 
response to RIC. Although this study did not directly measure platelet activation, 
degranulation and consequent SDF-1α expression is an established surrogate.413 
Therefore, in contrast to the study by Oberkofler et al., RIC appears not to activate 
platelets in the present study.411 Note that although the samples incubated with ADP 
were not significantly different from control samples, there was a clear trend and 
there was considered to be sufficient evidence to avoid further venepuncture of 
healthy volunteers and to terminate the study. 
These findings are supported by those of Cohen et al. who found that platelet-
depletion using anti-thrombocyte serum did not abrogate the cardioprotective effect 
of IPC in open-chest rats subjected to 30 min ischaemia and 2 h reperfusion.414 
Although this has not been tested in the context of RIC, the present results would 
predict a similar outcome. In the context of the study by Oberkofler et al. it remains 
possible that platelets play a role in cardioprotection, although this would appear not 
to be mediated by SDF-1α.411 The present study did not investigate the potential 
importance of other proteins contained within α-granules as this is beyond the scope 
of this project. Furthermore, it should be noted that MIF is expressed by platelets, 
although it does not co-localise with SDF-1α, has distinct activating stimuli and has 
delayed secretion kinetics.392, 393  Nonetheless, the role of platelet-expressed MIF in 
RIC is an attractive hypothesis for future investigation. 
7.7 Summary 
This chapter reports the successful characterisation and validation of an ELISA for the 
specific and robust detection of full-length SDF-1α using the novel antibody 
HCI.SDF1α. At the same time, frequently used commercial assays were found to 
report a combination of full-length and cleaved SDF-1α. These assays were used in 
combination to investigate the dynamics of SDF-1α after RIC, and unexpectedly 
demonstrated increased cleavage. The proposed mechanism relates to the increased 
activity of endothelial cell membrane-bound DPP4 in response to oxidative stress but 
is unlikely to be significant in the mechanism of remote preconditioning. 
 211 
 
Therefore, the third condition necessary to define a molecule as a mediator of 
cardioprotection, the increased production or maintenance of extracellular 
concentrations of the mediator(s) as a direct effect of RIC, has not been met. This is a 
difficult criterion to satisfy given the plethora of ways SDF-1α could contribute to RIC. 
The most likely outstanding hypotheses are that SDF-1α is important in either the 
trigger or effector phases of RIC, but is not the humoral factor, or that 
cardioprotection in response to RIC is related to altered CXCR4 dynamics rather than 
up-regulation of SDF-1α. These are addressed in Chapter 6 and Chapter 8, 
respectively.  
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Chapter 8 Is remote ischaemic conditioning still effective in cardiomyocyte-
specific CXCR4 null mice? 
8.1 Introduction 
The final condition, according to The Working Group of Cellular Biology of the Heart of 
the European Society of Cardiology,103  that must be satisfied to define a molecule as 
an endogenous mediator of cardioprotection is the absence of cardioprotection in 
animals, tissues or cells with genetic disruption of the mediator’s production or its 
receptor(s). 
As described in section 1.2, CXCR4 is critical in embryogenesis and transgenic mice 
with global CXCR4 deficiency suffer various lethal developmental abnormalities 
including VSD.57, 415, 416 Therefore, to investigate the effect of genetic disruption of 
CXCR4 it is necessary to use a cell-specific CXCR4 knockout model. 
As discussed in section 6.4.4, cardiomyocytes are the best described cardiac cell-type 
in the context of SDF-1α-CXCR4-mediated effects. Hu et al. demonstrated increased 
SDF-1α release from cardiomyocytes, but not cardiac fibroblasts, subjected to 
hypoxia and reoxygenation.46 Furthermore, isolated cardiomyocytes treated with 
exogenous SDF-1α responded by up-regulating the protective kinases Akt and Erk1/2. 
Similarly, Dong et al. demonstrated loss of benefit from infused MSCs after 
permanent LAD ligation in mice lacking cardiomyocyte CXCR4.75 Therefore, 
cardiomyocyte-specific CXCR4 deletion was selected to investigate the role of SDF-
1α in RIC in a murine model of myocardial IRI. 
Interestingly, congenital cardiomyocyte-specific CXCR4 deletion is not fatal in utero. 
Given the defective cardiogenesis apparent in mice with global CXCR4 deficiency, it 
is surprising that Agarwal et al. found CXCR4flox/flox mice that were crossed with 
MLC2v-Cre+/-, resulting in congenital cardiomyocyte-specific recombination and 
CXCR4 deletion, were viable, had normal cardiac function and no evidence of VSD.207 
Nonetheless, in order to ensure the absence of developmental effects, and in view of 
our laboratories experience with conditional knockout strains, the tamoxifen-
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inducible MYH6-MerCreMer mouse was used in the present study, as described in 
section 2.3. 
8.2 Research aims and objectives 
The main objective of this chapter was to investigate whether RIC remains effective 
in cardiomyocyte CXCR4 null mice. The research aims for this objective were: 
1. Confirm cardiomyocyte-specific deletion of CXCR4 after tamoxifen 
administration; 
2. Investigate whether RIC is effective in cardiomyocyte CXCR4 null mice. 
8.3 Aim 1: Confirm cardiomyocyte-specific deletion of CXCR4 after tamoxifen 
administration 
8.3.1 Background 
To investigate the hypothesis that RIC is not effective in cardiomyocyte-specific 
CXCR4 null mice subjected to in vivo myocardial IRI, it was first necessary to test the 
efficacy of CXCR4 ablation by Cre recombinase in mice treated with tamoxifen. 
In general, the MYH6-MerCreMer system is expected to result in approximately 70-
90% reduction of gene expression after 5-7 days of tamoxifen treatment.209, 211 The 
time-course of CXCR4 protein reduction depends on the efficacy of gene ablation and 
turnover rate of CXCR4. CXCR4flox/flox MYH6-MerCreMer mice that have been induced 
by tamoxifen injection have previously been used 3 weeks after the completion of 5 
days dosing with tamoxifen.75 This interval also allows any transient tamoxifen-
induced dilated cardiomyopathy to normalise prior to experimentation,417 although 
the inclusion of tamoxifen-injected MYH6-MerCreMer+/+ control mice also mitigates 
any confounding effect of this possibility. 
Using this protocol, Agarwal et al. confirmed CXCR4 deletion from genomic DNA using 
PCR of homogenate obtained from hearts, but not tails, of injected mice 1 week after 
completion of tamoxifen dosing.207 They subjected these mice to permanent LAD 
ligation 3 weeks after completion of dosing and were able to demonstrate reduction 
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of CXCR4 protein expression by immunofluorescence in cardiomyocytes, but not 
endothelial cells, 48 h later. This was quantified as a 90% reduction by Western blot 
analysis. 
The aim of this section was to confirm cardiomyocyte-specific deletion of CXCR4 after 
induction of MYH6-MerCreMer with tamoxifen. Several methods were attempted 
due to technical issues with reagents, which are described below. 
8.3.2 Methods 
This study first generated a colony of inducible cardiomyocyte-specific CXCR4flox/flox 
mice, as described in section 2.3. Male CXCR4flox/flox MYH6-MerCreMer+/- and 
CXCR4flox/flox MYH6-MerCreMer+/+ mice between 4 to 10 weeks old were injected IP 
with 20 mg/kg/day of tamoxifen continuously for 5 days. For brevity, the consequent 
phenotypes will henceforth be labelled CM-CXCR4KO and CM-CXCR4WT, respectively. 
Experiments were performed 3 weeks after completion of tamoxifen dosing. 
Ventricular samples or isolated cardiomyocytes were extracted and prepared for 
either Western blot or immunofluorescence as described in sections 2.5 and 2.6, 
respectively. The anti-CXCR4 primary antibody was either ab2074 or ab124824, both 
at a dilution of 1:100. The secondary antibody was anti-rabbit Alexa Fluor 488, diluted 
1:400. Control samples for immunofluorescence were incubated in Alexa Fluor 488 
in the absence of primary antibody, to exclude non-specific staining with secondary 
antibody. A positive control sample was taken from the spleen, which is abundant 
with CXCR4-expressing lymphohaematopoietic progenitor cells, and stained 
alongside ventricular samples. 
RNA extraction, cDNA synthesis and QPCR was performed as described in section 2.7. 
To avoid amplification of non-specific DNA products (including primer dimers) it was 
necessary to use the lowest concentration of primers possible without compromising 
the sensitivity of the assay. Therefore, primer concentrations between 0.25 µl and 
2.5 µl for both CXCR4 and the positive control genes GAPDH and HPRT were tested. 
It was then necessary to validate the PRC reaction by demonstrating Ct values that 
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were proportional to the quantity of template cDNA, for which a concentration range 
of 0.6-2.5 µl cDNA per reaction was tested. 
8.3.3 Results 
Western blot analysis of ventricular lysates from CM-CXCR4WT and CM-CXCR4KO mice, 
using ab2074 anti-CXCR4 primary antibody, did not successfully demonstrate loss of 
CXCR4 protein in the latter group (Figure 8-1). In fact, the Western blot suggested 
non-specific binding to proteins of a range of sizes, as indicated by the number of 
bands visible outside the expected size of 48 kDa. Despite optimisation of the 
protocol, including testing of different antibodies, adjustment of antibody 
concentrations, blocking buffer constitution, gel type for SDS-PAGE, washing 
protocol, quantity of protein loaded and sample preparation, this remained 
consistent. 
 
Figure 8-1: Western blot analysis of ventricular lysates from CM-CXCR4WT and CM-CXCR4KO 
mice using the monoclonal anti-CXCR4 antibody, ab2074 
Western blot analysis demonstrated several non-specific bands and no evidence of CXCR4 
deletion at the expected size of 48 kDa (red box). 
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Next, immunofluorescent staining of isolated cardiomyocytes was performed in a 
wild type C57BL/6 mouse, with a view to applying the technique to cells from 
experimental animals. However, initial characterisation using ab2074 anti-CXCR4 
primary antibody demonstrated apparently non-specific binding (Figure 8-2). 
 
Figure 8-2: Representative image showing immunofluorescent staining of isolated WT 
mouse cardiomyocytes with anti-CXCR4 (ab2074, green) 
(A) High signal intensity in cells treated with primary antibody; however, there is significant 
non-specific nuclear staining (arrowed); (B) Low signal intensity in cells stained with 
secondary antibody-only. 50 µm scale bar. 
Although ab2074 was well-described and used successfully for both published 
Western blots and immunohistochemistry,356, 418 it was unfortunately withdrawn 
from sale by Abcam for unspecified reasons. Further experiments were conducted 
using the recombinant rabbit monoclonal anti-CXCR4 antibody ab124824. 
Subsequent immunofluorescent staining of sections from CM-CXCR4WT and CM-
CXCR4KO mice showed no differences in signal intensity, although it is noteworthy 
that the greatest signal in both groups was apparently endothelial (Figure 8-3). 
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Figure 8-3: Representative images demonstrating immunofluorescent staining of 
ventricular sections from CM-CXCR4WT and CM-CXCR4KO mice with anti-CXCR4 (ab124824, 
green). Arrows indicate positive staining 
Greater signal intensity was observed after incubation with primary antibody compared to 
secondary antibody alone in all samples; however, no difference between CM-CXCR4WT and 
CM-CXCR4KO sections was observed (Panels A and B). Staining in both groups was 
predominantly endothelial (arrowed); (C) Positive CXCR4 immunofluorescence of B cells in 
mouse spleen. 25 µm scale bar. 
The final immunological approach to demonstrating CXCR4 loss in CM-CXCR4KO mice 
was Western blotting of isolated cardiomyocytes using ab124824. The use of isolated 
cells in combination with ab124824 reduced the non-specific binding present in 
Figure 8-1. Four animals were included per group and CXCR4 signal intensity was 
normalised to α-tubulin loading control. A CM-CXCR4WT sample that failed to run 
correctly was excluded. Despite optimisation, the band obtained was weak, even in 
CM-CXCR4WT samples, and subsequent analysis revealing reduced CXCR4 in the CM-
CXCR4KO group failed to reach statistical significance (CM-CXCR4WT 0.29±0.16 AU vs. 
CM-CXCR4KO 0.12±0.01 AU, n=3-4, P=NS, Figure 8-4). 
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Figure 8-4: PCR and Western blot analysis of isolated cardiomyocytes from CM-CXCR4WT 
and CM-CXCR4KO mice using the monoclonal anti-CXCR4 antibody, ab124824 
(A) PCR confirmed MYH6-MerCreMer status, with no band present in MYH6-MerCreMer+/+ 
mice and a 650 bp band in MYH6-MerCreMer+/- mice; (B) Western blot analysis using the 
monoclonal anti-CXCR4 antibody ab124824 demonstrated a specific band at 48 kDa; (C) α-
tubulin loading control; (D) Densitometry showed no significant difference between CM-
CXCR4WT and CM-CXCR4KO mice. Statistical significance was assessed using an unpaired t-test, 
n=3-4, P=NS. *Sample failed to run correctly. 
In view of the problems with antibodies, quantitative reverse transcriptase QPCR, 
which is a sensitive tool for even subtle changes in gene expression,419 was used 
instead to quantify CXCR4 expression. First it was necessary to optimise primer 
concentration. Primer concentrations between 0.25 µl and 2.5 µl for CXCR4, GAPDH 
and HPRT were tested (Figure 8-5). Based on the optimal signal:noise ratio, 1 µl of 
each primer was used per reaction for all subsequent experiments. 
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Figure 8-5: Evaluation of primer concentration in QPCR reaction using WT mouse cDNA 
0.25, 1 and 2.5 µl per reaction of each primer (forward and reverse) were tested for GAPDH, 
HPRT and CXCR4. Signal:noise was best when 1 µl of each primer was used. 
QPCR was then validated by performing reactions with 2.5, 1.3 and 0.6 µl cDNA. Using 
2-ΔΔCt analysis, no difference in expression was detectable between 2.5 µl and 1.3 µl 
samples. However, the expression fold change between samples containing 1.3 µl 
and 0.6 µl was 0.53. Therefore, the QPCR protocol was able to accurately differentiate 
0.6 µl from 1.3 µl of template cDNA and the latter volume was therefore used for all 
subsequent reactions. 
When cDNA isolated from CM-CXCR4WT and CM-CXCR4KO mice was analysed in this 
way, residual CXCR4 gene expression in CM-CXCR4KO mice was 38±35%. In the 
absence of gene expression, the receptor is expected to be eliminated from 3 weeks 
after the completion of 5 days dosing with tamoxifen, as discussed in section 8.3.1. 
8.3.4 Discussion 
This experiment investigated the efficacy of cardiomyocyte-specific CXCR4 deletion 
in a tamoxifen-inducible MerCreMer system and, overall, demonstrated residual 
CXCR4 gene expression in CM-CXCR4KO mice of 38±35%. 
Initial analysis of myocardial protein was obfuscated by a non-specific commercially 
available anti-CXCR4 antibody (ab2074). In isolated mouse cardiomyocytes, while 
staining with primary plus secondary antibodies exceeded that with secondary 
antibody alone, there was artefactual perinuclear staining. Furthermore, although 
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staining in the T-tubules was convincing, Segret et al. used confocal and electron 
microscopy to show that CXCR4 is localised on the plasma membrane of 
cardiomyocytes, not in the T-tubules.45 
Subsequent immunofluorescence experiments compared CM-CXCR4WT and CM-
CXCR4KO samples to define any confounding non-specific staining. Ventricular 
sections were used to facilitate assessment of the cellular distribution of CXCR4 
staining. Using an alternative antibody (ab124824) there was no difference between 
CM-CXCR4WT and CM-CXCR4KO samples, although fluorescence with primary plus 
secondary antibodies again exceeded that observed with secondary antibody alone. 
The lack of difference may have represented failure of inducible recombination or 
may signify non-specific binding. Given this absence of a difference between 
genotypes, it is worth considering that the positive CXCR4 immunofluorescence 
observed in isolated human trabeculae samples in section 6.4 may, in fact, be 
artefactual. 
These issues relate to the more general limitations of immunolabelling. The 
monoclonal antibodies used outght to be highly specific, but they are vulnerable to 
loss of their epitope as a result of protein post-translational modification or altered 
tertiary structure of the target protein.420 This can be exacerbated by cross-linking of 
amino acids as a result of formalin fixation resulting in further conformational 
change. Potential solutions include the use of heat-induced antigen retrieval or, as in 
the present experiments, fixation with HistoChoice®, which is designed to preserve 
antigenic sites.421 A further limitation is non-specific binding as a result of 
hydrophobic and ionic interactions.420 BSA was used to limit non-specific binding;  an 
alternative approach would be the addition of goat serum as a blocking agent, which 
was not tried here. 
Another potential reason for the present finding is failure of antibodies to permeate 
into the fixed ventricular samples, and groups using similar protocols to stain for 
CXCR4 have previously included a permeablisation step with 0.1% Triton X-100.422 In 
addition to permeablisation, it may also be possible to enhance the signal using, for 
 221 
 
example, tyramide signal amplification, although these techniques were not applied 
in this case.423 
Aside from technical limitations, the relative paucity of cardiomyocyte-specific CXCR4 
in either group may relate to a finding by Zhang et al. that CXCR4 is only up-regulated 
in cardiomyocytes after an insult.68 In particular, they demonstrated up-regulation of 
cardiomyocyte-specific CXCR4 in the infarct zone of mice subjected to permanent 
LAD ligation after 24 h, although they did not include a baseline sample. Furthermore, 
they did not report the specific Abcam antibody they used, which may have been the 
obsolete ab2074. Finally, Segret et al. have reported the presence of CXCR4 on 
cardiomyocytes at baseline.45 However, if cardiomyocyte-specific CXCR4 is only up-
regulated after MI it may not be relevant in the context of RIC-induced 
cardioprotection, unless it is speculated that RIC remotely up-regulates CXCR4 in the 
effector organ. 
It is also interesting to reflect on the relatively greater fluorescent signal on the 
endothelium in both CM-CXCR4WT and CM-CXCR4KO samples. Although this might be 
artefactual, the possible presence and importance of CXCR4 on endothelial cells 
warrants further investigation. This will be discussed in section 8.4.4. 
To overcome the problems with antibodies described above, QPCR was employed to 
demonstrate deletion of CXCR4. Despite large statistical error, this technique 
successfully demonstrated loss of CXCR4 in disrupted and homogenised ventricular 
samples. However, it should be acknowledged that this will reflect total mRNA, which 
may not necessarily correlate precisely with protein content and does not distinguish 
between intracellular and extracellular receptors. The observed residual expression 
is likely to reflect incomplete deletion and CXCR4 on other cardiac cell types, including 
vascular smooth muscle, endothelial cells and cardiac fibroblasts. To consolidate this 
result, it would be necessary to perform QPCR for CXCR4 cDNA in isolated 
cardiomyocytes, which was not attempted in thisstudy. Furthermore, it would be 
desirable to include positive and negative control samples, which could be achieved 
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using adenovirus-mediated CXCR4 over-expression and congenital cardiomyocyte 
CXCR4 deletion, both of which have been described in the literature.88, 207 
As discussed, MerCreMer systems are imperfect, resulting in absence of expression 
in approximately 70-90% of cardiomyocytes after treatment with tamoxifen.209, 211 
The cDNA for Cre recombinase is derived from the genome of a P1 bacteriophage 
that, as a non-eukaryote, is thought to result in suboptimal Cre expression when 
expressed in mammals.424 This has subsequently been remedied by developing iCre, 
or improved Cre, which has been optimised for codon usage for mammals and to 
reduce the chance of epigenetic silencing in mammals.424 This could be applied to 
future experiments of this type to mitigate the potential confounding effect of 
inefficient recombination. Interestingly, the best recombination with iCre has been 
reported in immature animals.425 In adult mice, however, reasonable recombination 
has been reported in tissues including the heart from qualitative evaluation in ROSA-
lacZ reporter mice. In these mice, Cre expression drives recombination and removal 
of a loxP-flanked stop sequence resulting in the expression of a lacZ transgene, which 
encodes β-galactosidase.426 This can be stained blue with X-gal. 
8.4 Aim 2: Investigate whether remote ischaemic conditioning is effective in cardiomyocyte 
CXCR4 null mice 
8.4.1 Background 
Once the reduction of CXCR4 expression in CM-CXCR4KO mice after tamoxifen 
administration was confirmed, it was possible to test the hypothesis that 
cardioprotection by RIC would be abolished in these mice. 
In view of the complexity of this experimental model, several control groups are 
potentially necessary to address a number of possible confounding factors.  These 
include tamoxifen toxicity, Cre recombinase toxicity and the effect of loxP site 
insertion. These have been reviewed by Davis et al. and are outlined in Table 8-1 with 
reference to the current study.211 
 223 
 
Group (genotype and 
treatment) 
Group Reason for inclusion 
CXCR4flox/flox MCM+/- + tamoxifen Control Knockout control group 
CXCR4flox/flox MCM+/- + vehicle RIC Wild type experimental group 
CXCR4flox/flox MCM+/- + tamoxifen RIC Knockout experimental group 
CXCR4flox/flox MCM+/+ + tamoxifen Control Wild type control for tamoxifen 
CXCR4+/+ MCM+/- + tamoxifen Control Wild type control for Cre 
recombinase 
CXCR4flox/flox MCM+/+ + vehicle Control Wild type control for LoxP insertion 
Table 8-1: Potential control groups required for experiments using the tamoxifen-inducible 
MYH6-MerCreMer system 
Experiments using this system have several potential confounding factors that require careful 
consideration. These have been reviewed by Davis et al.211 MCM, MerCreMer. 
Despite this, it is not practicable, or necessary, in view of a considerable literature,211 
to include an exhaustive list of control groups. In view of the transient but severe 
dilated cardiomyopathy that has been observed after tamoxifen administration,417 
the tamoxifen-injected CXCR4flox/flox MYH6-MerCreMer+/+ (CM-CXCR4WT) group is 
particularly important to control for tamoxifen administration. LoxP sites do not alter 
gene expression and are therefore not expected to affect IS or the ability to confer 
cardioprotection. Furthermore, all mice used in the experiments reported in Chapter 
4 and Chapter 5 had a CXCR4flox/flox Cre+/+ genotype and were neither excessively 
protected nor resistant to cardioprotection using RIC, hypothermia or exogenous 
SDF-1α. Despite the animals not being injected with vehicle, it suggests that 
controlling for the presence of LoxP sites is unnecessary. Regarding Cre recombinase, 
MerCreMer proteins can interact with oestrogen receptor signalling.427 As a result of 
the expression of several oestrogen receptor subtypes in the myocardium,428 
 224 
 
activated MerCreMer has been reported to have detrimental effects on cardiac 
function, myocardial Ca2+ handling and energy production.417 However, it has been 
used extensively in relation to SDF-1α-CXCR4 without unduly confounding the results 
and is therefore used here without a specific control group.75, 207 All control group 
animals were littermates of experimental animals to reduce other confounding 
factors, including environmental factors and genetic drift.211 
The aim of this section was to investigate whether the efficacy of RIC observed in 
Chapter 4 can be abrogated by cardiomyocyte-specific deletion of CXCR4 expression. 
8.4.2 Methods 
4-10 week old male and female mice were injected IP with 20 mg/kg/day of tamoxifen 
continuously for 5 days. To test the hypothesis that RIC would confer 
cardioprotection upon wild type but not CXCR4 knockout mice compared to control, 
experimental groups were defined a priori as follows: 
1. Tamoxifen-injected CXCR4flox/flox MYH6-MerCreMer+/- (CM-CXCR4KO) control; 
2. Tamoxifen-injected CXCR4flox/flox MYH6-MerCreMer+/- (CM-CXCR4KO) RIC; 
3. Tamoxifen-injected CXCR4flox/flox MYH6-MerCreMer+/+ (CM-CXCR4WT) control; 
4. Tamoxifen-injected CXCR4flox/flox MYH6-MerCreMer+/+ (CM-CXCR4WT) RIC. 
A vehicle-injected CXCR4flox/flox MYH6-MerCreMer+/- (wild type) RIC group was not 
included as this was accounted for by tamoxifen-injected CXCR4flox/flox MYH6-
MerCreMer+/+ (CM-CXCR4WT) mice and could be added if tamoxifen was 
unexpectedly suspected of conferring cardioprotection. Control groups for Cre 
recombinase expression and LoxP insertion were not included for the reasons 
outlined above. All mice were subjected to myocardial IRI aged 8-16 weeks, with 
subsequent analysis of IS/AAR. 
Sample size was calculated using a two-sided test for the comparison of two means. 
Based on the results described in section 4.4.3, the following assumptions were 
made: a 20% estimate of effect size, a control IS of 40%, an SD of 10%, a significance 
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level of 5% (α=0.05) and 80% power (β=0.2). This required a minimum sample size of 
four animals per group. 
8.4.3 Results 
The surgical complications encountered in this experiment were similar to those 
described in section 4.4, although the total proportion of included animals increased. 
A summary is given in Figure 8-6. 
 
Figure 8-6: Experimental success during investigation of whether cardiomyocyte-specific 
CXCR4 deletion abrogates the cardioprotective effect of remote ischaemic conditioning 
15 animals were used during the course of the experiment and 12 were included in the 
analysis (80%). All excluded animals were operator-dependent, and included anaesthetic and 
staining complications. 
This experiment measured IS as a proportion of AAR in transgenic mice following in 
vivo myocardial IRI. It became apparent that CM-CXCR4KO control mice had 
surprisingly small IS, therefore confounding any attempt to demonstrate the 
abrogation of RIC in these animals. Consequently, they were instead compared to 
CM-CXCR4WT control mice to ascertain whether Cre-induced recombination or 
tamoxifen administration triggered the observed protection. Six animals were 
included per group and analysis of their respective areas at risk, to ensure surgical 
consistency, revealed no significant differences (CM-CXCR4WT 53±4% vs. CM-CXCR4KO 
62±5%, n=6, P=NS, Figure 8-7). 
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Figure 8-7: Comparison of area at risk between CM-CXCR4WT and CM-CXCR4KO groups 
C57BL/6 CM-CXCR4WT and CM-CXCR4KO mice were anaesthetised and subjected to 40 min 
ischaemia and 2 h reperfusion in vivo. Analysis of their respective areas at risk, to ensure 
surgical consistency, revealed no statistically significant differences. Black points indicate 
male mice and red points indicate female mice. Statistical significance was assessed using an 
unpaired t-test, n=6, P=NS. Data presented as mean ± SEM. 
Analysis of IS demonstrated that CM-CXCR4KO had a marked reduction in IS as a 
proportion of AAR (12±3%, n=6) compared to CM-CXCR4WT mice (36±4%, n=6, 
P<0.001, Figure 8-8). Representative transverse heart sections are shown in Figure 
8-8. 
To test the hypothesis that baseline differences in cardiac function may have altered 
the susceptibility of CM-CXCR4KO mice to myocardial injury, baseline 
echocardiographic parameters were compared between CM-CXCR4WT and CM-
CXCR4KO mice. As expected, CM-CXCR4WT values were comparable to those described 
in Chapter 4 and no differences with CM-CXCR4KO mice were identified (Figure 8-9). 
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Figure 8-8: Infarct size following myocardial ischaemia-reperfusion injury in CM-CXCR4WT 
and CM-CXCR4KO groups 
CM-CXCR4WT and CM-CXCR4KO mice were anaesthetised and subjected to 40 min ischaemia 
and 2 h reperfusion in vivo. IS as a proportion of AAR was analysed using Evans Blue and TTC 
staining. (A) IS was significantly smaller in CM-CXCR4KO mice compared to CM-CXCR4WT mice. 
Black points indicate male mice and red points indicate female mice. Statistical significance 
was assessed using an unpaired t-test, n=6, ***P<0.001. Data presented as mean ± SEM; (B) 
Representative scanned transverse heart sections demonstrating Evans Blue area (blue), area 
at risk (pink) and infarct (white). 
 
Figure 8-9: Baseline echocardiographic parameters in CM-CXCR4WT and CM-CXCR4KO mice 
CM-CXCR4WT and CM-CXCR4KO were anaesthetised and transthoracic 2D echocardiography 
was performed at baseline. There were no statistically significant differences between CM-
CXCR4WT and CM-CXCR4KO groups with respect to fractional shortening, stroke volume or 
cardiac output. Statistical significance was assessed using unpaired t-tests, n=5-6, P=NS. 
In addition, there was no evidence of cardiac hypertrophy as a result of 
cardiomyocyte-specific CXCR4 deletion, with no differences in interventricular 
septum (IVSd), LV internal diameter (LVIDd) and posterior wall (LVPWd) dimensions 
evident in diastole between groups (Figure 8-10). 
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Figure 8-10: Left ventricular dimensions in CM-CXCR4WT and CM-CXCR4KO mice 
CM-CXCR4WT and CM-CXCR4KO were anaesthetised and transthoracic 2D echocardiography 
was performed at baseline. Echocardiography did not reveal any difference in IVSd, LVIDd or 
LPWDd between groups. Statistical significance was assessed using two-way ANOVA with 
Bonferroni correction for multiple comparisons, n=6, P=NS. 
8.4.4 Discussion 
This experiment unexpectedly demonstrated that cardiomyocyte-specific CXCR4 
deletion, 3 weeks after completion of tamoxifen dosing, significantly abrogated the 
acute injury associated with myocardial IRI. This precluded investigation of the original 
hypothesis that the beneficial effect of RIC would be abrogated by cardiomyocyte-
specific CXCR4 deletion, which was protective per se. It remains possible that another 
cardiac cell-type is important in this regard. This could be investigated using similar 
inducible or congenital transgenic models of CXCR4 deletion. For example, 4-
hydroxytamoxifen-inducible endothelial-specific platelet-derived growth factor 
subunit B (PDGFB)-iCreERT2 mice that have been reported in the literature.425 These 
could be crossed with CXCR4flox/flox transgenic mice to generate a tamoxifen-inducible 
endothelium-specific CXCR4flox/flox bitransgenic strain. It is important for this to be 
inducible as mutations involving the vasculature can be lethal in utero.425 An 
alternative approach would be to demonstrate the absence of cardioprotection in 
animals, tissues or cells with genetic disruption of the production of SDF-1α. However, 
this is complicated by the fact that animals lacking SDF-1α die in utero. Another 
possibility could instead be to use a neutralising antibody.57 
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The finding of cardioprotection in CM-CXCR4KO mice is surprising in view of the 
literature demonstrating a cardioprotective role for CXCR4, albeit generally in models 
of ventricular remodelling. However, many of these studies artificially recruit the SDF-
1α-CXCR4 axis, by various means, without necessarily implicating it in the intrinsic 
response to injury, about which less is known. For example, Agarwal et al. subjected 
mice with either inducible or congenital absence of cardiomyocyte-specific CXCR4 to 
permanent LAD ligation.207 At 21 days they found no difference in measures of 
cardiac function or adverse ventricular remodelling compared to CM-CXCR4WT mice, 
suggesting that CXCR4 has no endogenous role in these processes. Using a similar 
model, the same group administered MSCs following MI and observed improved 
progenitor cell recruitment, less apoptotic cell death and better echocardiographic 
parameters, all of which were abrogated in CM-CXCR4KO mice.75 They attribute these 
results to the asynchronous time courses of SDF-1α and CXCR4 expression after MI.75 
Specifically, SDF-1α is reportedly up-regulated 1 h after MI,76 while cardiomyocyte-
specific CXCR4 is not increased until 36-48 h later.68 
In the context of asynchronous time courses of SDF-1α and CXCR4, it is unsurprising 
that some studies have reported beneficial effects of artificially over-expressing 
CXCR4 with viral vectors at the time of peak SDF-1α expression. For example, Larocca 
et al. subjected mice over-expressing cardiac CXCR4 to aortic banding (pressure 
overload) and demonstrated advantageous effects on ventricular remodelling, 
capillary density, cardiac function and haemodynamics.429 Similarly, Cai et al. over-
expressed CXCR4 in isolated adult rat ventricular cardiomyocytes that were 
subsequently protected from hypoxia-reoxygenation injury, which they attributed to 
increased mitochondrial STAT3.84 
However, in a study with results that most closely reflect the present experiment and 
as discussed in 0, Chen et al. used adenovirus-mediated over-expression of CXCR4 
injected into the rat heart 1 week prior to myocardial IRI and found significantly 
increased scar size, worse fractional shortening, increased cardiomyocyte apoptosis 
and more LV hypertrophy at 24 h, which were associated with significantly higher 
inflammatory cell infiltrate at 24 h in CXCR4-overexpressed hearts.88 However, CXCR4 
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expression was driven by a cytomegalovirus promoter and, despite injection into the 
heart, CXCR4 is likely to have been constitutively over-expressed, including on 
inflammatory cells. It is therefore not clear that the effect they observed was driven 
by cardiomyocyte-specific CXCR4. 
Nonetheless, inflammatory cell infiltration is of interest in the context of the present 
results. The use of anti-inflammatories in myocardial IRI is controversial, especially 
given the acuity of the present experiments (reviewed by Baxter430). However, some 
pathways may remain relevant here. For example, Montecucco et al. investigated 
FK866, which inhibits nicotinamide adenine dinucleotide (NAD)-driven 
inflammation.431  They subjected male C57BL/6 mice treated with FK866 to in vivo 
myocardial IRI and found reduced IS, neutrophil infiltration and ROS production. 
Interestingly, these benefits were not replicated in a Langendorff model, suggesting 
a requirement for circulating leukocytes. Furthermore, FK866-treated mice had 
reduced circulating SDF-1α, which is also known to be diminished in CM-CXCR4KO 
mice.207 This therefore engenders the hypothesis that the cardioprotection observed 
in CM-CXCR4KO mice is related to a dampened inflammatory response. Interestingly, 
it is known that approximately 5% of all cells in the heart are resident leukocytes and 
it would be useful to explore whether this number is reduced in CM-CXCR4KO mice.355 
However, it is important to note that Montecucco et al. observed effects at 8 h, but 
not at 1 h, after reperfusion.431 Although a 2 h time point to reflect the model used 
in this thesis was not tested, an anti-inflammatory mechanism may be too slow to 
explain the present results. 
To complement studies of CXCR4 over-expression, Liehn et al. investigated the 
intrinsic functions of CXCR4 using an in vivo model of permanent LAD ligation in global 
CXCR4 heterozygous mice (that displayed significantly lower CXCR4 expression).432 
They unsurprisingly reported impaired basal coronary flow and defective 
neovascularisation after MI in CXCR4+/- mice, given the role of the SDF-1α-CXCR4 axis 
in angiogenesis. Interestingly, however, they reported smaller IS in heterozygous 
mice compared to wild types at 4 weeks, which they also attributed to an attenuated 
inflammatory response. Furthermore, they found phosphatidylserine-rich lipid 
 231 
 
deposits in CXCR4+/- mouse hearts, which protect cardiomyocytes from hypoxic stress 
in vitro, although the exact mechanisms are unclear. Such deposits are likely to 
represent an adaptive response to congenitally decreased coronary flow in CXCR4+/- 
mice and it is doubtful whether they could accumulate in the time course from 
tamoxifen administration in the present experiment. 
Finally, it is notable that the loss-of-function and gain-of-function studies described 
generally report a normal cardiac phenotype at baseline.75, 432 However, Wang et al. 
showed that cardiomyocyte-specific CXCR4 deletion results in unopposed β2 
adrenergic receptor-induced hypertrophy and worsened fractional shortening in 
response to isoproterenol administration.433 This was reportedly associated with up-
regulation of the apoptotic markers p53 and Bax, and was rescued by adenovirus-
mediated re-expression of CXCR4. Liehn et al. also described marked reduction in 
baseline cardiac perfusion in global CXCR4 heterozygous mice.432 Conversely, Cai et 
al. found reduced baseline contractility using in vitro adult rat ventricular 
cardiomyocytes when CXCR4 was over-expressed.84 Similarly, Pyo et al. found a 
negative inotropic effect of SDF-1 on murine papillary muscles and cardiomyocytes 
during calcium stimulation, an effect that was exacerbated by adenovirus-mediated 
over-expression of CXCR4 but attenuated by AMD3100.434 They attributed this to 
CXCR4-mediated modulation of L-type calcium channel activity. These studies are 
interesting because they suggest an intrinsic defect associated with CXCR4 that is 
unrelated to inflammatory cells. Therefore, a further hypothesis for the results 
described in this chapter might be that altered cardiac dimensions and function at 
baseline in CM-CXCR4KO mice may impact upon their susceptibility to infarction. 
However, the studies discussed above are challenged by data from our laboratory 
that shows better functional recovery of muscle treated with SDF-1 relative to control 
muscle.31, 151 Furthermore, no differences in baseline functional or dimensional 
parameters were identified between CM-CXCR4WT and CM-CXCR4KO mice in this 
section, making this mechanism unlikely. 
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8.5 Summary 
This chapter describes the development and investigation of a cardiomyocyte-
specific CXCR4 null transgenic mouse strain. This was used for the first time to 
examine its role in acute myocardial IRI. Surprisingly, the application of myocardial 
IRI in these mice caused significantly smaller IS than in littermate controls. 
This finding is difficult to reconcile with the findings in Chapter 5 and Chapter 6. 
However, it seems likely given the pleiotropic and opposing effects of the SDF-1α-
CXCR4 axis in different aspects of myocardial IRI, including acute cardioprotection, 
modulation of cardiomyocyte contractility and longer-scale processes such as 
angiogenesis and pro-inflammatory responses, that the timing of CXCR4 activation is 
key. For example, it could be hypothesised that SDF-1α has injurious effects during 
ischaemia but is beneficial in reperfusion and to prevent adverse ventricular 
remodelling. Future work should focus on ascertaining the importance of timing and 
the role of different cell types with respect to SDF-1α-CXCR4 in myocardial IRI. 
The final condition that must be satisfied to define a molecule as a mediator of 
cardioprotection is the absence of protection in animals with genetic disruption of the 
mediator’s receptor. The present finding precludes resolution of this condition because 
genetic disruption of the mediator’s receptor is protective per se. Instead, future studies 
might focus on genetic disruption of SDF-1α production or antibody neutralisation as a 
means to defining its potential role in RIC.  
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Chapter 9 Overall conclusions 
Reperfusion injury makes an important contribution to myocardial injury after a 
lethal ischaemic insult in animal models. RIC has emerged as a powerful protective 
phenomenon in the pre-clinical setting, which has heralded a hunt for the 
mechanism. This is thought to include a humoral factor(s) carried from the 
preconditioned organ or tissue to the heart, where endogenous pro-survival 
signalling pathways are activated. 
Current knowledge on the functions of SDF-1α broadly delineates dual effects on 
ischaemic myocardium: direct protection via intracellular pro-survival signal 
transduction pathways and stem cell mobilisation and gradient-guided homing to 
mitigate adverse ventricular remodelling, possibly via a paracrine mechanism. 
The aim of this project was to investigate the hypothesis that SDF-1α plays a central 
role in the mechanism of cardioprotection against acute myocardial IRI conferred by 
RIC. This thesis defined a paradigm for evidencing this role that included induction of 
pharmacological cardioprotection by exogenous administration of SDF-1α at the time 
of reperfusion, abolition of cardioprotection by specific antagonism of CXCR4, 
increased production of SDF-1α as a direct effect of RIC and absence of 
cardioprotection in CXCR4 deficient mice. Each of these facets has been discussed in 
detail in the previous chapters.   
This thesis provides the first description of cardioprotection against myocardial IRI as 
a result of the administration of exogenous SDF-1α prior to reperfusion, which has 
important therapeutic implications. Moreover, AMD3100, a highly specific inhibitor 
of CXCR4, abolishes the beneficial effect of RIC in vivo. Next, a novel ELISA specific for 
active SDF-1α was developed to circumvent the confounding effects of SDF-1α 
cleavage. This was exploited to ascertain the dynamics of circulating SDF-1α and 
unexpectedly demonstrated increased cleavage and inactivation of SDF-1α 
immediately after RIC, in both rats and humans, which may be attributable to up-
regulation of endothelial DPP4 in response to oxidative stress. Finally, this thesis 
established a transgenic mouse model of inducible, cardiomyocyte-specific CXCR4 
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deletion that was unexpectedly found to exhibit protection against myocardial IRI. 
The mechanism behind this protection was not established and, furthermore, it 
prohibited the use of these mice in experiments to validate the role of CXCR4 
signalling in RIC. 
Overall, it appears that SDF-1α has potential utility in cardioprotection against 
myocardial IRI. Whether it plays an intrinsic role in RIC is less clear, with only two of 
four criteria met, but modulation of the SDF-1α-CXCR4 axis with other approaches, 
including exogenous SDF-1α, appears to be a viable therapeutic target. 
With respect to RIC, further work should characterise the most effective protocol and 
continue pursuing the mechanism in pre-clinical models to maximise the chance of 
successful clinical translation. Despite recent setbacks in large clinical outcome studies, 
it remains a clinically feasible, non-invasive, inexpensive therapeutic intervention 
with the potential to avert a legacy of ischaemic cardiomyopathy in patients suffering 
STEMI. 
In regard to SDF-1α, further studies aimed at clarifying the target cell type, precise 
timing and intra-cellular mechanism of SDF-1α in IRI are required. In particular, cell-
specific inducible or congenital transgenic models of CXCR4 deletion are of particular 
interest. Furthermore, exogenous SDF-1α should be tested in animal models that 
reflect the complex risk factor, comorbidity and treatment profile of humans with 
cardiovascular disease to determine its potential clinical value. Nonetheless, SDF-1α 
remains of considerable interest, and unravelling its pleiotropic effects in 
cardioprotection is paramount for maximising its potential in cardiac patients. 
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